

























This	 thesis	 focuses	 on	 the	 use	 of	 a	 genomic	 approach	 to	 identify	 novel	molecular	markers	 to	
differentiate	Streptococcus	suis	 (S.	suis)	 isolates	 into	 two	populations,	 i)	disease-associated	and	
ii)	non-disease	associated.	 	S.	suis	 is	a	Gram-positive	coccus	 that	 is	considered	one	of	 the	most	
important	zoonotic	bacterial	pathogens	of	swine	responsible	 for	significant	economic	 losses	to	
swine	 production	worldwide.	 	 Importantly,	 S.	suis	 is	 not	 only	 an	 invasive	 pathogen	 but	 also	 a	
very	successful	coloniser	of	mucosal	surfaces;	often	endemic	in	swine	populations	sampled.			
	
The	 widescale	 use	 of	 antibiotics	 to	 control	 and	 prevent	 the	 various	 clinical	 manifestations	
caused	 by	 S.	suis	 has	 become	 unsustainable,	 due	 to	 increases	 in	 antibiotic	 resistance	 and	
government	pressures.		Other	popular	control	strategies,	such	as	the	development	of	efficacious	
vaccines,	 are	 hindered	 by	 differences	 in	 virulence	 not	 only	 between	 but	 also	 within	 S.	suis	
















These	 findings	 were	 taken	 further	 by	 using	 the	 pathotyping	 markers	 to	 screen	 material	
scrapped	from	the	palatine	tonsils	of	swine	with	no	obvious	signs	of	streptococcal	disease.		This	
produced	 an	 interesting	 result	 -	 the	 production	 of	 both	 invasive	 disease-associated	 and	 non-
disease	associated	multiplex-PCR	amplicons	from	the	same	experimental	sample.		Unsurprising	
in	 itself,	what	was	 surprising	 is	 the	 frequency	with	which	this	observation	was	 found.	 	Picking	
single	colonies	from	solid	agar	plates	is	a	crippling	bottleneck	of	existing	S.	suis	diagnostics,	and	
its	 removal	 has	 the	 potential	 to	 improve	 the	 sensitivity	 of	 surveillance	 and	 preventive	 health	




This	 thesis	 concludes	 with	 the	 description	 of	 efforts	 to	 address	 the	 lack	 of	 a	 comprehensive	
understanding	of	S.	suis	virulence/'virulence-associated'	factors.		Chapter	6	describes	the	design	
of	 an	 isogenic	 mutant	 knocking	 out	 the	 invasive	 disease-associated	 pathotyping	 marker,	
SSU1589	(also	known	as	virA).		That	is	then	evaluated	in	simple	in	vitro	and	in	vivo	experimental	
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material	 scrapped	 from	 the	 palatine	 tonsils	 of	 five-week	 old	 pigs	 estimated	 from	
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Figure	6.3.	 Schematic	 representation	 of	 the	P1/7	virA	 operon	 (SSU1588-1590)	 in	 comparison	 to	 a	
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Table	6.2.	 Comparison	 of	 Kaplan-Meier	 curves	 of	 Greater	 Wax	 Moth	 larvae	 survival	 following	
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Streptococcus	 suis	 (S.	suis)	 is	 one	 of	 the	 most	 important	 bacterial	 pathogens	 of	 pigs	 causing	
significant	 economic	 losses	 to	 the	 swine	 industry	 worldwide	 [1].	 	 The	 infectious	 agent	 is	
responsible	for	a	wide	range	of	clinical	manifestations,	including	septicaemia	with	sudden	death,	
arthritis,	endocarditis,	meningitis,	and	pneumonia	amongst	other	diseases	[2-11].		S.	suis	is	also	a	
zoonotic	 pathogen,	 and	 although	 considered	 a	 rare	 and	 sporadic	 event,	 associated	 with	




1951,	 meningo-encephalitis	 was	 first	 experimentally	 reproduced	 in	 pigs,	 and	 in	 1954,	 an	
inability	 to	maintain	balance	due	 to	meningo-encephalitis	 resulting	 from	 invasion	of	 the	brain	
and	 its	 meninges	 was	 first	 described	 in	 Great	 Britain	 [18].	 	 The	 incriminated	 haemolytic	





The	 prophylactic	 use	 of	 antibiotics	 in	 food	 and	 drinking	 water	 has	 proven	 unsuccessful	 in	
controlling	disease.		Antibiotics	are	becoming	less	effective	because	of	an	increase	in	resistance	
among	 S.	suis	 isolates.	 	 Blanket	 antibiotic	 use	 is	 also	 becoming	 less	 accepted	 because	 of	





Importantly,	 S.	suis	 is	 not	 only	 an	 invasive	 pathogen	 but	 also	 a	 very	 successful	 coloniser	 of	




Colonisation	 of	 adult	 pigs	 is	 common	 in	 almost	 all	 pig	 populations	 sampled,	 meaning	 that	
transfer	 of	S.	suis	 from	 sow	 to	 piglet	 during	 parturition	 and	 suckling	 is	 an	 important	 route	 of	
transmission	[23].	
	
Since	 S.	 sus	 is	 such	 a	 successful	 coloniser	 of	 mucosal	 surfaces	 this	 review	 starts	 with	 an	
introduction	 on	 its	 biology	 and	 the	 numerous	 existing	 approaches	 for	 identification,	
discrimination	of	phylogenetic	diversity	and	surveillance.		The	distribution	and	determinants	of	
health-related	states	or	events	(including	disease),	and	the	application	of	 this	 to	 the	control	of	
diseases	and	other	health	problems	 is	 then	discussed	(epidemiology).	 	Putative	and	confirmed	





S.	suis	 is	 a	 Gram-positive	 coccus	 of	 the	 order	 Lactobacillales	 (lactic	 acid	 bacteria),	 family	
Streptococcaeceae	 and	 genus	 Streptococcus.	 	 Other	 notable	 pathogenic	 species	 of	 the	 genus	
include	Streptococcus	orisratti,	 the	well-studied	Streptococcus	pneumoniae	 (the	pneumococcus)	
and	 Streptococcus	pyogenes.	 	 Concerning	 its	 biological	 features,	 S.	suis	 shares	 similarities	with	
the	 pneumococcus	 and	 group	 B	 streptococci	 (GBS),	 i.e.	 the	 occurrence	 of	 several	 capsular	
serotypes,	 the	significance	of	 the	capsular	polysaccharide	as	a	virulence	 factor,	 the	respiratory	
(and	genital)	tract	as	predominant	niche	within	the	host,	and	clinical	consequences	of	infection	
(septicaemia,	meningitis,	 pneumonia).	 	S.	suis	 is	 small,	 less	 than	 two	micrometres	 in	diameter.		
S.	suis	 is	 nonmotile,	 and	 often	 found	 singly,	 in	 pairs	 or	 (rarely)	 in	 short	 chains.	 	 S.	suis	 is	 a	
chemoorganotroph	 with	 facultative	 anaerobic	 and	 fermentative	 metabolisms.	 	 S.	suis	 isolates	
produce	 typically	 mucoid	 grey/white	 colonies	 that	 are	 α-haemolytic	 on	 solid	 agar	 plates	






of	 macroscopic	 lesions.	 	 Signs	 of	 acute	 infection	 start	 with	 anorexia,	 depression,	 fever	 and	
lassitude,	 followed	 by	 symptoms	 depending	 on	 the	 localisation	 i.e.	 arthritis,	 ataxia,	 blindness,	
convulsions,	 dyspnoea,	 erythrema,	 lameness,	 opisthotonus,	 paddling	 and	 tremor	 [11].	 	 Some	
animals	with	acute	 infection	survive,	 resulting	 in	persistent	or	chronic	 infection.	 	 In	 the	 latter,	
lameness	 and	 residual	 nervous	 signs	 such	 as	 otitis	 interna	 can	 be	 evident,	 as	well	 as	 chronic	
arthritis	[9,	25].	
	
Diagnosis	 is	 then	confirmed	by	 the	 recognition	of	microscopic	 lesions,	and	 the	 isolation	of	 the	
infectious	 agent	 followed	 by	 a	 combination	 of	 simple	 biochemical	 tests	 and	 serotyping	 [1].		




infectious	 agent	 is	 isolated	 from	 diseased	 pigs	 and	 serotyping	 is	 available,	 an	 α-haemolytic	




the	development	of	 a	 fibrin-haemorrhagic	pneumonia	 [9].	 	 Indeed,	 isolation	of	S.	suis	 from	 the	
lungs	must	 be	 interpreted	with	 caution,	 as	 the	 organism	 is	 considered	 endemic	 in	 pig	 herds,	
often	 without	 causing	 clinical	 signs	 of	 disease[11].	 	 The	 identification	 of	 non-symptomatic	
carriage	of	S.	suis	can	be	achieved	through	detection	of	the	organism	using	classic	microbiology	
techniques.	 	However,	 isolation	 of	 bacteria	 from	 sites	 such	 as	 the	 upper	 respiratory	 tract	 is	 a	
laborious	 and	 time	 consuming	 process	 associated	 with	 low	 sensitivity	 due	 to	 phenotypically	
similar	 streptococcal	 species	 difficult	 to	 distinguish	 on	 the	 basis	 of	 colony	morphology	 alone	
[27].	 	 In	 fact,	 detection	 of	 S.	suis	 from	 the	 upper	 respiratory	 tract	 is	 deemed	 to	 be	 of	 little	






summarises	 the	biochemical	properties	of	S.	suis.	 	S.	suis	 is	an	encapsulated	coccus	 that	retains	
the	crystal	violet	stain	when	treated	by	Gram’s	method	(Gram-positive).	 	Different	biochemical	
tests	have	been	used	for	the	identification	of	S.	suis,	although	biochemical	variations	have	been	
noted	among	different	strains	 [10,	24].	 	Since	 the	 first	study	 to	 include	a	complete	scheme	 for	
identification	 [28],	 the	 minimum	 of	 standardised	 biochemical	 tests	 required	 to	 differentiate	
S.	suis	 from	 the	 other	 species	 of	 streptococci	 has	 been	 proposed	 by	 numerous	 authors	 as	
awareness	of	the	organism	increased	[10,	24,	26,	29,	30].		The	use	of	at	least	four	tests	has	been	
proposed	for	a	presumptive	identification	of	S.	suis,	including	i)	the	production	of	amylase,	ii)	the	
production	 of	 acid	 in	 salicin	 and	 trehalose	 broth,	 iii)	 a	 negative	 Voges-Proskauer	 (acetoin)	
reaction	 and	 iv)	 the	 absence	 of	 growth	 on	 6.5%	NaCl	 agar	 [24,	 26],	 where	 the	 production	 of	
































































S.	suis	 possesses	 cell	 wall	 antigenic	 determinates	 belonging	 to	 Lancefield	 group	 D	 [31-33].		
Lancefield	grouping	is	the	serological	differentiation	of	haemolytic	streptococci	into	distinct	and	
orderly	groups	[34].		When	first	described,	although	cultural	and	biochemical	tests	were	useful	
in	 differentiation	 of	 haemolytic	 streptococci	 from	 various	 sources,	 a	 serological	 test	 added	
considerable	 weight	 to	 conclusions	 regarding	 the	 origin	 of	 a	 particular	 strain.	 	 Lancefield’s	
approach,	by	means	of	the	precipitin	reaction	[35],	is	"dependent	on	the	presence	in	streptococci	






D	antiserum	and	are	often	 found	 together,	 but	 in	differing	 relative	proportions,	 depending	on	
the	method	of	extraction	[32,	36].		This	disparity	in	extraction	methods	is	important	and	has	led	
to	considerable	confusion	resulting	 in	 the	description	of	new	Lancefield	groups	R,	S,	RS	and	T	







Serotyping	 is	 an	 important	 part	 of	 the	 routine	 diagnosis	 procedure	 for	 S.	suis	 often	 used	 in	
combination	with	a	minimum	of	 simple	biochemical	 tests	 [26,	39].	 	Different	 techniques	exist,	
including	 i)	 the	 capillary	 precipitation	 test,	 ii)	 the	 coagglutination	 test	 [40]	 or	 iii)	 Neufeld’s	
capsular	 reaction;	 all	 of	 which	 require	 serotype-specific	 reference	 antisera.	 	 The	 capsular	




capsular	 polysaccharide	 antigens	 [31,	 37,	 38,	 42-44].	 	 Serotype	 reference	 strains	 have	 been	
derived	from	a	variety	of	sources,	including	diseased	pigs,	the	nasal	cavities	of	clinically	healthy	
pigs	 and	 other	 animal	 species	 including	 humans.	 	 However,	 since	 their	 original	 descriptions	
evidence	now	exists	for	the	reclassification	of	serotypes	20	and	22	as	Streptococcus	orisratti,	and	
serotypes	26,	32,	33	and	34	as	belonging	to	a	bacterial	species	different	from	S.	suis	[45-49].		As	




to	 be	 associated	 with	 clinical	 disease	 in	 both	 pigs	 and	 humans	 worldwide	 [41].	 	 In	 China,	
serotype	 2	 accounts	 for	 more	 than	 70%	 of	 the	 systemic	 S.	suis	 disease	 in	 piglets	 [51].		




Canada	 and	 the	United	 States	 -	 a	 similar	 serotype	distribution	 that	might	be	 explained	by	 the	




the	 UK,	 have	 not	 recently	 reported	 the	 distribution	 of	 serotypes	 [17];	 although	 in	 the	 UK	 (in	
addition	 to	 serotype	 2)	 serotypes	 1	 and	 14,	 in	 the	 past,	 have	 been	 documented	 as	 being	
responsible	 for	 invasive	 S.	suis	 disease	 in	 predominately	 suckling	 piglets	 [60,	 61].	 	 Broadly	
speaking	 serotypes	1-9	 and	1/2	are	most	 frequently	 recovered	 from	diseased	pigs	worldwide	




antigenic	 determinants	 [24].	 	 The	 following	 cross-reactions	 are	 well	 documented:	 serotype	 1	
with	type	14	antisera,	serotype	1/2	with	type	1	and	2	antisera,	serotype	6	with	type	16	antisera	
(and	 vice	 versa)	 and	 serotype	 22	 with	 type	 2	 antisera.	 	 In	 some	 cases,	 absorption	 to	 obtain	
monospecific	antisera	is	recommended	to	reduce	the	number	of	cross-reactions	[24,	38].		Since	
most	 serotypable	 isolates	associated	with	 clinical	disease	belong	 to	 serotypes	1	 -	9	and	1/2	 it	
has	been	suggested	that	it	is	impractical	for	diagnostic	laboratories	to	stock	expensive	antisera	
corresponding	to	all	of	the	35	originally	described	S.	suis	serotypes.		Instead,	to	save	expense	and	
laborious	 processing	 time	 diagnostic	 laboratories	 should	 use	 only	 reference	 antisera	 for	
serotypes	 1	 -	 9	 and	 1/2,	 then	 sending	 all	 non-serotypable	 isolates	 to	 a	 centralised	 reference	
laboratory	[44].	
	
Only	 encapsulated	 isolates	 can	 be	 serotyped	 [24].	 	 Non-serotypable	 isolates	 are	 commonly	
recovered	 from	 the	 upper	 respiratory	 tract	 of	 clinically	 healthy	 pigs	with	 similar	 biochemical	
and	morphological	features.		It	is	difficult	to	be	certain	if	isolates	not	reacting	with	the	reference	
antisera	are	truly	non-encapsulated	or	possess	a	novel	capsular	polysaccharide	antigen	to	which	
reference	antisera	have	not	previously	been	 raised	 [16]	 -	 a	 feasible	possibility	as	 traditionally	
antisera	 were	 only	 raised	 against	 capsular	 polysaccharide	 antigens	 associated	 with	 clinical	
disease.		Loss	of	capsule	has	been	reported	among	some	S.	suis	isolates	[63,	64].		It	has	also	been	





It	 is	 important	 to	 note	 that	 some	 reported	 cases	 of	 human	 infection	 have	 been	 attributed	 to	
S.	suis	 serotype	 2	 based	 on	 biochemical	 analyses	 obtained	 using	 commercial	 multi-test	 kits.		
However,	there	is	no	evidence	of	a	correlation	between	a	specific	serotype	and	its	biochemical	
properties	 [17].	 	The	apiweb	database	(Biomerieux)	 identifies	 isolates	as	 “Streptococcus	suis	I”	





as	 an	 attractive	 alternative	 and/or	 complement	 to	 the	 existing	 serological	 tests	 [50,	 66-75].		
Serotyping	 of	 S.	suis	 is	 one	 of	 the	 most	 useful	 methods	 to	 understand	 the	 epidemiology	 of	 a	
particular	 outbreak	 and	 monitor	 the	 prevalence	 of	 potentially	 hazardous	 strains,	 however,	
traditional	 serotyping	 techniques	 are	 time-consuming,	 and	 preparing	 the	 antisera	 is	 not	 easy	
due	 to	 the	high	 cost	 and	 labor	 associated	with	 its	 production.	 	 Therefore,	 the	development	 of	
more	practical	and	easier	serotyping	methods	is	desirable.	 	The	S.	suis	capsular	polysaccharide	
synthesis	(cps)	genes	are	clustered	on	a	single	locus	of	the	chromosome,	and	as	in	other	Gram-
positive	 bacteria,	 such	 as	 Streptococcus	pneumoniae,	 the	 capsular	 polysaccharides	 of	 all	 S.	suis	
serotypes	are	synthesised	by	the	Wzx/Wzy-dependent	pathway	[76-78].	 	The	two	most	recent	
molecular	serotyping	schemes	for	S.	suis,	published	within	six	months	of	one	another,	both	use	
multiple	multiplex-PCR	 (mPCR)	 assays	 to	 target	 serotype-specific	 differences	 in	 the	 cps	 genes	
[74,	75].		For	example,	the	Liu	et	al.	[74]	scheme	uses	a	combination	of	four	mPCRs	to	assign	33	
of	 the	35	originally	described	S.	suis	 serotypes	 to	 isolates	 (serotypes	32	and	34	were	excluded	
from	analyses	as	these	were	considered	by	the	authors	to	have	been	reassigned	to	Streptococcus	
orisratti).		The	first	mPCR	of	which	targets	the	serotypes	most	commonly	associated	with	clinical	
disease	 in	pigs	 (serotypes	1-10,	14	and	1/2),	 by	 targeting	 serotype-specific	differences	 in	 five	
	 12	
cps	genes	(I,	J,	K,	L	and	M)	using	a	total	of	ten	oligonucleotide	primer	pairs.		In	comparison,	the	
molecular	 serotyping	 scheme	 described	 by	 Okura	 et	 al.	 [75]	 uses	 just	 two	 mPCRs,	 an	 initial	




Most	 singleplex	 and	 mPCR	 assays	 designed	 to	 identify	 S.	suis	 serotypes	 have	 reported	
assignment	of	a	'serotype'	to	isolates	deemed	to	be	non-serotypable	using	antisera,	as	well	as	to	
isolates	 deemed	 to	 be	 truly	 non-encapsulated	 based	 on	 surface	 hydrophobicity	 and	 electron	
microscopy	[79,	80].		However,	even	with	the	use	of	molecular	'serotyping'	based	on	PCR	assays,	
non-serotypeable	 isolates	 are	 still	 commonly	 recovered	 from	 both	 clinically	 healthy	 and	






control	 of	 swine	 infections	 since	 different	 serotypes	 are	 prevalent	 in	 different	 geographic	
locales,	 and	 based	 on	 current	 data	 serotypes	 2	 and	 14	 are	 most	 strongly	 associated	 with	
zoonotic	 disease	 [17].	 	 However,	 neither	 traditional	 serotyping	 techniques	 nor	 molecular	
'serotyping'	can	discriminate	between	serotypes	1	and	14	or	between	serotypes	2	and	1/2,	as	
each	of	these	pairs	cross-react	in	vitro	and	are	also	inseparable	by	mPCR	due	to	the	similar	gene	
content	 of	 the	 respective	 cps	 loci.	 	 Recently,	 development	 of	 an	 automated	 pipeline	 has	 been	
shown	 to	 solve	 this	 three-decade	 longstanding	 S.	suis	 serotyping	 issue	 by	 using	 differential	
alignment	of	 short	 read	DNA	sequencing	data	 to	 a	 custom	built	cps	 loci	database,	 successfully	










gel	 electrophoresis	 (PFGE)	 [57,	 91-94],	 repetitive	 extragenic	 palindromic	 (REP)	 or	
enterobacterial	 repetitive	 intergenic	 consensus	 (ERIC)	 PCR	 [95-97],	 restriction	 endonuclease	
analysis	 [98-101]	 and	 ribotyping	 [102-106].	 	 Of	 these	 methods,	 PFGE	 has	 been	 shown	 to	 be	
highly	 discriminatory	 and	 reproducible	 [92,	 93],	 but	 is	 also	 laborious	 and	 time	 consuming.		
MLST	 has	 also	 been	 shown	 to	 have	 a	 high	 discriminatory	 power	 and	 high	 degree	 of	
reproducibility	but	is	difficult	to	apply	to	routine	diagnostic	testing.	 	In	fact,	each	approach	has	
its	own	limitations	either	requiring	large	amounts	of	sample	DNA,	which	is	labour	intensive	and	
cumbersome,	 or	 requiring	 high	 levels	 of	 technical	 competence	 and	 so	 these	 have	 been	
superceded	as	sequencing	technologies	have	become	more	accessible.	
	
It	 has	 been	 observed	 that	 S.	suis	 isolates	 recovered	 from	 clinically	 healthy	 animals	 are	 more	
heterogeneous	in	comparison	to	the	majority	of	isolates	recovered	from	cases	of	disease	in	pigs	
or	 humans	 [91,	 101,	 106].	 	 For	 example,	 most	 serotype	 2	 isolates	 recovered	 from	 cases	 of	
septicaemia	were	 found	 to	produce	 a	 common	 ribotype	 that	was	distinct	 from	heterogeneous	






An	 important	 observation	 of	 epidemiological	 studies	 using	 the	 aforementioned	 molecular	
techniques	 to	 characterise	 and	 sub-type	 S.	suis	 is	 many	 used	 a	 small	 sample	 size	 of	 isolates.		
	 14	
Furthermore,	 epidemiological	 studies	 have	 often	 been	 restricted	 to	 a	 single	 S.	suis	 serotype	
(more	 often	 than	 not	 serotype	 2	 [41])	 or	 single	 geographical	 locale,	 and	 use	 a	 variety	 of	






MLST	 is	 a	 simple	 and	 unambiguous	 procedure	 for	 characterising	 isolates	 of	 bacterial	 species	
using	the	sequences	of	internal	fragments	of	core	metabolic	(housekeeping)	genes	[107].		Since	
first	described,	using	Neisserria	meningitidis	(the	meningococcus;	also	a	highly	recombinogenic	
species)	 as	 a	model	 organism,	MLST	 has	 since	 been	 applied	 to	 numerous	 pathogenic	 species,	
including	 Staphylococcus	 aureus,	 Streptococcus	 pneumoniae	 and	 Streptococcus	 pyogenes	 [108-
110].	 	 There	 are	 two	 approaches	 to	 achieve	 high-levels	 of	 discrimination	 between	 bacterial	
strains	within	 a	 population.	 	 The	 approach	 employed	 by	more	 traditional	 techniques	 such	 as	
PFGE	 and	 ribotyping	 targets	 uncharacterised	 regions	 of	 the	 genome	 that	 are	 highly	 variable	
within	the	bacterial	population,	and	as	a	consequence	the	output	signal	is	complex	and	changes	
significantly	 over	 time	 as	 diversity	 in	 those	 regions	 progresses.	 	 The	 alternative	 approach,	
typified	by	multilocus	enzyme	electrophoresis	(MLEE),	uses	variation	that	is	accumulating	very	
slowly	 in	 the	population	 and	 that	 is	 likely	 to	be	 selectively	neutral.	 	 Although	 a	much	 smaller	
number	of	 alleles	 can	be	 identified	within	 the	population,	high	 levels	of	discrimination	can	be	
achieved	by	analyses	of	multiple	loci,	ideally	spread	across	the	genome.		MLST	is	an	adaptation	
of	 the	useful	and	proven	concepts	of	MLEE,	 identifying	diversity	of	alleles	 from	the	nucleotide	
sequences	 of	 internal	 fragments	 of	 housekeeping	 genes	 rather	 than	 by	 comparing	 the	
electrophoresis	motilities	of	the	enzymes	they	encode	[107].		The	advantage	of	MLST	over	other	





schemes	 have	 a	 number	 of	 loci	 in	 common,	 it	 has	 not	 proved	 possible	 to	 define	 a	 set	 of	 core	
metabolic	 genes	 that	 are	 universally	 applicable	 to	 a	wide	 range	 of	 bacterial	 pathogens	 [111].		
The	MLST	scheme	for	S.	suis	uses	specific	loci	of	the	following	seven	core	metabolic	genes:	aroA	
(encoding	 5-enolpyruvylshikimate	 3-phosphate	 synthase),	 cpn60	 (encoding	 a	 60	 kDa	
chaperonin),	 dpr	 (encoding	 a	 putative	 peroxide	 resistance	 protein),	 gki	 (encoding	 glucose	
kinase),	 mutS	 (encoding	 a	 DNA	 mismatch	 repair	 enzyme),	 recA	 (encoding	 homologous	
recombination	 factor)	 and	 thrA	 (encoding	 aspartokinase/homoserine	 dehydrogenase)	 [90].		
Originally	developed	using	294	 isolates	of	S.	suis,	a	 total	of	92	unique	sequence	types	(ST)	and	
three	major	ST,	or	clonal,	complexes	(ST1,	ST27	and	ST87)	were	defined.		ST1	complex	was	the	
largest	 (representing	 165	 of	 the	 original	 isolates	 studied)	 and	most	 strongly	 associated	 with	
classic	 S.	suis	 invasive	 diseases,	 including	 arthritis,	 meningitis	 and	 septicaemia	 [90].	 	 In	
comparison,	 ST27	 and	 ST87	 complexes	 were	 found	 to	 represent	 a	 significantly	 higher	
proportion	of	isolates	associated	with	pneumonia.		No	evidence	was	found	of	S.	suis	clones	with	
a	 preference	 to	 infect	 humans,	 in	 fact	 the	 authors	 speculated	 that	 the	 incidence	 of	 human	
infection	may	 simply	 follow	 the	 dominant	 clones	 in	 the	 local	 pig	 population	 [90].	 	 Isolates	 of	
many	of	the	most	common	serotypes	were	distributed	widely	across	the	MLST	dendrogram.		As	
well	as	highlighting	that	serotype	is	often	a	poor	indicator	of	genetic	relatedness	between	S.	suis	
isolates,	 these	 findings	 suggest	 that	 capsular	 genes	 may	 be	 moving	 horizontally	 through	 the	
S.	suis	population;	a	feature	that	might	be	responsible	for	the	change	in	most	prevalent	serotypes	
over	 time	 in	 certain	geographical	 locations	 [90].	 	The	horizontal	 spread	of	 capsular	 genes	has	
been	demonstrated	in	Streptococcus	pneumonia	[112],	where,	as	in	S.	suis,	capsular	genes	which	













spread	 around	 the	 world.	 	 MLST	 is	 a	 popular	 technique	 due	 to	 the	 ease	 of	 carrying	 out	 the	
technique	 and	 ability	 to	 share	 comparable	 information	 between	 laboratories,	 on	 the	 Internet	
(https://pubmlst.org/ssuis/),	before	peer	review.		The	repeated	finding	of	ST1	complex	isolates	
causing	 invasive	 disease	 indicates	 this	 ST	 defines	 strains	with	 an	 increased	 capacity	 to	 cause	
disease.		This	might	be	reflective	of	a	variety	of	factors	such	as	increased	fitness,	the	possession	
of	certain	virulence	factors	or	allelic	variants	thereof,	or	particular	antibiotic	resistance	profiles.		
Facts	 that	appear	 to	be	confirmed	by	 the	analysis	of	whole	genome	sequencing	data	of	strains	
belonging	to	ST1	and	ST27	complexes.		However,	the	MLST	of	20	S.	suis	isolates	recovered	from	
human	 cases	 of	 infection	 in	 Thailand	 assigned	 80%	 to	 the	 ST27	 complex	 [114].	 	 This	 is	 an	
interesting	 finding,	 as	 these	 isolates	 were	 recovered	 from	 the	 blood	 or	 cerebrospinal	 fluid	
suggesting	a	high	degree	of	invasiveness,	and	brings	into	question	the	proposed	lower	potential	
of	 ST27	 complex	 strains	 to	 cause	 invasive	 disease	 in	 swine.	 	 However,	 as	 mentioned	 above	





Minimum	 core	 genome	 (MCG)	 sequence	 typing	 is	 a	method	 only	 recently	 described	 for	S.	suis	
that	uses	 the	Bayesian	 clustering	 tool	STRUCTURE	 to	 establish	population	genetics-based	 sub-
divisions	for	strain	identification	and	typing	[115,	116].		MLST	has	become	the	preferred	method	
for	genotyping	many	biological	 species	due	 to	 its	ability	 to	 identify	major	phylogenetic	 clades,	




than	 characterise	 isolates	 based	 on	 the	 slowly	 accumulating	 variation	 in	 the	 aforementioned	
seven	 core	 metabolic	 (housekeeping)	 genes	 described	 for	 MLST	 [90],	 is	 one	 approach	 that	
exploits	 advances	 in	 next-generation	 sequencing	 and	 uses	 genomics	 derived	 data	 to	 identify	
novel	regions	of	the	core-genome	that	can	be	used	to	identify	and	type	S.	suis	into	"MCG	groups"	
that	can	later	be	associated	with	clinical	phenotypes.	 	A	total	of	ten	SNPs	distributed	across	six	
genes	 are	 required	 for	MCG	 sequence	 typing,	 including	 i)	 SSGZ1_0088	 (SNP	positions:	 81404,	















Ea	 1	 2	 3	 4	 5	 6	 7-1	 7-2	 7-3	 Nb	
2028696	 A	 G	 G	 G	 G	 G	 G	 G	 G	 G	 G	
2028744	 A	 A	 G	 G	 G	 G	 G	 G	 G	 G	 G	
824818	 T	 T	 C	 T	 T	 T	 T	 T	 T	 T	 T	
822644	 C	 C	 C	 T	 C	 C	 C	 C	 C	 C	 C	
107453	 A	 A	 A	 A	 G	 A	 A	 A	 A	 A	 A	
825000	 G	 G	 G	 G	 G	 A	 G	 G	 G	 G	 G	
81999	 G	 G	 G	 G	 G	 G	 T	 G	 G	 G	 G	
81404	 A	 A	 A	 A	 A	 A	 A	 G	 A	 A	 A	
81419	 T	 T	 T	 T	 T	 T	 T	 T	 G	 T	 T	






of	S.	suis,	 although	 the	 organism	 can	be	 recovered	 from	 the	 gastrointestinal	 and	 genital	 tracts	
[11].		Pigs	of	any	age	can	be	infected	with	S.	suis,	but	susceptibility	generally	decreases	with	age	
post	weaning	[59].		Broadly	speaking	serotypes	1-9	and	1/2	are	most	frequently	recovered	from	
diseased	pigs	worldwide,	 and	 serotypes	10-34	most	 likely	 to	 sub	 clinically	 colonise	 the	upper	





S.	suis	 is	 considered	 the	 incriminated	 haemolytic	 streptococci	 responsible	 for	 a	wide	 range	 of	
clinical	 manifestations,	 including	 septicaemia	 with	 sudden	 death,	 arthritis,	 endocarditis,	
meningitis,	 and	 pneumonia	 amongst	 other	 diseases	 [2-11].	 	 Other	 less	 common	 outcomes	 of	
S.	suis	 infection	 are	 also	 possible,	 including	 abortion,	 bronchopneumonia,	 pericarditis,	
polyserositis	 and	 rhinitis	 [11].	 	 The	most	 consistent	 clinical	 signs	of	 acute	 infection	 start	with	
anorexia,	depression,	fever,	lassitude	and	lateral	recumbency,	followed	by	symptoms	depending	





possible	 meningo-encephalitic	 lesions	 have	 been	 found	 during	 histopathological	 analyses	 [9,	
119].	 	In	cases	of	septicemia,	the	positive	detection	of	S.	suis	from	the	brain,	heart,	liver	and/or	
spleen	 is	 common,	 and	 inflammatory	 lesions	 are	 often	 found	 within	 organs	 (but	 without	 a	
typical	pattern	of	lesion)	[120].		Suppurative	or	fibrinopurulent	inflammation	of	the	brain,	heart,	
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disease,	 however,	 it	 is	 unclear	 whether	 S.	suis	 is	 responsible	 for	 pneumonia.	 	 S.	suis	 is	 often	
recovered	 from	 the	 respiratory	 tract	 in	 combination	 with	 other	 confirmed	 respiratory	
pathogens,	 including	 Actinobacillus	 pleuropneumoniae,	 Bordetella	 bronchiseptica,	 Haemophilus	
parasuis	and/or	Pasteurella	multocida	[120,	121].		Indeed,	concurrent	viral	infections	might	also	
predispose	pigs	to	infection	with	S.	suis,	including	Aujeszky's	disease	(Suid	herpesvirus),	porcine	
circovirus	 (PCV)	 and/or	 porcine	 reproductive	 and	 respiratory	 syndrome	 (PRRS)	 virus	 [122-
124].	 	 It	 has	been	 suggested	 that	S.	suis	 is	 an	opportunistic	pulmonary	pathogen,	 a	hypothesis	
supported	by	 the	 reported	difficulty	 to	 reproduce	observed	 clinical	 phenotypes	of	 respiratory	









occur	 later	 in	growing	pigs.	 	Vertical	 transfer	 from	sow	 to	piglet	occurs	during	parturition	via	
contamination	from	vaginal	colonisation,	or	shortly	after	during	suckling,	or	due	to	close	contact	
with	the	sow,	her	faeces,	and	the	surrounding	environment	[98,	125,	126].		It	has	been	proposed	
that	 once	 a	 pig	 is	 infected	 with	 S.	suis	 serotype	 2,	 it	 may	 remain	 a	 carrier	 for	 life	 [125].		













days.	 	S.	suis	 is	 also	able	 to	 survive	 in	dust	at	0	 ˚C	 for	up	 to	54	days	at	9	 ˚C	 for	up	 to	25	days;	
however,	 isolation	 from	dust	 incubated	 at	 room	 temperature	 (22-25	 ˚C)	 for	24	h	 failed	 [127].		
S.	suis	 viability	 is	 also	 retained	 in	 rotting	 pig	 carcasses	 stored	 at	 4	 ˚C	 for	 six	 weeks	 and	 in	




The	biological	mechanisms	 that	 lead	 to	a	diseased	 state	 in	pigs	 (and	 in	humans)	due	 to	S.	suis	
infection	 are	 not	 well	 understood.	 	 Hampered	 by	 the	 controversial	 definition	 of	 virulent	 and	
avirulent	 strains,	most	 studies	 on	 pathogenesis	 of	 infection	 have	 been	 carried	 out	with	 S.	suis	
serotype	2	strains	[41].	 	A	well-documented	invasive	pathogen,	S.	suis	 is	also	considered	a	very	
successful	coloniser	of	mucosal	surfaces	and	thought	to	be	able	to	colonise	the	palatine	tonsils	of	








laryngeal	 epithelial	 cell	 line	 of	 human	 origin	 [132].	 	 However,	 invasion	 of	 epithelial	 cells	 is	
controversial	since	adhesion	but	failure	to	invade	epithelial	cells	has	been	reported	in	studies	of	
other	 epithelial	 cell	 lines	 using	 virulent	 strains	 of	 S.	suis	 [133],	 although	 importantly	 both	 the	






early	 “Trojan	 horse	 theory”	 suggested	 that,	 in	 the	 absence	 of	 specific	 antibodies,	 S.	suis	 is	
phagocytosed	 by	 monocytes	 and	 transits	 the	 bloodstream	 intracellularly	 crossing	 the	 blood-
brain	barrier	 inside	monocytes	 [136,	137].	 	However,	 subsequent	 studies	 in	numerous	groups	




















other	additional	 factors	also	capable	of	 contributing	 to	 the	development	of	a	diseased	state	 in	
pigs.	 	 S.	suis	 emerged	 as	 an	 important	 bacterial	 pathogen	 early	 in	 the	 20th	 Century	 alongside	
intensification	 of	 the	 swine	 industry	 [11,	 141].	 	 S.	suis	 has	 been	 reported	 worldwide	 in	 both	
traditional	 backyard	 and	modern	 intensive	 swine	 operations,	 and	 as	with	 other	 bacterial	 and	
viral	 infections,	 stress	 can	 precipitate	 S.	suis	 infection.	 	 Crowding,	 poor	 ventilation,	 sudden	
weather	 change,	 mixing,	 moving,	 vaccination	 and	 concurrent	 disease	 are	 all	 stresses	 that	
predispose	 pigs	 to	 S.	suis	 infections	 [142].	 	 Understanding	 and	 the	 control	 of	 these	 individual	





predisposing	 factors	 of	 S.	suis	 infection	 [143].	 	 Control	 of	 the	 environment	 and	 stress	 factors	
such	 as	 moving	 and	 mixing,	 (decreasing)	 population	 density	 and	 (increasing)	 ventilation,	
coupled	with	an	all-in/all-out	system	of	housing	-	with	adequate	cleaning	and	drying	of	rooms	





been	 used	 to	 improve	 the	 health	 status	 of	 pig	 populations	 and	 to	 eliminate	 some	 infectious	
organisms,	but	proven	 ineffective	 for	 the	elimination	of	S.	suis	 carriage	 [95,	143,	144].	 	 In	 fact,	
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S.	suis	 has	 been	 recovered	 from	 the	 palatine	 tonsils	 of	 pigs	 in	 the	 presence	 of	 circulating	
antibodies	 in	 the	 bloodstream,	 as	well	 as	 in	 pigs	 receiving	 penicillin	 via	 feed.	 	 Such	 a	 finding	





the	use	of	 antimicrobial	 agents	has	become	 increasingly	 important	 in	 treating	 and	 controlling	
the	 various	 clinical	 manifestations	 caused	 by	 S.	suis	 infection.	 	 Numerous	 studies	 have	
investigated	 the	 antimicrobial	 susceptibility	 of	S.	suis	 strains	 recovered	 from	diseased	 [21,	 22,	
145-152]	 and	 clinically	 healthy	 pigs	 [145,	 147,	 152-155]	 in	 different	 countries,	 reporting	
differences	 in	 the	 level	 of	 resistance	 and	 susceptibility	 to	 antimicrobials	 between	 countries,	




In	 general,	 S.	suis	 is	 sensitive	 to	 the	 inhibitory	 effects	 on	 bacterial	 cell	wall	 biosynthesis	 of	β-
lactam	antibiotics,	a	feature	that	has	led	to	the	prophylactic	use	of	this	broad-spectrum	group	of	
antibiotics	at	periods	of	high	risk	such	as	weaning.	 	Clinically	 infected	pigs	are	usually	 treated	
with	 ampicillin	 or	 benzylpenicillin	 (penicillin	 G),	 although	 most	 S.	suis	 isolates	 are	 also	
susceptible	to	amoxicillin,	ceftiofur,	cefquinome,	cephalexin,	enrofloxacin	and	florfenicol	[21,	22,	
146,	 147,	 149,	 156,	 157].	 	 As	 in	 humans	 the	 host	 inflammatory	 response	 against	 bacterial	
infection	 may	 be	 detrimental	 in	 some	 cases	 and	 adjunctive	 therapy	 with	 anti-inflammatory	
agents	is	recommended	for	treatment	of	S.	suis	meningitis	in	pigs.	
	
β-lactam	antibiotics	other	 than	 cephalosporins	 (ceftiofur	 and	 cefquinome,	 antibiotics	 reserved	
for	use	only	as	a	 last	resort	by	the	UK’s	Pig	Veterinary	Society),	especially	penams	(ampicillin,	
amoxicillin,	penicillin)	are	considered	 the	 first	option	 to	 treat	S.	suis	 related	disease	 in	 the	UK.		
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varying	 levels	 of	 resistance	 to	 clindamycin,	 erythromycin,	 gentamycin,	 kanamycin,	
spectinomycin,	sulfisoxazole,	 tetracycline,	 tilmicosin	and	trimethoprim/sulfamethoxazole	[152,	
154,	 160].	 	 Variations	 in	 antimicrobial	 usage	 from	 one	 country	 to	 another,	 variations	 in	
laboratory	methodologies	or	variations	 in	 the	 serotypes	 tested	may	all	 contribute	 to	apparent	
differences	in	antibiotic	susceptibility.		A	major	point	of	concern	is	the	relatively	high	proportion	






to	 suggest	 that	 these	 emerging	 rates	 of	 resistance	might	 be	 explained	 by	 the	 intensive	 use	 of	
macrolides	and	tetracycline	[21].		Whether	this	suggestion	is	also	valid	for	S.	suis	strains	isolated	




(negative	 or	 positive)	 in	 S.	suis	 resistance	 to	 amoxicillin,	 penicillin	 or	 amoxicillin/clavulanate	





Reports	 based	 on	 routine	 surveillance	 that	 describe	 the	 isolation	 of	 only	 a	 small	 number	 of	
penicillin-resistant	 S.	suis	 isolates	 since	 2009	 with	 no	 evidence	 of	 an	 increasing	 trend	 in	
penicillin	MIC’s	[161].		However,	the	presence	of	resistant	and	intermediate	strains	to	penicillin	





S.	suis	 infections.	 	 Indeed,	 in	 (1966)	 early	 studies	 Elliot	 et	al.	 [31]	 showed	 that	 the	 transfer	 of	
serum	 from	 convalescent	 piglets	 provided	 other	 pigs	 with	 complete	 protection	 against	
homologous	challenge	with	S.	suis	serotype	2	infection,	indicating	that	some	S.	suis	antigens	are	
able	to	provoke	a	specific	immune	response	that	is	capable	of	preventing	subsequent	infection.		
However,	despite	ever	 increasing	approaches	and	studies	no	effective	vaccine	 is	available	 that	
can	protect	 against	 all	S.	suis	 infections	 in	pigs	or	 in	humans	 regardless	of	 serotype	 [11,	 162].		
Numerous	reasons	hamper	 the	development	of	effective	vaccines,	 including	but	not	 limited	to,	
the	number	of	existing	serotypes,	variation	in	virulence	seen	both	among	and	within	serotypic	






Whole	 cell	 vaccines	 (bacterins)	 can	 be	 split	 into	 two	 groups,	 i)	 inactivated	 and	 ii)	 live,	
attenuated.		Autogenous	bacterins,	prepared	from	the	virulent	strain	of	S.	suis	isolated	on	a	farm	
with	clinical	problems	and	then	applied	to	the	same	farm,	are	frequently	used	in	the	field	[165-
167].	 	 However,	 in	 comparison	 to	 experimental	 and	 commercial	 bacterins,	 limited	 (if	 any)	
vaccine	safety	data	is	produced	for	autogenous	bacterins	and	severe	adverse	reactions	can	occur	
[168,	 169].	 	 Inactivated	 vaccines	 are	 produced	 by	 killing	 the	 disease-causing	 agent	 with	
chemicals,	heat	or	radiation	resulting	in	a	safe	and	stable	microbe	that	cannot	revert	back	to	a	
disease-causing	 state.	 	 Inactivated	 (killed)	 whole-cell	 vaccines	 seem	 to	 induce	 significant	
protection	against	challenge	with	a	homologous	S.	suis	 strain,	but	 the	protection	appears	 to	be	
serotype	specific	and	inconsistent.	 	For	example,	a	formalin-killed	pathogenic	S.	suis	serotype	2	
bacterin	 has	 been	 shown	 to	 stimulate	 a	 complete	 protective	 response	 against	 homologous	
challenge	in	piglets	-	although,	did	require	very	high	doses	(~109)	of	formalin-killed	bacterins	or	
repeated	 intravenous	 injections	 to	 induce	 protection	 (and	 could	 not	 be	 repeated	 using	 heat-
killed	 organisms)	 [170].	 	 In	 contrast,	 later	 studies	 of	 formalin-killed	 bacterins	 found	 no	
significant	effect	on	the	production	of	specific	antibodies	in	vaccinated	piglets,	and	the	absence	
of	 passive	 protection	 against	 homologous	S.	suis	 serotype	 2	 challenges	 in	mice	 [140].	 	 Results	
obtained	 from	 experimental	 infection	 challenges	 were	 paralleled	 by	 field	 studies	 of	 a	
commercial	 serotype	 2	 bacterin	 that	 also	 failed	 to	 protect	 against	 nursery	 mortality	 among	








Strong	 humoral	 immunity	 in	 piglets	 has	 been	 induced	 following	 challenge	 with	 live	 S.	suis	
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serotype	 9	 bacteria,	 despite	 other	 piglets	 presenting	 no	 detectable	 specific	 antibody	 response	
after	 bacterin	 immunisation	 [173].	 	 As	 a	 result,	 of	 this	 and	 other	 similar	 observations	 it	 was	
suggested	 that	 a	 single	dose	of	 live	 either	pathogenic	or	non-pathogenic	S.	suis	 could	 induce	a	
strong	 protective	 response	 against	 subsequent	 challenge	 with	 homologous	 strains	 [123,	 139,	




serotype	1/2	mutant	 that	 also	provided	protection	 to	 challenge	with	 serotype	1	and	2	 strains	
[174].		In	addition,	the	potential	of	a	streptomycin-dependent	mutant	of	S.	suis	serotype	1/2	has	
also	been	evaluated	in	mice	as	a	vaccine	candidate,	where	homologous	and	heterologous	trials	
resulted	 in	 complete	within	 serotype	protection	against	 challenge	with	S.	suis	serotypes	1	 and	
1/2	but	only	partial	protection	was	observed	against	a	challenge	with	S.	suis	serotype	2	strains	






whole	 cell	 inactivated	 or	 live	 attenuated	 bacteria	 (bacterins).	 	 A	 subunit	 vaccine	 based	 on	
purified	 suilysin	 (see	 section	1.1.3.1.2)	has	been	 shown	 to	protect	 pigs	 against	 challenge	with	
virulent	 S.	suis	 serotype	 2	 strains	 [176].	 	 However,	 the	 absence	 of	 suilysin	 in	 a	 substantial	
number	 of	 isolates	 recovered	 from	 diseased	 pigs	 limits	 the	 value	 of	 this	 vaccine	 [177].		






this	 subunit	 vaccine	 [11].	 	 In	 addition,	 a	 multitude	 of	 putative	 protective	 candidates	 for	
vaccination	 against	 S.	suis	 infection	 have	 been	 reported	 by	 several	 research	 groups,	 using	





[125,	 127].	 	 Indeed,	 chlorhexadine,	 formaldehyde,	 5%	 hypochlorite,	 3%	 iodine,	 phenol	 and	
quaternary	ammonium	have	all	been	shown	to	be	effective	disinfectants	against	S.	suis,	although	




S.	suis	 is	 a	 zoonotic	 pathogen	 that	 causes	 similar	 clinical	manifestations	 in	 humans	 as	 in	 pigs.		
Purulent	or	non-purulent	meningitis	is	most	common	clinical	symptom,	followed	by	sepsis	and	
septic	shock	[16,	17,	162,	183,	184].	 	In	humans,	other	clinical	manifestations	include	cellulitis,	
endocarditis,	 endophtalmitis,	 pneumonia,	 rhabdomylysis	 and	 uveitis	 [184].	 	 Arthritis	 is	 also	
common,	affecting	elbows,	hips,	 the	sacroiliac	 joint,	 the	spine,	 thumbs	and	wrists,	and	 in	most	
cases	 is	 thought	 to	reflect	generalised	septicaemia	 [185].	 	Some	 instances	of	meningitis	due	to	
S.	suis	infection	lead	to	sequela	such	as	hearing	loss	and	vestibular	dysfunction	[186,	187].	 	For	
unknown	reasons,	the	recorded	incidence	of	hearing	loss	due	to	S.	suis	 infection	is	consistently	
higher	 than	 in	patients	with	meningitis	due	 to	other	bacterial	 infections,	 such	as	Haemophilus	
influenza,	 Neisseria	meniningitidis	 and	 Streptococcus	 pneumonia,	 reaching	 50%	 in	 Europe	 and	
60%	in	Asia	[188-190].		In	addition,	septicaemia	with	streptococcal	toxic	shock	syndrome	(STSS)	
has	been	documented	as	a	 feature	of	an	 important	outbreak	of	acute	 infection	 in	China	during	
2005	(see	section	1.1.2.2.1).		However,	STSS	[191,	192]	had	not	(nor	since)	been	reported	due	to	
S.	suis	 infection,	 although	 has	 been	 described	 in	 invasive	 and	 non-invasive	 group	 A	
(Streptococcus	pyogenes)	[193]	and	Staphylococcus	aureus	[194,	195]	infections.	
	
In	 general,	 human	 S.	suis	 infection	 is	 considered	 a	 rare	 and	 sporadic	 event	 associated	 with	
prolonged	exposure	to	pigs	or	pork-derived	products	[190].		Most	cases	of	human	infection	are	
reported	in	adult	male	dominated	professions,	such	as	abattoir	workers,	butchers,	pig	farmers,	
meat	 inspectors	and	veterinary	practitioners	[11].	 	Since	the	 first	human	case	was	reported	 in	
Denmark	 in	 1968	 [12],	 in	 the	 region	 of	 ~1600	 human	 cases	 of	 S.	suis	 infection	 have	 been	
reported	in	European	(Austria	[196],	Belgium	[197],	Croatia	[198],	France	[199-203],	Germany	
[187,	 204-207],	 Greece	 [208-210],	 Hungary,	 Ireland	 [211],	 Italy	 [212-215],	 the	 Netherlands	
[190,	 216],	 Poland	 [217,	 218],	 Portugal	 [219,	 220],	 Spain	 [58,	 221-224],	 Sweden	 [225],	 the	
Untied	 Kingdom	 [186,	 226-235])	 and	 Asian	 countries	 (China	 [183,	 236-238],	 Hong	 Kong	 [14,	
158,	 239-242],	 Japan	 [243],	 Korea	 [244],	 Madagascar	 [245],	 Malaysia	 [246],	 Singapore	 [247-




diagnosed	 or	 misdiagnosed	 [17].	 	 Surprisingly,	 no	 cases	 have	 yet	 been	 reported	 in	 Russia,	 a	
country	with	an	increased	and	developing	pig	production	[17].	 	However,	S.	suis	 is	 increasingly	







markets	 has	 been	 found	 to	 be	 contaminated	with	 S.	suis	 [241,	 280])	 and	 consume	 "high-risk"	
lightly	cooked	pork	derived	products	[162,	281].	
	
In	humans,	 the	 route	of	S.	suis	 entry	 into	 the	 cardiovascular	 system	 is	 unclear.	 	Under	natural	
conditions,	 pigs	 are	 considered	 to	 be	 infected	 with	 S.	suis	 serotype	 2	 via	 the	 mucosae	 of	 the	
nasopharynx	and	 the	palatine	 tonsils,	whereas	humans	may	be	 infected	via	 small	 skin	 lesions,	
such	 as	 occupational	wounds	 [190].	 	 Popular	 opinion	 suggests	 entry	 to	 the	 cardiovascular	 or	
lymphatic	system	is	most	probably	through	lesions	in	the	skin,	however,	in	some	cases	wounds	
are	 not	 always	 obvious	 [162].	 	 S.	suis	 may	 colonise	 the	 nasopharynx,	 as	 well	 as,	 the	









pigs	 [53,	 178].	 	 It	 is	 difficult	 to	 understand	why	 isolates	 recovered	 from	 humans	 are	 weakly	









and	 39	 deaths	 were	 attributed	 to	 the	 outbreak	 across	 12	 prefectures	 and	 203	 villages;	 far	
exceeding	 the	 ten	 cases	 of	 meningococcal	 meningitis	 expected	 per	 month	 based	 on	 routine	





slaughter	 and	 consumption	 of	 sick	 pigs	 through	provincial	 legislation,	 that	was	 enforced	with	






The	 Sichuan	 outbreak	 in	 2005	 is	 the	 largest	 reported	 outbreak	 of	 severe	 acute	 disease	 in	
humans	 attributed	 to	 S.	suis	 (attracting	 worldwide	 news	 coverage)	 surpassing	 a	 previous	
outbreak	that	took	place	in	the	eastern	Chinese	province	of	Jiangsu	in	1998.		Killing	14	of	the	25	
human	 patients	 and	 responsible	 for	 the	 death	 or	 culling	 of	 80,000	 pigs	 [236]	 little	 is	 known	






the	bacterium.	 	As	described	 in	pigs	 the	 tonsil	 is	a	common	carriage	site,	although	recovery	of	
viable	isolates	from	the	anal	flora,	genital	tract	and	intestine	is	possible	[11].		Isolation	from	cats	
and	dogs	 [288-290],	hamsters	 [291],	horses	 [26,	290,	292],	wild	boar	 [293,	294],	wild	 rabbits	
[295]	 and	 ruminants	 including	 calves,	 deer	 and	 lambs	 [44],	 as	 well	 as,	 birds	 [296]	 raise	 the	
importance	 of	 these	 animals	 as	 reservoirs	 in	 infections	 of	 pigs	 and	 humans.	 	 Indeed,	 the	
prevalence	of	S.	suis	 in	wild	boar	 (Sus	scrofa	ferus)	 and	wild	 rabbits	 (Oryctolagus	cuniculus;	 an	
animal	 species	 far	 from	 pigs)	 is	 of	 particular	 importance	 regarding	 human	 infection,	 as	
numerous	reports	of	hunters	and	poachers	infected	with	S.	suis	after	slaughtering	wild	animals	






in	 other	 Gram-positive	 organisms	 has	 been	 shown,	 through	 targeted	 mutagenesis	 studies,	 to	
influence	the	virulence	of	S.	suis	strains	[299-301].		Virulence	and	virulence-associated	factors	in	
S.	suis	(summarised	in	Table	1.3)	have	been	the	subject	of	a	number	of	comprehensive	reviews,	
one	 in	 particular	 by	 Fittipaldi	 et	 al.	 in	 2012	 [129].	 	 Indeed,	 the	 increasing	 severity	 of	 human	
infections,	 including	 a	 shorter	 incubation	 time,	 more	 rapid	 disease	 progression	 and	 a	 higher	








as	 the	 relative	 ability	 to	 cause	 harm	 to	 the	 natural	 host,	 but	 discrepancies	 in	 the	 clinical	
outcomes	of	challenge	studies	have	been	reported	for	the	same	strains	of	S.	suis	[54,	305,	306].		
This	 feature	 is	 presumably	 due	 to	 differences	 in	 experimental	 design,	 pathogenicity	 being	 a	
quantitative	 trait	 with	 influences	 of	 pathogen	 genetics,	 host	 genetics	 and	 the	 environment.		
Indeed,	 it	 could	 equally	 be	 a	 product	 of	 important	 discrepancies	 existing	 in	 the	 concept	 of	
virulence	between	research	groups.	 	For	example,	different	studies	have	designated	S.	suis	field	
strains	as	virulent	or	avirulent	based	on	 i)	 the	observed	clinical	phenotype	of	pigs	 from	which	
the	 isolate	 was	 recovered	 (loosely	 grouped	 as	 diseased	 or	 clinically	 healthy	 animals),	 ii)	 the	
positive	 detection	 of	 virulence-associated	 proteins	 or	 iii)	 the	 use	 of	 different	 experimental	
challenge	 models;	 using	 different	 murine	 models,	 or	 pigs	 of	 different	 ages	 from	 either	




Curiously,	 the	positive	detection	of	some	proposed	virulence	factors	 in	S.	suis	 isolates	does	not	
necessarily	 define	 an	 isolate	 as	 virulent	 [129].	 	 In	 fact,	 some	 isolates	 detecting	 positive	 for	 a	
specific	virulence	factor	are	avirulent	while	other	isolates	devoid	of	the	same	factor	are	still	able	
to	 cause	 disease	 [129].	 	 The	 bacterial	 virulence-associated	 factors	 extracellular	 factor	 protein	













































































































































































































Since	 the	 early	 1990s	 and	 for	 several	 years	 thereafter,	 the	 capsular	 polysaccharide,	 the	 thiol-
activated	 haemolysin	 known	 as	 suilysin,	 and	 the	 two	 proteins	 extracellular	 factor	 and	
muramidase-released	protein	were	considered	the	most	important	virulence-associated	factors	
of	 S.	suis,	 resulting	 in	 the	 incorporation	 of	 serotyping	 and	 virulence-associated	 gene	 profiling	
into	 the	 routine	 diagnosis	 procedure	 for	 S.	suis	 [11,	 131].	 	 Although	 the	 exact	 contribution	 of	






is	 an	 important	 virulence	 factor	 [76,	 305].	 	 The	 capsular	 polysaccharide	 (CP)	 is	 recognised	 to	





with	 increased	 hydrophobicity	 of	 S.	suis,	 and	 increased	 phagocytosis	 by	murine	macrophages	
and	both	porcine	macrophages	[76,	305]	and	neutrophils	[322].	 	As	a	result,	non-encapsulated	





central	nervous	 system,	 joints	 and	 serosa	using	 an	 intranasal	 experimental	model	 of	 infection	





Cell	wall	 components	 of	S.	suis	 induce	 a	 significant	 release	 of	 host	 proinflammatory	 cytokines	
(TNF-α,	IL-1β	and	IL-6)	and	chemokines	(IL-8).		It	is	thought	that	the	CP	reduces	the	production	
of	such	cytokines	by	blocking	the	 interaction	of	cell	wall	components	with	pattern-recognition	
receptors	 such	as	Toll-like	 receptor	2	 [138,	382,	383].	 	 Isolates	of	S.	suis	 serotype	2	 recovered	
from	 diseased	 pigs	 have	 been	 reported	 to	 possess	 thicker	 capsule	 in	 comparison	 to	 isolates	




enters	 the	 bloodstream	 [41].	 	 However,	 other	 studies	 have	 been	 unable	 to	 reproduce	 any	
correlation	between	thickness	of	the	capsular	material	and	virulence	[11].		S.	suis	serotype	2	is	





be	 due	 to	 the	 composition	 of	 the	 capsular	material	 itself,	which	 contains	N-acetyl	 neuraminic	
acid	 (sialic	 acid).	 	 Sialic	 acid	 has	 been	 proposed	 as	 an	 important	 virulence	 factor	 for	 several	




to	 harbour	 the	 genes	 involved	 in	 sialic	 acid	 synthesis	 [77].	 	 Surface-associated	 sialic	 acid	
contributes	 to	 adhesion	of	S.	suis	 serotype	2	 isolates	 to	murine	macrophages,	 an	 adhesion	not	
accompanied	 by	 phagocytosis	 [138].	 	 As	 a	 result,	 the	 "modified	 Trojan	 horse	 theory"	 was	
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Suilysin	 (SLY)	 is	 a	 pore-forming	 thiol-activated	 cholesterol-dependant	 cytolysin,	 similar	 in	




vitro,	 SLY	 is	 an	 extracellular	 protein	 produced	 in	 the	 culture	 supernatant	 at	 the	 end	 of	 the	
exponential	growth	phase,	peaking	around	15	-	24	h.		Haemolysis,	in	haemolytic	units	per	mg,	is	
comparable	 to	 listeriolysin	O	and	pneumolysin,	and	 is	completely	 inhibited	by	 free	cholesterol	
[367,	 368].	 	 As	 with	 other	 thiol-activated	 toxins,	 haemolysis	 is	 significantly	 increased	 when	
incubated	with	 a	 reducing	 agent,	 such	 as	 Dithiothreitol	 (DTT).	 	 Indeed,	 treatment	 of	 cell-free	
supernatant	with	oxygen	significantly	reduces	haemolytic	activity,	but	 is	 fully	 reversible	when	




Thiol-activated	 toxins	 are	 produced	by	 several	 genera	 of	 pathogenic,	 primarily	Gram-positive,	
bacteria	 that	 cause	 very	 different	 diseases,	 and	 as	more	 information	 becomes	 available	 about	
their	 role	 as	 important	 virulence	 factors	 it	 is	 apparent	 that	 their	 effects	might	 be	much	more	
subtle	 than	simple	destruction	through	pore	 formation	[388].	 	First	purified	and	characterised	
from	 European	 virulent	 reference	 strains	 P1/7	 [367,	 391]	 and	 Henrichsen	 S735	 [368],	 SLY	
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haemolysis	was	associated	with	the	pathogenic	attributes	of	these	isolates.	 	However,	although	
described	 in	 pathogenic	 strains	 across	 an	 extensive	 number	 of	 serotypes	 in	 Europe	 [392],	 an	
equivalent	number	of	other	virulent	strains,	including	many	North	American	serotype	2	isolates	
[80,	 393],	 were	 shown	 not	 to	 produce	 SLY;	 indicating	 SLY	 may	 not	 play	 a	 critical	 role	 in	
virulence	 [302,	 394].	 	 Numerous	 studies	 using	 SLY	 isogenic	mutants	 and	 ST104	 strains,	 with	
reduced	SLY	production	due	to	two	nucleotide	 insertions	 in	the	sly	promoter	[395],	have	been	
used	to	understand	the	actual	role	of	SLY	in	virulence	but	the	results	are	inconclusive.		Indeed,	
murine	 intraperitoneal	 infection	 model	 experiments	 show	 SLY	 has	 an	 unequivocal	 role	 in	





well	 as,	 being	 shown	 to	 have	 antiphagocytic	 and	 antibactericidal	 properties	 directed	 against	
neutrophils	and	macrophages/monocytes	[322,	399].		In	summary,	SLY	cannot	be	considered	a	







properties	 of	 S.	suis	 serotype	 2	 isolates	 in	 newborn	 germfree	 pigs	 [52,	 178].	 	 To	 date,	 the	







The	 110	 kDa	 EF	 protein	 (encoded	 by	 the	 gene	 epf)	was	 identified	 due	 to	 its	 association	with	
virulent	serotype	1	and	serotype	2	strains	in	newborn	germfree	pigs	[178].		To	date,	the	function	
of	EF	is	still	unknown.		Isogenic	epf	mutants	of	serotype	1	and	2	strains	have	been	shown	to	be	
as	 virulent	 as	 the	 parental	 wild-type	 strain	 in	 experimental	 infections	 indicating	 that	 EF	 is	
associated	 but	 not	 essential	 for	 virulence	 [330].	 	 Large	 molecular	 weight	 (EF*;	 >110	 kDa)	
variants	 of	 EF	 are	 expressed	 by	 some	 serotype	 2	 strains,	 and	 are	 characterised	 by	 long	 C-
terminal	 tandem	 repeats	 (each	 76	 amino	 acids	 long).	 	 Based	 on	 the	 number	 of	 repeated	
sequence	 five	different	classes	of	EF*	proteins	have	been	differentiated	 [329].	 	Monoplex-	and	
multiplex-PCR	 assays	 are	 available	 for	 differentiation	 of	 the	 different	 size	 variants	 of	 epf	 [68,	




phase	 sera	 from	 animals	 infected	 either	 with	 MRP+	 EF+	 or	 MRP+	 EF*	 serotype	 2	 strains	
generally	 contain	 high	 antibody	 titers	 against	 EF	 [401].	 	 Immunisation	with	 EF	 alone	 did	 not	
elicit	protection	against	MRP+	EF+	serotype	2	experimental	 infection	challenges,	but	a	vaccine	
containing	 purified	MRP	 and	 EF	 together	with	 a	water-in-oil	 adjuvant	was	 as	 protective	 as	 a	
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pigs)	 serotype	 2	 strains	 after	 treatment	 with	 muramidase	 (lysozyme)	 [178].	 	 MRP	 is	
predominantly	 present	 in	 protoplast	 supernatant.	 	 Sequence	 analysis	 of	 the	 3771	 bp	 gene	
encoding	 MRP	 (mrp;	 SSU0706)	 and	 corresponding	 1256	 amino	 acid	 sequence	 revealed	 an	






been	 described,	 such	 as	 the	M	 protein	 in	 group	A	 streptococci	 that	 is	 an	 important	 virulence	
factor	as	only	M	protein-positive	 strains	 resist	phagocytosis	 and	adhere	 to	humans	cells	 [402,	
403].	 	The	N-terminal	of	MRP	shares	some	similarity	(17.2%	across	377-amino	acids)	with	the	
sequence	of	the	fibrinogen-binding	protein	of	Staphylococcus	aureus	[404],	although	the	binding	
of	MRP	to	human	fibrinogen	could	not	be	detected	[345].	 	However,	 in	contrast	 to	the	original	
finding	more	 recent	 studies	 indicate	MRP	can	 in	 fact	bind	 to	 the	blood	protein	 fibrinogen	and	
this	could	be	an	essential	step	in	the	development	of	S.	suis	meningitis	[405,	406].	
	
Large	 (MRP*;	 >136	 kDa)	 and	 small	 (MRPS;	 <136	 kDa)	 molecular	 weight	 variants	 have	 been	
described	[400].		Duplication	of	162	bp	units	of	repetitive	sequence	present	in	mrp	encoding	for	
the	 136	 kDa	 protein	 is	 responsible	 for	 the	 larger	 size	 of	 MRP*	 [345].	 	 The	 variability	 of	 the	
number	of	repeats	 found	among	the	different	mrp	variants	 is	reminiscent	of	 the	mechanism	of	
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size	variation	in	other	streptococcal	surface-associated	proteins,	such	as	SfbI	[407].		In	contrast,	
MRPS	 is	 found	 in	 culture	 supernatant	 and	 thought	 to	 be	 due	 to	 MRP	 breaking	 from	 the	
peptidoglycan	 layer	 during	 growth	 of	 bacteria,	 resulting	 in	 unbound	 MRP	 in	 the	 culture	
supernatant	that	has	a	 lower	molecular	weight	 than	bound	MRP	in	the	protoplast	supernatant	
[178].		Due	to	the	correlation	of	MRP	with	virulence,	despite	the	role	of	MRP	remaining	unclear,	
the	 determination	 of	 mrp	 genotype	 (or	 the	 respective	 phenotype)	 has	 been	 performed	 in	
numerous	epidemiological	studies	[400,	408,	409],	and	is	now	included	in	the	routine	diagnosis	
of	 S.	suis	 in	 several	 laboratories	 [131].	 	 No	 difference	 in	 virulence	was	 seen	 between	 isogenic	






This	 review	 of	 virulence	 factors	 so	 far	 focuses	 on	 four	 "classical	 virulence	 factors"	 for	 S.	suis,	
including	the	CP,	the	thiol-activated	haemolysin	known	as	SLY,	and	the	two	virulence-associated	
proteins	 EF	 and	MRP.	 	 In	 fact,	 a	 wide	 range	 of	 homologs	 of	 virulence	 factors	 found	 in	 other	
Gram-positive	 organisms	 has	 been	 shown	 to	 affect	 the	 virulence	 of	 S.	suis	 strains	 through	




fibrinogen/fibrinogen-binding	 proteins	 [180,	 332,	 419-421].	 	 All	 have	 been	 the	 subject	 of	 a	








virulence	 potential	 of	 S.	suis	 isolates	 [302-304].	 	 At	 present,	molecular	markers	 are	 unable	 to	
distinguish	 virulent	 isolates	 of	 S.	suis	 from	 avirulent	 commensal-like	 isolates,	 emphasising	 the	
need	for	better	disease-associated	genomic	markers	and/or	animal	models	to	quickly	assess	the	
virulence	potential	 of	different	 isolates.	 	One	of	 the	most	 commonly	used	models	 for	 studying	
microbial	 infections	 is	 the	 rodent	 (mice	 and	 rats)	 model.	 	 However,	 as	 with	 pigs,	 there	 are	
budgetary,	 ethical	 and	 logistical	 hurdles	 associated	with	 rodents	 as	 infection	models.	 	 Firstly,	
maintaining	 a	 sufficient	 number	 of	 animals	 required	 to	 generate	 statistically	 relevant	 data	 is	
expensive	 and	 often	 regarded	 as	 ethically	 objectionable.	 	 Secondly,	 mammals	 have	 lengthy	
reproduction	times,	which	slow	the	progress	of	experiments.		The	3Rs	(Replacement,	Reduction	
and	Refinement)	are	increasingly	seen	as	a	framework	for	conducting	high	quality	science	in	the	
academic	 and	 industrial	 sectors	 with	 more	 focus	 on	 developing	 alternative	 approaches	 that	
avoid	 the	 use	 of	 animals	 [422].	 	 It	 is	 therefore	 useful	 to	 contemplate	 alternative	 invertebrate	
models,	 if	 these	 can	 be	 shown	 to	 yield	 useful	 data.	 	 As	 a	 result,	 invertebrate	 hosts,	 such	 as	
Caenorhabditis	elegans,	Danio	rerio,	Drosophila	melanogaster	and	Galleria	mellonella	larvae,	have	
been	 introduced	as	alternative	in	vivo	models	 to	study	microbial	 infections.	 	Such	models	have	




Certainly,	 the	 pig	 remains	 the	most	 valuable	 experimental	model	 of	 infection	 [302].	 	 Popular	
opinion	 considers	 field	 isolates	 of	 S.	suis	 to	 breach	 the	 mucosal	 epithelium	 in	 the	 upper	
respiratory	tract	of	pigs	(see	section	1.1.2.1.4).		However,	it	has	proved	challenging	to	replicate	
clinical	disease	using	natural	routes	of	exposure	producing	consistent	and	reproducible	results.		
As	 a	 result,	 a	 number	 of	 models	 have	 been	 developed	 where	 bacteria	 are	 inoculated	 i)	
intraperitoneally	 [425],	 ii)	 intravenously	 [426],	 iii)	 intranasally	 [52,	 53]	or	 iv)	 subcutaneously	
[427].	 	However,	as	with	other	well-established	experimental	models	of	 infection	variations	 in	
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that	are	highly	prevalent	 in	pig	populations,	 such	as	S.	suis	 this	method	may	be	 inadequate,	as	
most	pigs	have	antibodies	against	these	pathogens,	either	maternal	or	acquired,	or	are	actively	
infected	with	 the	 pathogen	 of	 interest.	 	 Indeed,	 S.	suis	 is	 considered	 a	 normal	member	 of	 the	
swine	 microflora,	 and	 the	 carrier	 rates	 of	 this	 "early	 colonizer"	 can	 be	 up	 to	 100%;	 with	
prevalence	of	disease	generally	being	not	more	than	5%	[431,	432].		As	a	result,	researchers	may	
have	to	screen	a	large	number	of	farms	and	pigs	to	obtain	a	reliable	pig	source	and	then	select	
pigs	 after	 the	 level	 of	maternally	 derived	 antibodies	 has	waned.	 	Unfortunately,	 despite	 being	
developed	over	 the	 last	 40	 years,	 the	definition	 of	 SPF	pigs	 is	 still	 controversial	 and	does	not	








experiential	 infection	 model	 devoid	 of	 maternal	 immunity,	 and	 where	 the	 upper	 respiratory	
tract	is	confirmed	to	be	free	of	S.	suis.		Although	the	CDCD	and	gnotobiotic	methods	are	reliable	
for	 obtaining	 pathogen-free	 pigs,	 they	 have	 several	 disadvantages,	 including	 the	 need	 for	
surgery,	 specialised	 facilities,	 and	 sterile	 compartments,	 and	 a	 greater	 cost.	 	 CDCD	 pigs	 are	
considered	 to	 produce	 fairly	 consistent	 results,	 however,	 results	 from	 CDCD	 pigs	 should	 be	
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Intraperitoneal	 and	 intravenous	 mouse	 models	 have	 been	 used	 to	 better	 understand	 S.	suis	
pathogenesis	[439,	440].	 	However,	a	number	of	studies	have	reported	isolates	associated	with	
disease	in	pigs	to	appear	much	less	virulent	or	avirulent	in	murine	models,	and	vice-versa	[307,	
308].	 	 Animal	 age	 and	 the	 volume	 of	 inoculum	 have	 been	 documented	 as	 influencing	murine	
models.		In	fact,	mucosal	irritation	by	acetic	acid	is	often	required	in	order	to	observe	disease	in	
mice.	 	 Such	 observations	 indicate	 that	 murine	 models	 do	 not	 mimic	 events	 in	 pigs,	 and	 that	
S.	suis	 pathogenesis	 could	 be	 species	 dependant.	 	 As	 a	 result,	 wherever	 ethically	 possible	
experimental	model	infections	should	be	performed	in	the	natural	host	(the	pig)	[441].	
	
In	 summary,	 there	 remains	 an	 urgent	 need	 to	 reach	 a	 consensus	 in	 i)	 the	 experimental	
conditions,	 ii)	 which	 inbred/outbred	 mouse	 strain	 to	 use,	 iii)	 the	 most	 appropriate	 and	






was	 first	 identified	as	a	genetically	 tractable	organism	in	the	1980s.	 	Although	 its	contribution	
has	already	been	substantial	(notably	to	understanding	basic	vertebrate	biology	and	vertebrate	
development,	 as	well	 as,	 factors	 controlling	 the	 specification	 of	 cell	 types,	 organ	 systems	 and	
body	 axes	 of	 vertebrates	 [442-444]),	 zebrafish	 research	 holds	 further	 promise	 to	 enhance	
understanding	of	 the	detailed	 roles	of	 specific	 genes	 in	disease,	 both	 rare	 and	 common	 [445].		
Zebrafish	are	members	of	the	teleostei	infraclass,	a	monophyletic	group	that	is	thought	to	have	
arisen	 approximately	 340	 million	 years	 ago	 [446].	 	 Although	 mammals	 may	 appear	 to	 be	
extremely	 different	 than	 zebrafish,	 a	 direct	 comparison	 of	 the	 zebrafish	 and	 human	 protein-





Thus,	 any	 type	 of	 disease	 that	 causes	 changes	 in	 these	 body	 parts	 in	 mammals	 could	
theoretically	be	modeled	in	zebrafish.		In	fact,	zebrafish	have	been	used	extensively	as	an	animal	
infection	model	for	a	wide	range	of	Gram-negative	and	-positive	bacterial	pathogens,	 including	








numbers,	 and	 exempt	 from	 ethical	 legislation.	 	 The	 zebrafish	 embryonal	 and	 larval	 innate	
immune	 system	 develops	 rapidly,	 resulting	 in	 the	 presence	 of	 functional	 phagocytes,	
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complement	 factors,	 and	 antimicrobial	 enzymes	 in	 the	 embryo	 before	 or	 soon	 after	 hatching	
[454-456].		This	has	allowed	high-throughput	screens	to	be	performed	that	would	be	much	less	
feasible	 in	mammalian	experimental	models	of	 infection.	 	Pre-feeding	 zebrafish	 larvae	at	72	h	
post	 fertilization	 have	 been	 shown	 to	 be	 susceptible	 to	 infection	 by	S.	suis	 isolates	 virulent	 in	
pigs	 [424].	 	 In	 fact,	microinjection	of	 different	S.	suis	 isolates	 into	pre-feeding	 zebrafish	 larvae	







the	 identification	 of	 189	 genes	 (125	 genes	 up-	 and	 64	 genes	 down-regulated)	 differentially	
expressed	 during	 S.	suis	 infection	 [452,	 453].	 	 However,	 as	with	 the	 natural	mammalian	 host,	







family	 Pyralidae	 of	 Lepidopteran	 order.	 	 Greater	 and	 close	 relative	 Lesser	 (Lepidoptera:	
Pyralidae,	Achroia	grisella)	wax	moths	are	ubiquitous	pests	of	honeybee	colonies.		The	economic	
importance	 of	 wax	 moths	 has	 led	 to	 a	 number	 of	 investigations	 into	 wax	 moth	 behaviour,	
biology,	ecology,	molecular	biology,	physiology	and	control.		However,	despite	the	importance	of	
wax	 moths	 to	 the	 apicultural	 industry,	 they	 are	 investigated	 considerably	 more	 as	 a	 model	
organism	 for	 studies	 in	genomics,	 insect	physiology	and	proteomics;	 this	 is	 especially	 true	 for	
the	Greater	Wax	Moth	[457].	
	
Greater	 Wax	 Moth	 larvae	 have	 recently	 been	 explored	 as	 a	 simple	 and	 cost-effective	 in	 vivo	
experimental	 infection	 model	 to	 screen	 the	 virulence	 potential	 of	 S.	suis	 isolates	 [423].		
Experimental	 infection	with	S.	suis	 isolates	belonging	 to	different	serotypes	killed	Greater	Wax	
Moth	 larvae	 in	a	dose-dependent	manner.	 	Crucially,	 the	observed	virulence	was	 in	agreement	
with	virulence	observed	in	piglets	and	humans,	as	well	as,	other	experimental	infection	models	
such	 as	mice	 and	 zebrafish	 larvae	 [424].	 	 Infection	with	 heat-inactivated	 bacteria	 or	 bacteria-
free	culture	supernatants	showed	that	in	most	cases	live	bacteria	are	needed	to	cause	mortality	






It	 is	 the	 caterpillar	 larvae	 (or	 'wax	worm')	 and	 not	 the	 adult	moth	 that	 is	 used	 as	 an	 animal	
model.		Larvae	of	the	Greater	Wax	Moth	have	been	shown	to	be	an	excellent	model	organism	for	
in	vivo	models	of	microbial	 infection	and	for	antimicrobial	drug	screening,	replacing	the	use	of	








polipod	 (eruciform),	with	six	 legs	on	 the	 thorax	and	a	number	of	prolegs	on	 the	 third	 to	sixth	
abdominal	 segments.	 	 The	 larvae	 are	 cream	 white	 in	 colour,	 with	 sclerotized	 body	 parts,	
although	 darken	 with	 each	 successful	 molt	 [465].	 	 At	 the	 larval	 stage,	 sexing	 into	 male	 and	
female	 is	 not	 possible	 due	 to	 the	 absence	 of	 sex	 specific	 external	 morphological	 characters.		
Upon	hatching,	Greater	Wax	Moth	larvae	are	~1–3	mm	in	length	and	0.12–0.15	mm	in	diameter.		










The	duration	 taken	 to	 complete	 the	 life	 cycle	 varies	 from	weeks	 to	months	 and	 is	 affected	by	





and	 Drosophila	 melanogaster,	 the	 Greater	 Wax	 Moth	 larvae	 can	 survive	 at	 37	 ˚C	 (body	









overcome	 by	 using	 a	 technically	 more	 challenging	 force-feeding	 method	 [473].	 	 Microbial	
inoculums	should	be	washed	prior	to	infection,	to	minimise	the	introduction	of	virulence	factors	
secreted	 during	 in-vitro	 growth	 of	 microorganisms.	 	 It	 is	 recommended	 to	 apply	 a	 placebo	




Despite	 its	 advantages,	 uptake	 of	 the	 Greater	 Wax	 Moth	 model	 has	 been	 limited	 due	 to	
significant	 variation	 in	 the	behavior	of	 larvae	both	within	 and	between	batches.	 	Greater	Wax	
Moth	larvae	for	experimental	infection	models	are	often	purchased	from	unregulated	pet	shops,	
such	 as	 Livefood	 UK	 Ltd.	 	 In	 response	 to	 this,	 BioSystems	 Technology	 Ltd.	 has	 developed	
TruLarv;	standardised	research	grade	Greater	Wax	Moth	larvae	that	are	age	and	weight	defined,	
surface	 decontaminated	 and	 inbred	 from	 a	 genome	 sequenced	 dedicated	 breeding	 colony	
without	the	use	of	antimicrobials,	hormones	or	other	drugs.	 	As	a	result,	TruLarv	behave	more	





At	present	 (March	2018),	a	 total	of	42	S.	suis	 'finished'	complete	genome	sequences	and	1,219	
S.	suis	 'unfinished'	 draft	 genome	 sequences	 can	 be	 found	 in	 public	 databases.	 	 However,	 in	
October	2013,	at	 the	beginning	of	 this	PhD	project,	 just	14	S.	suis	 complete	genome	sequences	
had	been	uploaded	to	GenBank;	sequenced	at	either	the	Beijing	Institute	of	Genomics	(China)	or	
Wellcome	Trust	Sanger	 Institute	 (Cambridge,	UK)	 [476-482].	 	The	reason	 for	 this	explosion	 in	
the	amount	of	detailed	genetic	information	for	S.	suis	is	i)	rapid	advances	and	reductions	in	cost	







single	 circular	 chromosome	 with	 an	 approximate	 size	 of	 2.1	 (median	 2.09612)	 Mb	 in	 length	
[477].	 	Median	 GC	 content	 is	 41.2%.	 	 Approximately	 2,000	 (median	 1981)	 predicted	 protein-
encoding	 sequences	 are	 contained	 within	 the	 S.	suis	 genome,	 resulting	 in	 a	 genome	 coding	
density	 of	 ~88%.	 	 Comparative	 genomic	 analysis	 of	 391	 S.	suis	 isolates	 by	 Weinert	 et	 al.	
identified	a	S.	suis	core-genome	(i.e.	prevalent	 in	all	 isolates,	as	opposed	the	accessory-genome	


























































































































































































































































































































other	 Streptococcus	 species	 [477].	 	 Importantly,	 it	 should	 be	 noted	 that	 S.	suis	 phylogenies	














identified	 four	 regions	 (designated	 genomic	 islands)	 in	 the	 P1/7	 genome	 that	 had	 properties	
indicative	 of	 recent	 acquisition,	 which	 included	 one	 prophage-like	 region	 and	 three	
miscellaneous	 islands	 [477].	 	None	 of	 these	 genomic	 islands	 carried	 characterised	 or	 putative	
virulence	factors.		Equivalent	genomic	islands	were	also	observed	in	the	SC84	genome,	however,	
BM407	contained	only	three	of	the	genomic	islands	present	in	P1/7	[477].		In	contrast	to	other	









like	 elements	 sharing	 a	 large	 recombination	 protein,	 as	 well	 as	 VirB4-type	 and	 VirD4-type	
proteins.		Furthermore,	a	genus-wide	comparison	of	streptococcal	ICE	reveals	a	surprising	level	
of	 similarity	 in	 their	 complement	 of	 cargo	 genes.	 	 The	 pezAT	 addiction	 toxin	 system,	 first	
identified	 in	 the	 chromosome	 of	 Streptococcus	 pneumoniae,	 is	 found	 on	 elements	 present	 in	
Streptococcus	agalactiae,	Streptococcus	pneumoniae	and	S.	suis,	presumably	aiding	fixation	of	the	
transposon	following	integration.		Bacteriocins,	either	alone	or	as	part	of	a	gene	cluster	encoding	





One	 ICE,	 an	 additional	 89	 Kb	 DNA	 fragment	 designated	 "89K",	 has	 been	 reported	 in	 highly	
virulent	 S.	suis	 isolates	 [476].	 	 89K	 was	 originally	 identified	 in	 S.	suis	 isolates	 98HAH12	 and	
	 58	
05ZYH33,	 using	 the	 combination	 of	 a	 genome-wide	 display	 of	 GC	 content	 and	 co-linearity	
comparison.	 	 Further	 investigation	 showed	 it	was	possible	 to	detect	89K	 in	23	highly	virulent	
Chinese	isolates	recovered	during	the	1998	Jiangsu	and	2005	Sichuan	outbreaks,	characterised	
by	 the	 rapid	 onset	 of	 disease	 affecting	 a	 large	 number	 of	 individuals	 and	 distinctive	 clinical	
manifestations	 (meningitis,	 sepsis	 or	 STSS;	 see	 sections	 1.1.2.2.1	 and	 1.1.2.2.2).	 	 The	 fact	 that	
89K	could	not	be	positively	detected	in	avirulent	Chinese	isolates,	such	as	05HAS68,	 led	to	the	
hypothesis	that	ICE	89K	was	a	specific	pathogenicity	island	candidate	in	Chinese	highly	virulent	




three	different	components	of	Type	IV	secretion	systems.	 	 In	 fact,	 the	major	features	of	typical	
pathogenicity	 islands	 are	 all	 present	 in	 89K.	 	 However,	 despite	 89K	 being	 present	 in	 Chinese	
highly	 virulent	 isolates	 and	 absent	 in	 Chinese	 avirulent	 isolates,	 indicating	 its	 potential	




Plasmids	 have	 been	 reported	 to	 be	 present	 in	 three	 of	 the	 1,261	 S.	suis	 isolates	 available	 in	
GenBank.	 	 Table	 1.5	 summarises	 the	 characteristics	 of	 the	 four	 S.	suis	 plasmids	 pBM407,	
pNSU1060a,	 pNSU1060b	 and	 pSSU1;	 of	 which	 pNSU1060a	 and	 pNSU1060b	 were	 recovered	
from	the	same	 isolate,	NSU1060	(serotype	2,	ST25).	 	Plasmids	reported	 in	S.	suis	 range	 in	size	









sensitive	 recipients	 were	 unsuccessful	 [489].	 	 No	 known	 antibiotic	 resistance	 genes	 were	
reported	to	be	encoded	on	the	plasmids	listed	in	Table	1.5,	and	other	mechanisms	exist	for	the	




Plasmid	 Size	(bp)	 GC	content	(%)	 CDSs	 Coding	density	(%)	 GenBank	 Reference	
pBM407	 24,579	 36.4	 18	 -	 FM252033	 Holden	et	al.	[477]	
pNSUI060a		 11,393	 40.7	 16	 -	 CP012912	 Athey	et	al.	[493]	
pNSUI060b		 5,581	 37.7	 6	 -	 CP012913	 Athey	et	al.	[493]	
pSSU1	 4,975	 36.9	 6	 75.6	 AB019522	 Takamatsu	et	al.	[494]	
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A	number	of	prophages	have	been	 identified	 in	 the	whole-genome	sequences	of	S.	suis	isolates	
[479,	 495-497].	 	 A	 prophage	 is	 a	 bacteriophage	 genome	 inserted	 and	 integrated	 into	 the	
bacterial	 chromosome	or	existing	as	 a	plasmid.	 	This	 is	 a	 latent	 form	of	 a	phage,	 in	which	 the	
viral	 genes	 are	 present	 in	 the	 bacterium	 without	 causing	 disruption	 of	 the	 bacterial	 cell.		
However,	 due	 to	 their	 highly	 specific	 host	 recognition,	 bacteriophages	 have	 potential	 as	
therapeutic	 agents	 in	 the	 treatment	 of	 infections	 [498,	 499].	 	 Phage	 can	 be	 classified	 by	 their	
lifestyle,	as	either	lytic	phage	or	temperate	phage	[500].		Temperate	phage,	such	as	S.	suis	phage	
Ss1	 [495]	 or	 ϕNJ2	 (GenBank	 accession	 number:	 JX879087)	 [497],	 have	 been	 the	 subject	 of	
attention	because	they	play	an	important	role	in	bacterial	pathogenesis	and	the	dissemination	of	
genes	encoding	virulence	factors	by	horizontal	transfer	of	DNA	[501-503],	whereas	lytic	phage	
provide	potential	 tools	 for	classifying	bacterial	 strains	and	combating	 the	antibiotic	 resistance	
crisis	[504].	 	To	date,	phage	SMP	is	the	only	reported	lytic	phage	of	S.	suis,	 isolated	from	S.	suis	
serotype	2	strains	recovered	from	nasal	swabs	of	healthy	Bama	minipigs	[505].		Phage	SMP	was	
reported	 to	 have	 an	 isometric	 head	 of	 50	 nm,	 a	 noncontractile	 tail	 of	 ~135	 nm	 and	 a	 linear	






Even	 before	 the	 explosion	 in	 the	 amount	 of	 detailed	 genetic	 information	 for	 S.	suis	 molecular	
typing	approaches	had	shown	the	S.	suis	species	to	be	genetically	very	heterogeneous.		A	feature	
that	 should	 be	 the	 focus	 of	 and	 exploited	 by	 future	 programs	 to	 control	 S.	suis	 disease.		
Population	genetic	studies	have	described	at	least	121	sequence	types	for	S.	suis,	but	neither	the	
authors	or	 follow	on	studies	have	been	able	to	observe	a	strict	relationship	between	sequence	
type	 and	 disease	 (or	 serotype)	 in	 pigs	 or	 humans	 [90].	 	 One	 of	 the	 drawbacks	 of	 population	
genetic	 studies	 such	 as	MLST	 is	 that	 they	 can	 lack	discriminatory	power	due	 to	high	 levels	 of	
sequence	 conservation	 (and	 as	 a	 result	 slow	 accumulation	 of	 genetic	 variation)	 in	 the	 target	
housekeeping	genes,	resulting	in	an	inability	to	differentiate	bacterial	strains.		In	addition	to	this,	
MLST	 struggles	 to	 monitor	 virulence	 factors,	 genes	 typically	 associated	 with	 high	 levels	 of	
recombination	 and	mobility	 in	 comparison	 to	 the	 population	 genetic	 framework.	 	 In	 terms	 of	




thought	 to	 be	 responsible	 for	 antibiotic	 resistance	 in	S.	suis	 isolates	 causing	human	disease	 in	
China	[477].		However,	despite	89K	being	present	in	Chinese	highly	virulent	isolates	and	absent	
in	 Chinese	 avirulent	 isolates,	 indicating	 its	 potential	 relationship	 to	 high	 pathogenicity,	 89K	
could	not	be	positively	detected	in	Canadian	or	European	isolates	tested	regardless	of	virulence	
potential	 [476].	 	 Other	 analyses	 have	 identified	 SNPs	 resulting	 from	 point	 mutations	 and	
recombination,	and	have	been	proposed	 to	be	 responsible	 for	 subtle	effects	on	 the	expression	
and	 function	 of	 virulence	 genes	 [115,	 477].	 	 Importantly	 whole-genome	 sequencing	 and	 the	
detailed	annotation	of	S.	suis	genomes	 is	providing	 the	valuable	data	 for	studying	evolutionary	
events	that	are	shaping	the	virulence	and	drug	resistance	of	this	pathogen.	
	
Indeed,	 bioinformatics	 analyses	 in	 our	 group	 have	 revealed	 significant	 genomic	 differences	
between	non-clinical	 isolates	 of	S.	suis	 recovered	 from	 the	 upper	 respiratory	 tract	 of	 pigs	 and	
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isolates	 causing	 systemic	disease	 [141].	 	 In	 doing	 so	post-doctoral	 research	 associate	Dr	 Lucy	
Weinert	and	colleagues	showed	S.	suis	isolates	causing	systemic	disease	had	substantially	fewer	
genes	(on	average)	than	non-clinical	isolates	from	the	upper	respiratory	tract,	inferring	that	the	
loss	 of	 protein-encoding	 sequences	 had	 led	 to	 a	 smaller	 genome	 with	 increased	 virulence	
potential;	 a	 phenomenon	 that	 has	 also	 been	 reported	 in	 other	 bacteria,	 such	 as	 Salmonella	
enterica,	 Shigella	 flexneri	 and	 Yersinia	 pestis	 [506-509].	 	 Curiously,	 despite	 this	 genomic	
reduction,	 an	 overrepresentation	 of	 genes	 encoding	 previously	 reported	 "virulence-factors"	
associated	 with	 S.	suis	 was	 also	 found	 in	 isolates	 causing	 systemic	 disease	 in	 pigs	 [141].		
Crucially,	 Dr	 Lucy	 Weinert	 and	 colleagues	 realised	 the	 potential	 of	 using	 whole-genome	









and	 phenotype	 by	 combing	 whole-genome	 sequencing	 data	 with	 carefully	 defined	 clinical	
metadata.	 	 These	 genetic	markers	would	 then	be	used	 to	predict	 the	 invasive	disease	 causing	
potential	of	isolates	being	carried	asymptomatically	in	pig	populations	on	farms	in	England	and	
Wales.	 	With	 access	 to	 the	whole-genome	 sequencing	data	of	 an	 initial	 (training)	 collection	of	





1.	 To	 identify	 significant	 associations	 between	 genotype	 and	 phenotype	 by	
combining	 whole-genome	 sequencing	 data	 with	 carefully	 defined	 clinical	
metadata	 –	 in	 doing	 so	 identifying	 regions	 of	 the	 genome	 associated	 with	
invasive	disease	caused	by	S.	suis		
2.	 To	 design	 and	 evaluate	 a	 pathotyping	 tool	 to	 predict	 the	 potential	 to	 cause	
invasive	 disease	 of	 S.	suis	 isolates	 recovered	 from	 intensive	 pig	 production	
systems	in	England	and	Wales	
3.	 To	use	the	newly-defined	"pathotyping	markers"	to	estimate	the	bacterial	load	of	














AC88	Balance	 	 	 	 	 Mettler,	Zurich,	Switzerland	
Airstream	Class	II	Biological	Safety	Cabinet	 Esco	Micro	Pte.	Ltd.,	Singapore	
Bioscreen	C	 	 	 	 	 OY	Growth	Curves,	Finland	
Centrifuge	5415C,	5804	 	 	 Eppendorf,	Stevenage,	UK	
Dri-Block	DB-2D	 	 	 	 Techne	Ltd.,	Cambridge,	UK	




Heraeus	Pico17	Centrifuge	 	 	 Thermo	Fisher	Scientific,	Paisley,	UK	
Innova43	Incubator	shaker	 	 	 New	Brunswick	Scientific	Ltd,	Maldon,	UK	
Gilson	Pipette	Pipetman,	adjustable	 	 Gilson	Scientific	Ltd.,	Dunstable,	UK	
Power	Pac	300		 	 	 	 Bio-Rad	Laboratories,	Inc.,	Hertfordshire,	UK	
Qubit	2.0	Fluorometer	 	 	 	 Invitrogen,	Paisley,	UK	
Rotor-Gene	Q	PCR	cycler	 	 	 Qiagen,	Manchester,	UK	
SpectraMaxM5	Microplate	Reader	 	 Molecular	Devices	LLC,	California,	USA	
SUB	Aqua	12	Plus	Water	bath	 	 	 Grant	Instruments,	Cambridge,	UK	
T100	Thermal	Cycler	 	 	 	 Bio-Rad	Laboratories	Inc.,	Hertfordshire,	UK	
Tridak	STEPPER	 	 	 	 Dymax	Corporation,	Connecticut,	USA	
Ultra	Low	Temp	-85	˚C	Freezer	U57085	 New	Brunswick	Scientific	Ltd,	Maldon,	UK	
UV1101	Biotech	Photometer	 	 	 WPA,	Cambridge,	UK	
UV	Transilluminator	 	 	 	 UVP,	Upland,	USA	








DNA	Loading	Buffer,	Blue	 	 	 Bioline,	London,	UK	
Glycerol	 	 	 	 	 Fisher	Scientific,	Loughborough,	UK	




TBE	buffer	(10x)	 	 	 	 Promega	Corporation,	Madison,	USA	
TE	buffer	 	 	 	 	 Invitrogen,	Paisley,	UK	
Tris-Cl	(pH	8.5)	 	 	 	 Qiagen,	Manchester,	UK	
Todd-Hewitt	broth	 	 	 	 Oxoid	Ltd,	Basingstoke,	UK	






Disposable	Scalpel	blades	 	 	 Swann	Morton,	Sheffield,	UK	
Disposable	Serological	Pipette		 	 Thermo	Fisher	Scientific,	Paisley,	UK	
Dry	swab,	Fine	tip	plastic	 	 	 Medical	Wire	&	Equipment,	Corsham,	UK	
Dry	swab,	Standard	plastic	 	 	 Medical	Wire	&	Equipment,	Corsham,	UK	
Filter	tips,	beveled;	20,	200,	300,	1000	µL	 Star	Lab,	Milton	Keynes,	UK	
Flat-bottom	96-well	tissue	culture	plates	 Greiner	Bio-One	Ltd.	Gloucestershire,	UK	




Petri	dishes	(90	mm)	 	 	 	 Thermo	Fisher	Scientific,	Paisley,	UK	
Skirted	96-well	PCR	Plate	 	 	 Thermo	Fisher	Scientific,	Paisley,	UK	
Strip	Tubes	and	Caps	(0.1	mL)		 	 Qiagen,	Manchester,	UK	
Syringe	driven	filter	unit	(0.22	µm)	 	 Millex	(Merck),	Darmstadt,	Germany	




API®	20	STREP	 	 	 	 Biomerieux,	Inc.,	Basingstoke	UK	
API®	RAPID	ID	32	STREP	 	 	 Biomerieux,	Inc.,	Basingstoke	UK	
GenElute	Bacterial	Genomic	DNA	Kit	 	 Sigma-Aldrich,	Haverhill,	UK	
Genomic-tip	100/G	Columns	 	 	 Qiagen,	Manchester,	UK	




Multiplex	PCR	Plus	Kit	 	 	 	 Qiagen,	Manchester,	UK	
Qubit	dsDNA	BR	Assay	Kit	 	 	 Invitrogen,	Paisley,	UK	






ii)	 an	 out-of-sample	 test	 collection	 of	 138	 previously	 uncharacterised	 isolates.	 	The	 original	
training	collection	was	used	to	identify	genetic	markers	associated	with	i)	invasive	disease	or	
ii)	 asymptomatic	 carriage	 on	 the	 palatine	 tonsils	 of	 pigs,	 with	 an	 aim	 to	 in	 the	 future	
differentiate	S.	suis	 isolates	into	i)	disease-associated	and	ii)	non-disease	associated	phenotypic	




post-mortem	material	 at	 the	Animal	Health	and	Veterinary	Laboratories	Agency	 (AHVLA;	now	
the	 Animal	 and	 Plant	 Health	 Agency,	 APHA)	 in	 2010,	 and	 contribute	 to	 a	 larger	 collection	
(denoted:	 the	 "LoLa	 collection")	 previously	 described	 in	 2015	 by	Weinert	 et	 al.	 [141].	 	Well-
defined	 phenotypic	metadata	 were	 available	 allowing	 each	 isolate	 to	 be	 categorised	 as	 being	
associated	with	invasive	S.	suis	disease	(n=53;	recovered	from	systemic	sites	in	the	presence	of	
clinical	 signs	 (arthritis,	meningitis,	 septicaemia)	and/or	gross	pathology	consistent	with	S.	suis	
infection)	 or	 as	 being	 non-disease	 associated	 (n=62;	 recovered	 from	 the	 tonsil	 or	 trachea-
bronchus	of	pigs	without	any	typical	signs	of	infection,	but	diagnosed	with	disease	unrelated	to	
S.	suis,	 such	 as	 enteric	disease).	 	The	 out-of-sample	 test	 collection	was	used	 to	 evaluate	 the	
molecular	pathotyping	tool.	 	Out-of-sample	forecasting	is	a	common	approach	used	to	evaluate	
the	performance	of	binary	diagnostic	tests.		To	avoid	reducing	statistical	power,	rather	than	split	












Isolate	 Collection	 Ante	 Post	 Origin	 Phenotype	
P1/7	 Training	 -	 Meningitis	 Blood	 Disease-associated	
SS002	 Training	 Nervous	 Meningitis	 Brain	 Disease-associated	
SS004	 Training	 Found	dead	 Meningitis	 Meninges	 Disease-associated	
SS005	 Training	 Swollen	joints	 Arthritis	 Joint	 Disease-associated	
SS006	 Training	 Found	dead	 Arthritis	 Brain	 Disease-associated	
SS007	 Training	 Nervous	 Septicaemia	 Brain	 Disease-associated	
SS008	 Training	 Found	dead	 Pericarditis	 Pericardium	 Disease-associated	
SS010	 Training	 Nervous	 Meningitis	 Brain	 Disease-associated	
SS012	 Training	 Lameness	 Arthritis	 Joint	 Disease-associated	
SS013	 Training	 Lameness	 Arthritis	 Left	carpus	 Disease-associated	
SS015	 Training	 Found	dead	 Aortic	stenosis	 Brain	 Disease-associated	
SS016	 Training	 Lameness	 Arthritis	 Joint	 Disease-associated	
SS017	 Training	 -	 -	 Joint	 Disease-associated	
SS018	 Training	 Ill	thrift	 Pneumonia	 Pericardium	 Disease-associated	
SS021	 Training	 Found	dead	 Septicaemia	 Joint	 Disease-associated	
SS022	 Training	 Lameness	 Arthritis	 Brain	 Disease-associated	
SS024	 Training	 Ill	thrift	 Arthritis	 Brain	 Disease-associated	
SS025	 Training	 -	 -	 Brain	 Disease-associated	
SS028	 Training	 Found	dead	 Meningitis	 Brain	 Disease-associated	
SS029	 Training	 Nervous	 Meningitis	 Joint	 Disease-associated	
SS035	 Training	 Found	dead	 Septicaemia	 Joint	 Disease-associated	
SS036	 Training	 Nervous	 Septicaemia	 Brain	 Disease-associated	
SS038	 Training	 -	 -	 Liver	 Disease-associated	
SS041	 Training	 Found	dead	 Polyserositis	 Brain	 Disease-associated	
SS042	 Training	 Nervous	 Meningitis	 Brain	 Disease-associated	
SS044	 Training	 Found	dead	 Arthritis	 Joint	 Disease-associated	
SS045	 Training	 Found	dead	 Meningitis	 Meninges	 Disease-associated	




SS057	 Training	 Nervous	 Meningitis	 Liver	 Disease-associated	
SS058	 Training	 Nervous	 Meningitis	 Brain	 Disease-associated	
SS060	 Training	 Nervous	 Meningitis	 Brain	 Disease-associated	
SS062	 Training	 Found	dead	 Polyserositis	 Brain	 Disease-associated	
SS063	 Training	 Found	dead	 Arthritis	 Joint	 Disease-associated	
SS065	 Training	 Found	dead	 Septicaemia	 Lymph	node	 Disease-associated	
SS066	 Training	 Ill	thrift	 Polyserositis	 Brain	 Disease-associated	
SS068	 Training	 Ill	thrift	 Pneumonia	 Brain	 Disease-associated	
SS069	 Training	 Found	dead	 Pneumonia	 Liver	 Disease-associated	
SS071	 Training	 Nervous	 Pneumonia	 Brain	 Disease-associated	
SS072	 Training	 Nervous	 Arthritis	 Joint	 Disease-associated	
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SS077	 Training	 Lameness	 Meningitis	 Brain	 Disease-associated	
SS083	 Training	 Ill	thrift	 Pneumonia	 Meninges	 Disease-associated	
SS085	 Training	 Ill	thrift	 Pneumonia	 Brain	 Disease-associated	
SS086	 Training	 -	 -	 Peritoneum	 Disease-associated	
SS087	 Training	 Nervous	 Meningitis	 Brain	 Disease-associated	
SS088	 Training	 Nervous	 Pneumonia	 Joint	 Disease-associated	
SS093	 Training	 Found	dead	 Meningitis	 Brain	 Disease-associated	
SS095	 Training	 Found	dead	 Meningitis	 Brain	 Disease-associated	
SS096	 Training	 Found	dead	 Meningitis	 Brain	 Disease-associated	
SS097	 Training	 Found	dead	 Anaemia	 Spleen	 Disease-associated	
SS098	 Training	 Found	dead	 Meningitis	 Brain	 Disease-associated	
SS099	 Training	 Found	dead	 Meningitis	 Brain	 Disease-associated	
SS100	 Training	 -	 -	 Brain	 Disease-associated	
LSS001	 Training	 Ill	thrift	 Pneumonia	 Tracheo-bronchus	 Non-disease	associated	
LSS003	 Training	 Found	dead	 Pneumonia	 Tracheo-bronchus	 Non-disease	associated	
LSS009	 Training	 Ill	thrift	 -	 Palatine	tonsils	 Non-disease	associated	
LSS011	 Training	 Nervous	 Water	deprivation	 Palatine	tonsils	 Non-disease	associated	
LSS018	 Training	 Ill	thrift	 Enterocolitis	 Tracheo-bronchus	 Non-disease	associated	
LSS020	 Training	 Ill	thrift	 Enterocolitis	 Tracheo-bronchus	 Non-disease	associated	
LSS023	 Training	 Found	dead	 Septicaemia	 Tracheo-bronchus	 Non-disease	associated	
LSS025	 Training	 Found	dead	 PCVAD	 Tracheo-bronchus	 Non-disease	associated	
LSS027	 Training	 Lameness	 Anaemia	 Palatine	tonsils	 Non-disease	associated	
LSS030	 Training	 Found	dead	 Septicaemia	 Palatine	tonsils	 Non-disease	associated	
LSS031	 Training	 Found	dead	 Gut	torsion	 Palatine	tonsils	 Non-disease	associated	
LSS032	 Training	 Found	dead	 Gut	torsion	 Palatine	tonsils	 Non-disease	associated	
LSS034	 Training	 -	 -	 Nasal	 Non-disease	associated	
LSS037	 Training	 Found	dead	 Peritonitis	 Tracheo-bronchus	 Non-disease	associated	
LSS038	 Training	 Found	dead	 Peritonitis	 Palatine	tonsils	 Non-disease	associated	
LSS039	 Training	 Found	dead	 Peritonitis	 Tracheo-bronchus	 Non-disease	associated	
LSS040	 Training	 Ill	thrift	 Arthritis	 Tracheo-bronchus	 Non-disease	associated	
LSS041	 Training	 Ill	thrift	 Arthritis	 Tracheo-bronchus	 Non-disease	associated	
LSS042	 Training	 Ill	thrift	 Arthritis	 Palatine	tonsils	 Non-disease	associated	
LSS044	 Training	 Ill	thrift	 Arthritis	 Palatine	tonsils	 Non-disease	associated	
LSS047	 Training	 Found	dead	 Septicaemia	 Palatine	tonsils	 Non-disease	associated	
LSS048	 Training	 Found	dead	 Septicaemia	 Tracheo-bronchus	 Non-disease	associated	
LSS049	 Training	 Found	dead	 Enterocolitis	 Tracheo-bronchus	 Non-disease	associated	
LSS053	 Training	 Nervous	 Neuropathy	 Tracheo-bronchus	 Non-disease	associated	
LSS054	 Training	 Ill	thrift	 Navel	illl	 Palatine	tonsils	 Non-disease	associated	
LSS055	 Training	 Ill	thrift	 Navel	illl	 Palatine	tonsils	 Non-disease	associated	
LSS057	 Training	 Found	dead	 PCVAD	 Tracheo-bronchus	 Non-disease	associated	
LSS058	 Training	 Nervous	 Enterocolitis	 Tracheo-bronchus	 Non-disease	associated	
LSS059	 Training	 Nervous	 Enterocolitis	 Tracheo-bronchus	 Non-disease	associated	
LSS060	 Training	 Nervous	 Enterocolitis	 Palatine	tonsils	 Non-disease	associated	
LSS061	 Training	 Nervous	 Enterocolitis	 Palatine	tonsils	 Non-disease	associated	
LSS062	 Training	 Nervous	 Enterocolitis	 Tracheo-bronchus	 Non-disease	associated	
LSS063	 Training	 Nervous	 Enterocolitis	 Tracheo-bronchus	 Non-disease	associated	
LSS064	 Training	 Ill	thrift	 Pneumonia	 Palatine	tonsils	 Non-disease	associated	
LSS065	 Training	 Found	dead	 Septicaemia	 Palatine	tonsils	 Non-disease	associated	
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LSS067	 Training	 Found	dead	 Pneumonia	 Palatine	tonsils	 Non-disease	associated	
LSS068	 Training	 Found	dead	 Pneumonia	 Tracheo-bronchus	 Non-disease	associated	
LSS069	 Training	 Found	dead	 Pneumonia	 Tracheo-bronchus	 Non-disease	associated	
LSS070	 Training	 Lameness	 Fracture	 Tracheo-bronchus	 Non-disease	associated	
LSS071	 Training	 Ill	thrift	 PCVAD	 Tracheo-bronchus	 Non-disease	associated	
LSS072	 Training	 Ill	thrift	 Pneumonia	 Tracheo-bronchus	 Non-disease	associated	
LSS075	 Training	 Ill	thrift	 Pneumonia	 Palatine	tonsils	 Non-disease	associated	
LSS076	 Training	 -	 -	 Palatine	tonsils	 Non-disease	associated	
LSS077	 Training	 Nervous	 Neuropathy	 Tracheo-bronchus	 Non-disease	associated	
LSS078	 Training	 Found	dead	 Gut	torsion	 Tracheo-bronchus	 Non-disease	associated	
LSS079	 Training	 Found	dead	 Gut	torsion	 Palatine	tonsils	 Non-disease	associated	
LSS080	 Training	 Found	dead	 Gut	torsion	 Tracheo-bronchus	 Non-disease	associated	
LSS081	 Training	 Found	dead	 Polyserositis	 Palatine	tonsils	 Non-disease	associated	
LSS082	 Training	 Ill	thrift	 Arthritis	 Tracheo-bronchus	 Non-disease	associated	
LSS083	 Training	 Respiratory	 Pneumonia	 Palatine	tonsils	 Non-disease	associated	
LSS084	 Training	 Respiratory	 Pneumonia	 Tracheo-bronchus	 Non-disease	associated	
LSS085	 Training	 Respiratory	 Pneumonia	 Palatine	tonsils	 Non-disease	associated	
LSS086	 Training	 Respiratory	 Pneumonia	 Tracheo-bronchus	 Non-disease	associated	
LSS088	 Training	 Ill	thrift	 Lymphadenitis	 Palatine	tonsils	 Non-disease	associated	
LSS089	 Training	 Respiratory	 Pneumonia	 Palatine	tonsils	 Non-disease	associated	
LSS090	 Training	 Respiratory	 Pneumonia	 Palatine	tonsils	 Non-disease	associated	
LSS091	 Training	 Diarrhoea	 Colibacillosis	 Palatine	tonsils	 Non-disease	associated	
LSS092	 Training	 Diarrhoea	 Colibacillosis	 Palatine	tonsils	 Non-disease	associated	
LSS094	 Training	 Diarrhoea	 Colitis	 Tracheo-bronchus	 Non-disease	associated	
LSS095	 Training	 Diarrhoea	 Enterocolitis	 Palatine	tonsils	 Non-disease	associated	
LSS096	 Training	 Diarrhoea	 Enterocolitis	 Palatine	tonsils	 Non-disease	associated	
SS027	 Training	 Found	dead	 Enteropathy	 Trachea	 Non-disease	associated	
tmw001	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw002	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw003	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw004	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw005	 Out-of-sample	 Found	dead	 -	 -	 Disease-associated	
tmw006	 Out-of-sample	 Lameness	 Endocarditis	 Joint	 Disease-associated	
tmw007	 Out-of-sample	 Nervous	 Meningitis	 Brain	 Disease-associated	
tmw008	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw010	 Out-of-sample	 Respiratory	 -	 -	 Disease-associated	
tmw011	 Out-of-sample	 Found	dead	 Endocarditis	 -	 Disease-associated	
tmw012	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw013	 Out-of-sample	 Ill	thrift	 Pericarditis	 Pericardium	 Disease-associated	
tmw014	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw015	 Out-of-sample	 Nervous	 -	 -	 Disease-associated	
tmw016	 Out-of-sample	 Nervous	 -	 -	 Disease-associated	
tmw017	 Out-of-sample	 Lameness	 Meningitis	 -	 Disease-associated	
tmw020	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw021	 Out-of-sample	 Malaise	 Pericarditis	 Pericardium	 Disease-associated	
tmw022	 Out-of-sample	 Found	dead	 -	 Brain	 Disease-associated	
tmw023	 Out-of-sample	 Found	dead	 Septicaemia	 Liver	 Disease-associated	
tmw025	 Out-of-sample	 -	 -	 -	 Disease-associated	
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tmw029	 Out-of-sample	 Abortion	 -	
Foetal	stomach	
content	 Disease-associated	
tmw030	 Out-of-sample	 Lameness	 Arthritis	 Joint	 Disease-associated	
tmw031	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw034	 Out-of-sample	 Nervous	 Meningitis	 -	 Disease-associated	
tmw035	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw036	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw037	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw038	 Out-of-sample	 Found	dead	 Meningitis	 Brain	 Disease-associated	
tmw040	 Out-of-sample	 Found	dead	 Meningitis	 Brain	 Disease-associated	
tmw047	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw049	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw051	 Out-of-sample	 Found	dead	 Pneumonia	 Brain	 Disease-associated	
tmw052	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw053	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw055	 Out-of-sample	 Found	dead	 Pericarditis	 -	 Disease-associated	
tmw056	 Out-of-sample	 Found	dead	 -	 -	 Disease-associated	
tmw057	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw058	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw059	 Out-of-sample	 Nervous	 Meningitis	 Brain	 Disease-associated	
tmw060	 Out-of-sample	 Nervous	 Meningitis	 Brain	 Disease-associated	
tmw061	 Out-of-sample	 Found	dead	 Arthritis	 Joint	 Disease-associated	
tmw062	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw065	 Out-of-sample	 -	 -	
	
Disease-associated	
tmw066	 Out-of-sample	 Found	dead	 -	 -	 Disease-associated	
tmw069	 Out-of-sample	 Nervous	 Meningitis	 -	 Disease-associated	
tmw071	 Out-of-sample	 Malaise	 Peritonitis	 Brain	 Disease-associated	
tmw072	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw075	 Out-of-sample	 Diarrhoea	 -	 Navel	 Disease-associated	
tmw077	 Out-of-sample	 Lameness	 Arthritis	 -	 Disease-associated	
tmw078	 Out-of-sample	 Malaise	 Meningitis	 Kidney	 Disease-associated	
tmw080	 Out-of-sample	 Respiratory	 Pneumonia	 Spleen	 Disease-associated	
tmw081	 Out-of-sample	 Found	dead	 Meningitis	 Brain	 Disease-associated	
tmw083	 Out-of-sample	 Nervous	 Meningitis	 Brain	 Disease-associated	
tmw084	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw086	 Out-of-sample	 Nervous	 Meningitis	 Brain	 Disease-associated	
tmw089	 Out-of-sample	 Lameness	 Endocarditis	 -	 Disease-associated	
tmw090	 Out-of-sample	 Nervous	 Arthritis	 Brain	 Disease-associated	
tmw092	 Out-of-sample	 Nervous	 Meningitis	 -	 Disease-associated	
tmw093	 Out-of-sample	
Wasted	
recumbent	 Septicaemia	 Liver	 Disease-associated	
tmw094	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw095	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw096	 Out-of-sample	 Found	dead	 Septicaemia	 Brain	 Disease-associated	
tmw097	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw098	 Out-of-sample	 -	 -	 -	 Disease-associated	
tmw099	 Out-of-sample	 Lameness	 Arthritis	 Pericardium	 Disease-associated	
tmw100	 Out-of-sample	 Respiratory	 Pneumonia	 -	 Disease-associated	
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tmw101	 Out-of-sample	 -	 Pneumonia	 -	 Disease-associated	
tmw102	 Out-of-sample	 Found	dead	 -	 -	 Disease-associated	
083/01C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
083/02A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
083/02B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
083/03A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
083/13A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
083/17A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
083/17B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
083/17C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
083/22A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
083/24C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
083/25C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
125/01A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
270/06A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
270/16A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
207/21B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
270/21C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
270/23C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
359/06B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
427/05B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
427/07C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
427/17B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
427/17C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
632/04A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
632/07B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
632/07C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
632/09A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
632/09C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
635/03A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
635/06B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
635/06C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
635/08C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
635/09A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
635/09C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
635/10C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/01B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/02A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/03A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/03B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/03C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/04A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/05A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/05B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/06A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/06B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/06C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/07C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
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684/08A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/09B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/10A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/11B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/11C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/12A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/12B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/12C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/13A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/13C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/14B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/14C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/15B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/16A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/17C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/18B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/18C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/19B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/20A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/20C	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/21A	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	
684/21B	 Out-of-sample	 -	 -	 Palatine	tonsils	 Non-disease	associated	







original	 LoLa	 collection	was	 put	 together	 investigate	 the	 evolution	 of	 S.	suis	 and	 address	 two	
specific	 questions	 i)	 the	 evolution	 of	 S.	suis	 disease	 in	 swine	 and	 ii)	 the	 evolution	 of	 S.	suis	
disease	in	humans,	and	resulted	in	the	Nature	Communications	publication	"Genomic	signatures	
of	 human	 and	 animal	 disease	 in	 the	 zoonotic	 pathogen	 Streptococcus	 suis"	 [141].	 	 For	
completeness	 this	 section	briefly	describe	 the	WGS	and	 initial	processing	of	 the	raw	sequence	
data.	
	
Paired-end	whole-genome	 sequencing	 was	 performed	 on	 Illumina	 HiSeq	 2000	 instruments	
according	 to	 the	manufacturer’s	 instructions	at	The	Wellcome	Trust	Sanger	 Institute,	Hinxton,	
Cambridgeshire,	UK.	 	Single	colonies	were	picked	from	90	mm	Columbia	agar	base	with	sheep	
blood	plates	(Oxoid	Ltd.)	incubated	at	37	˚C	overnight,	and	used	to	inoculate	Todd-Hewitt	broth	
(Oxoid)	 supplemented	 with	 0.2%	 Yeast	 Extract	 (Fisher	 Scientific)	 then	 incubated	 at	 37	 ˚C	
overnight	 without	 agitation.	 	 All	 genomic	 and	 plasmid	 DNA	 was	 extracted	 from	 overnight	
cultures	using	the	MasterPure	Gram	Positive	DNA	Purification	Kit	 (epicentre)	according	to	 the	
manufacturer’s	 instructions.	 	De	novo	 assemblies	were	 generated	using	Velvet	 [511]	 version	
1.1	 with	 parameter	 selection	 taken	 from	 VelvetOptimiser	 and	 the	 quality	 of	 draft	 genome	
assemblies	 checked	 by	 mapping	 the	 raw	 reads	 back	 to	 the	 assemblies.	 	 Annotation	 was	
performed	 using	 Prokka.	 	 The	 S.	suis	 core-genome	 (ie.	 genes	 present	 in	 all	 isolates)	 was	
identified	by	extracting	all	annotated	protein-encoding	sequences	from	the	published	genome	of	
S.	suis	 strain	 P1/7	 (GenBank	 accession:	 AM946016)	 [477,	 510],	 and	 using	 them	 as	 BLASTp	
queries	against	a	bespoke	BLAST	database	of	all	de	novo	assemblies	and	known	complete	S.	suis	
genome	sequences.		Protein-encoding	sequences	that	showed	at	least	80%	identity	over	at	least	




more	 isolates	 or	 unique	 to	 a	 given	 isolate)	 was	 reconstructed	 using	 the	 program	 OrthoMCL	
[512-514].	 	 Protein-encoding	 sequences	 were	 predicted	 using	 default	 parameters	 in	 Prodigal	




was	 then	 used	 to	 identify	 reciprocal	 best	 similarity	 protein	 pairs,	 and	 homology	 groups	
identified	by	clustering	with	MCL	using	a	low	inflation	value	parameter.		Assignment	of	protein-
encoding	sequences	to	homology	groups	can	be	 inaccurate	 for	a	number	of	reasons,	 including:	
sequencing	errors,	assembly	errors,	failure	to	distinguish	between	orthologues	and	paralogues,	





Bayesian	 inference	of	 the	genetic	 population	 structure	 in	S.	suis	 [141]	was	performed	using	
Bayesian	 Analysis	 of	 Population	 Structure	 (BAPS)	 software	 version	 6.0,	 in	 particular	 the	
hierBAPS	module	that	fits	lineages	to	genome	data	using	nested	clustering.		Three	nested	levels	
of	molecular	variation	were	fitted	to	core-genome	alignments	and	five	clusters	at	level	one	of	the	










at	 two	 time	 points,	 five	 weeks	 and	 20	 weeks	 of	 age.	 	 Each	 farm	 operated	 an	 all-in-all-out	
management	 system,	 holding	 pigs	 from	weaning	 (four	weeks	 of	 age)	 until	 slaughter	 (~20-25	











Unless	 otherwise	 stated,	 all	 statistical	 analyses	 were	 performed	 using	 the	 standard	 R	






sequences	 (genotype)	 and	 phenotype	 (invasive	 disease-associated	 and	non-disease	 associated	
groups).		The	Chi-squared	test	for	independence	compared	observed	frequencies	with	expected	
frequencies,	and	in	doing	so	calculated	a	test	statistic	that	if	greater	than	the	critical	value	was	




The	 Cochran-Mantel-Haenszel	 (CMH)	 Chi-squared	 test	 for	 count	 data,	 implemented	 in	 the	 R	
package:	 stats	 [516],	 was	 used	 to	 minimise	 the	 number	 of	 spurious	 associations	 due	 to	 an	
underlying	 bacterial	 population	 structure.	 	 The	 Chi-squared	 test	 for	 independence	 model	
compares	 observed	 frequencies	 with	 expected	 but	 does	 not	 take	 into	 consideration	 bacterial	
population	structure.		Population	groups	identified	by	Bayesian	Analysis	of	Population	Structure	
(BAPS)	have	previously	been	described	for	S.	suis	by	Weinert	et	al.	[141]	(see	Appendix	8.x).		The	
CMH	Chi-squared	test	 for	count	data	generated	a	 test	statistic	 that	across	all	 five	BAPS	groups	







The	Discriminant	Analysis	 of	 Principal	 Components	 (DAPC)	 [517,	 518],	 implemented	 in	 the	R	
package:	 adegenet	 [519,	 520],	 was	 used	 to	 identify	 genetic	 differences	 between	 pre-defined	
(invasive	 disease-associated	 and	 non-disease	 associated)	 phenotypic	 groups.	 	 DAPC	 is	 a	
multivariate	 genome-wide	 association	methodology	 that	 identified	 genetic	 structures	without	
making	 assumptions	 about	 underlying	 population	 genetic	 models.	 	 Identified	 by	 principal	
component	 analysis	 (PCA)	 overall	 genetic	 variation	 was	 partitioned	 and	 then	 the	 best	





The	 total	 amount	 of	 original	 variation	 retained	 in	 the	 DAPC	 model	 affected	 which	 protein-
encoding	 sequences	 contributed	most	 to	 the	 separation	of	 genetic	 structures.	 	To	assess	what	
impact	the	total	amount	of	original	variation	retained	had	on	the	DAPC	model	four	independent	
DAPC	 analyses	were	 performed	 retaining	 60,	 70,	 80	 or	 90%	 of	 the	 original	 genetic	 variation.		
The	1%	of	ranked	protein-encoding	sequences	contributing	most	 to	 the	discrimination	of	pre-




Logistic	 regression	 in	 the	 form	 of	 a	 generalised	 linear	 model	 (GLM),	 implemented	 in	 the	 R	
package:	 logistf	[521],	was	 used	 for	 the	 final	 selection	 of	 genetic	markers	 to	 pathotype	S.	suis.		
Logistic	regression	is	a	statistical	method	for	the	analysis	of	a	dataset	in	which	there	are	one	or	
more	 independent	 explanatory	 variables	 (shortlisted	 genetic	 markers)	 that	 are	 expected	 to	
influence	 the	 binary	 dependent	 variable	 (observed	 clinical	 phenotype;	 invasive	 disease-
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associated:	 1,	 non-disease	 associated:	 0).	 	 Backwards	 step-wise	 selection,	 using	 penalised	
likelihood	 ratio	 tests,	was	 used	 to	 select	 the	 fewest	 statistically	 significant	 genetic	markers	 to	








(sensitivity)	 and	 false	 positive	 rate	 (1-specificity)	 in	 comparison	 to	 the	 observed	 clinical	
phenotype	(considered	to	be	the	'gold-standard').		DeLong’s	test	for	two	correlated	ROC	curves,	
implemented	in	the	R	package:	pROC	[524],	was	used	to	identify	statistically	significant	(p-value	
<0.05)	 differences	 between	 two	 ROC	 curves	 generated	 using	 different	 explanatory	 variables	
from	the	same	data	set.	
	
2.2.1.5.2	 Selection	of	 a	 cutoff	 to	 convert	 the	 real-valued	output	 of	 a	 generalised	
linear	model	into	a	binary	classification	decision	
The	real-valued	output	of	a	logistic	regression	model,	i.e.	the	probability	of	causing	disease,	was	
converted	 into	 a	 binary	 class	 decision	 (disease-/non-disease	 associated)	 by	 selecting	 a	 cutoff	
threshold.	 	 Typical	 measures	 of	 binary	 diagnostic	 tests	 are	 the	 performance	 metrics:	 true	
positive	 rate	 (sensitivity;	 i.e.	 the	 proportion	 of	 isolates	 recovered	 from	 systemic	 sites	 and	
predicted	 to	 be	 invasive	 disease	 causing	 isolates),	 the	 true	 negative	 rate	 (specificity;	 i.e.	 the	
proportion	of	 isolates	recovered	 from	the	upper	respiratory	 tract	of	a	healthy	pig	without	any	
typical	 signs	 of	 S.	suis	 infection	 and	 predicted	 to	 be	 non-disease	 causing	 isolates),	 positive	
predictive	value	 (PPV,	precision;	 i.e.	 the	proportion	of	 isolates	predicted	 to	be	disease	causing	
isolates	 that	 were	 recovered	 from	 a	 systemic	 site),	 negative	 predictive	 value	 (NPV;	 i.e.	 the	
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proportion	of	isolates	predicted	to	be	non-disease	causing	isolates	that	were	recovered	from	the	
upper	 respiratory	 tract	 of	 a	 healthy	 pig	 without	 any	 typical	 signs	 of	 S.	suis	 infection)	 and	
accuracy.	 	Performance	metrics	are	heavily	dependent	on	 the	 cutoff	 chosen.	 	As	no	cutoff	was	
optimal	 according	 to	 all	 possible	 performance	 criteria,	 cutoff	 choice	 involved	 a	 trade-off	 of	
different	performance	metrics.		The	false	negative	rate	(analogous	to	Type	II	error)	was	chosen	
as	 the	most	 valuable	 performance	metric	 for	 pathotyping	 S.	suis,	with	 a	 view	 to	 establish	 and	
then	maintain	a	pig	population	free	of	invasive	disease-associated	strains.		False	negative	rate	is	
equivalent	to	1	–	sensitivity,	therefore,	selection	of	a	cutoff	producing	a	low	false	negative	rate	is	
the	 equivalent	 of	 selecting	 a	 cutoff	 producing	 a	 high	 sensitivity.	 	 False	 negative	 rate	 was	
calculated	using	the	equation:		
False negative rate = False negative (Type II error)Phenotype positive 	
	
In	order	 to	establish	and	maintain	a	population	 free	of	disease-associated	 strains	 the	F1	 score	
was	 also	 deemed	 to	 be	 a	 valuable	 performance	 metric.	 	 In	 statistical	 analysis	 of	 binary	
classification	the	F1	score	is	a	measure	of	accuracy	that	is	the	harmonic	average	of	the	sensitivity	












rate	 closest	 to	 0.	 	 Table	 2.2	 shows	 an	 extended	 2x2	 contingency	 table	 of	 commonly	 used	




































































McNemar’s	 Chi-squared	 Test	 for	 Count	 Data,	 implemented	 in	 the	 R	 package:	 stats	 [516],	 was	
used	to	test	for	a	statistically	significant	difference	in	the	sensitivity	and	specificity	of	two	binary	
diagnostic	tests	in	a	paired	study.	 	The	Weighted	Generalised	Score	Statistic	for	Comparison	of	
Predictive	 Values	 as	 proposed	 by	 Kosinski	 [525],	 implemented	 in	 the	 R	 package:	DTComPair	




McNemar’s	 Chi-squared	 Test	 for	 Count	 Data,	 implemented	 in	 the	 R	 package:	 stats	 [516],	 was	
used	 to	 test	 for	 significant	 differences	 in	 the	 sensitivities	 and	 specificities	 of	 two	 binary	
diagnostic	 tests	 in	a	paired	study.	 	McNemar’s	Chi-squared	Test	 for	Count	Data	 is	applied	 to	a	
2x2	contingency	table,	and	tests	for	consistency	in	responses	across	two	variables.	
	
2.2.1.8	 The	Weighted	Generalised	 Score	 Statistic	 for	 Comparison	of	 Predictive	
Values	

















((X1+X2)/(n1+n2)),	and	! = 1 − !.		Testing	the	null	hypothesis	(H0):	p1=p2	
	













Traditional	 serotyping	 (by	 capillary	 precipitation)	 data	 was	 unavailable	 for	 all	 S.	suis	 isolates	
described	 in	 this	 thesis,	 therefore,	molecular	 'serotyping'	was	 performed	 using	 an	 adaptation	
(for	in	silico	use)	of	the	mPCR	assays	described	by	Liu	et	al.	[74].		Primer	sequences	were	used	as	
BLASTn	 queries	 (word_size	 10)	 against	 a	 bespoke	 BLAST	 database	 consisting	 of	 the	 draft	
genome	assemblies	of	all	isolates	described	in	this	thesis.		Nucleotide	level	matches	to	>95%	of	






Investigation	 into	 the	 prevalence	 of	 published	 putative	 "virulence-factors",	 extracted	 from	 a	
previous	 comprehensive	 review	 [129],	 in	 the	 training	 collection	was	 performed	 in	 silico.	 	 The	
protein-encoding	 sequences	 of	 the	 list	 of	 71	 putative	 "virulence-factors"	 (Table	 1.3)	 was	
extracted	 from	GenBank.	Protein-encoding	sequences	were	used	as	 tBLASTn	queries	against	a	
bespoke	BLAST	database	consisting	of	 the	draft	genome	assemblies	of	all	 isolates	described	 in	
this	 thesis	 (Table	2.1).	 	Amino	acid	 level	matches	 to	>80%	of	>80%	of	 the	 total	 length	of	each	
translated	 protein-encoding	 sequence	 were	 considered	 hits.	 	 The	 function	 geom_bar,	






To	 estimate	 the	 minimum	 number	 of	 genetic	 markers	 required	 to	 pathotype	 S.	suis,	 the	
proportion	of	the	disease-associated	phenotype	explained	by	increasing	the	cumulative	number	
of	genetic	markers	was	calculated	using	a	bespoke	R	script	written	by	Post	Doctoral	Research	
Associate	 Dr	 Lucy	 Weinert	 (Department	 of	 Veterinary	 Medicine,	 University	 of	 Cambridge).		
Estimates	were	generated	by	simple	random	sampling	of	1	of	the	14	shortlisted	genetic	markers	
and	 calculating	 the	 proportion	 of	 the	 invasive	 disease-associated	 isolates	 in	 the	 training	
collection	 (n=53)	positive	 for	 that	marker,	 and	 this	 process	 then	 repeated	 for	 10,000	 random	
sampling	 events.	 	 To	 investigate	 the	 effect	 of	 increasing	 the	 cumulative	 number	 of	 genetic	
markers,	 the	number	of	 genetic	markers	 randomly	 sampled	 from	was	 increased	 to	x,	where	x	
takes	a	value	between	1	and	14,	and	the	proportion	of	invasive	disease-associated	isolates	in	the	
training	 collection	 testing	 positive	 for	 x	 markers	 calculated;	 again	 this	 process	 was	 then	
repeated	 for	 10,000	 random	 sampling	 events.	 	 The	 process	 of	 increasing	 the	 number	 of	
candidate	 markers	 randomly	 sampled	 from	 by	 one	 was	 repeated	 until	 x=14.	 	 Boxplot,	
implemented	 in	 the	 R	 package:	 graphics,	 was	 used	 to	 plot	 boxes	 representative	 of	 the	 1st	






silico	 use,	 of	 the	 method	 described	 by	 Silva	 et	 al.	 [400].	 	 mPCR	 and	 singleplex-PCR	 primer	








Large	 and	 small	 molecular	 weight	 variants	 [53,	 409,	 530]	 of	 extracellular	 factor	 and	
muramidase-released	protein	were	determined	using	an	adaptation,	for	in	silico	use,	of	the	gene	
profiling	method	described	by	Silva	et	al.	[400].	 	PCR	primer	 sequences	were	used	as	BLASTn	









Minimum	 core	 genome	 (MCG)	 sequence	 typing	 is	 one	 of	 the	 most	 recent	 methods	 used	 to	
characterise	and	sub-type	S.	suis,	and	was	performed	using	an	adaptation,	for	in	silico	use,	of	the	
method	described	 by	 Zheng	 et	al.	 [116].	 	Multiplex-PCR	 and	 singleplex-PCR	primer	 sequences	
were	used	as	BLASTn	queries	 (word_size	10)	against	 a	bespoke	BLAST	database	 consisting	of	
the	(unfinished)	draft	genome	assemblies	of	all	253	isolates	described	in	this	thesis.		Nucleotide	
level	matches	to	>95%	of	the	total	length	of	each	query	sequence	were	considered	hits,	and	the	










Unless	 otherwise	 stated,	 S.	suis	 isolates	 were	 recovered	 from	 storage	 (-80	 ˚C	 in	 20%	 (v/v)	
glycerol)	on	90	mm	Columbia	agar	base	with	5%	sheep	blood	plates	(Oxoid	Ltd.)	at	37	˚C	for	18	–	
24	h	in	the	presence	of	5%	CO2.		Liquid	cultures,	inoculated	with	a	single	colony	pick	first	grown	
on	 solid	 agar,	 were	 grown	 in	 Todd-Hewitt	 broth	 (THB;	 Oxoid	 Ltd.)	 [531]	 supplemented	with	
0.2%	Yeast	Extract	(Fisher	Scientific)	at	37	˚C	for	18	-	24	h	without	agitation.		Prior	to	use	THB	
was	sterilised	by	autoclaving	at	115	 ˚C	 for	10	minutes	 in	a	Falcon	30	autoclave	(LTE	Scientific	
Ltd.).	 	When	appropriate	growth	medium	was	supplemented,	after	being	autoclaved,	with	100	






of	 the	S.	suis	 isolates	 in	the	original	 training	collection	was	performed	using	reference	antisera	
and	the	capillary	precipitation	technique	at	the	APHA.		Isolates	that	could	not	be	assigned	to	one	





Independent	 overnight	 THB	 cultures	were	 diluted	 to	 an	 OD595	 =	 0.05	with	 fresh	 pre-warmed	
THB,	 and	 300	 µL	 added	 to	 wells	 of	 a	 sterile	 10x10-well	 flat-bottom	 Honeycomb	 plate	 (OY	
Growth	 Curves).	 	 Bacterial	 cultures	 were	 incubated	 at	 37	 ˚C	 for	 24	 h	 without	 agitation	 on	 a	
Bioscreen	 C	 instrument	 (OY	 Growth	 Curves),	 and	 A595,	 used	 as	 a	 proxy	 for	 bacterial	 growth,	
measured	every	1	h.		Bacterial	growth	data	was	analysed	using	Prism	6	(GraphPad	Software,	CA,	
USA).	 	 Multiple	 t-tests	 were	 performed	 to	 identify	 statistically	 significant	 (p-values	 <0.05)	




Bacterial	 isolates	 were	 tested	 for	 production	 of	 biofilm	 using	 the	 Microtiter	 plate	 biofilm	
formation	 assay	 protocol	 originally	 described	 by	 Grenier	 and	 colleagues	 [532,	 533]	 with	
modifications	taken	from	Wang	et	al.	[534].	 	 Independent	overnight	THB	cultures	were	diluted	
to	an	OD595	of	0.2	with	THB,	and	100	µL	added	 to	wells	of	 a	 sterile	96-well	 flat-bottom	 tissue	
culture	plate	(Greiner	Bio-One	Ltd.)	containing	100	µL	fresh	THB.		Plates	were	incubated	at	37	˚C	


















was	 performed	 using	 the	 GenElute	 Bacterial	 DNA	 Kit	 (Sigma-Aldrich)	 with	 adaptation	 of	 the	
manufacturer’s	recommendations	for	sample	preparation.		Material	on	a	swab	was	resuspended	
in	 1	mL	 1x	 PBS	 and	 vortexed	 for	 10	 s.	 	 A	 total	 of	 500	 µL	 of	 resuspended	material	 was	 then	
centrifuged	at	16,000	rpm	for	1	min,	and	the	supernatant	discarded.		The	remaining	pellet	was	






Kit	 (Novagen).	 	 Unless	 otherwise	 stated,	 all	 PCR	 experiments	 contained	 the	 same	 reagents	
except	for	primers	and	template	DNA.		The	reaction	mixture	(50	μL)	for	each	PCR	consisted	of	1x	
KOD	Hot	Start	DNA	Polymerase	buffer,	1.5	mM	MgSO4,	0.2	mM	dNTPs	 (each),	0.3	mM	of	 each	
primer,	 0.02	 U/µL	 KOD	 Hot	 Start	 DNA	 Polymerase	 and	 10	 ng	 DNA,	 made	 up	 to	 50	 µL	 with	


















Where	 appropriate,	 PCR	 products	 were	 Sanger	 sequenced	 using	 the	 Source	 Bioscience	
Lifesciences	 Sanger	 Sequencing	 Service.	 	 Sequencing	 data	was	 returned	using	 the	 SpeedREAD	















The	 online	 software	 primer3	 version	 4.0.0	 (http://primer3.ut.ee)	 was	 used	 to	 design	 mPCR	
oligonucleotide	 primers.	 	 Multiplex-PCR	 primers	 were	 designed	 to	 target	 conserved	 regions	
within	 the	 protein-encoding	 sequence	 of	 markers	 (as	 opposed	 to	 flanking	 regions).	 	 Primers	
were	 designed	 to	 have	 similar	 physical	 characteristics,	 enabling	 simultaneous	 amplification	
under	the	same	thermal	cycling	conditions	and	in	multiplex	reactions.		Primer	length	(21-30	bp),	
GC	content	(40-60%),	melting	temperature	(>68	˚C	if	possible;	but	at	least	60	˚C),	and	expected	
amplicon	 size	 (100-1000	bp)	were	 based	 on	 the	manufacturer’s	 recommendations	 for	 primer	
design	 from	 the	Multiplex	 PCR	Plus	 Kit	 (Qiagen).	 	 Prior	 to	 ordering,	 all	 primers	were	 queried	











ROX	 Mix,	 3.4	 µL	 nuclease-free	 water,	 400	 nM	 (final	 concentration)	 of	 each	 primer	 and	 5	 µL	
template	DNA.		The	three-step	thermal	cycling	program	for	all	reactions	was	as	follows:	95	˚C	for	
3	minutes,	followed	by	40	cycles	of	95	˚C	for	5	s	(denaturation),	65	˚C	for	10	s	(annealing)	and	72	
˚C	 for	 5	 s	 (extension);	 with	 a	 final	 melt	 curve	 analysis	 from	 65	 ˚C	 to	 95	 ˚C	 (increasing	 by	




effect	 of	 differences	 in	 pH	 or	 salt	 concentration,	 a	 pre-mix	 of	 working	 concentration	 qPCR	
reagents	was	created.		The	pre-mix,	large	enough	for	the	whole	experiment,	was	then	aliquoted	
into	 single-use	 volumes	 and	 stored	 at	 -20	 ˚C.	 	 Those	 qPCR	 reagents	 unable	 to	 be	 premixed	
(primers	and	template	DNA)	were	also	aliquoted	 into	single-use	volumes	and	stored	at	 -20	 ˚C.		






The	 online	 software	 primer3	 version	 4.0.0	 (http://primer3.ut.ee)	 was	 used	 to	 design	 qPCR	
oligonucleotide	primers.		Quantitative	real-time	PCR	primers	were	designed	to	target	conserved	
regions	 within	 the	 protein-encoding	 sequence	 of	 markers	 (as	 opposed	 to	 flanking	 regions).		
Primers	 were	 designed	 to	 have	 similar	 physical	 characteristics,	 enabling	 simultaneous	
amplification	under	the	same	thermal	cycling	conditions.		Primer	length	(18-24	bp),	GC	content	










Robust	 and	 precise	 qPCR	 experiments	 are	 associated	with	 high	 PCR	 amplification	 efficiencies	
[535].		PCR	efficiencies	are	a	measurement	of	the	rate	at	which	a	PCR	amplicon	is	generated,	and	
are	 dependent	 on	 the	 primers	 used.	 	 Amplification	 efficiencies	 (or	 'primer	 efficiencies'),	 per	
primer	pair,	were	calculated	over	the	range	~1x	100	-	1x	107	genome	copies	per	reaction	using	a	
calibration	curve	and	the	equation:	









C = (Mass of DNA (ng))(Avogadro
!s constant)












Standard	 curve	 equations,	 per	 primer	 pair,	 were	 used	 to	 estimate	 the	 unknown	 number	 of	
genome	copies	in	experimental	samples.		A	standard	curve	was	generated	for	each	primer	pair,	
over	the	range	~1x	101	-	1x	105	genome	copies	per	reaction.		Each	standard	curve	was	generated	
from	 four	biological	 repeats	using	 independent	 single-use	qPCR	premixes,	 and	 each	biological	
repeat	performed	in	triplicate	per	10-fold	serial	dilution	of	template	DNA.		The	concentration	of	
DNA	 was	 linked	 to	 the	 number	 of	 thermal	 cycles	 (Ct)	 required	 to	 reach	 the	 fluorescence	
threshold	at	which	point	individual	amplification	reactions	contained	identical	amounts	of	DNA	
using	the	standard	curve	equation:	







to	 assess	 both	 i)	 the	 performance	 and	 variability	 between	 rotor	 runs	 and	 ii)	 estimate	 the	
number	 of	 genome	 copies	 in	 experimental	 samples.	 	 The	 "Auto-Find	 Threshold"	 function	 of	
Rotor-Gene	 Q	 analysis	 software	 version	 2.3.1	 (Qiagen)	 was	 used	 to	 find	 the	 fluorescence	
threshold	that	delivered	the	best-fit	of	each	standard	curve	to	the	samples	defined	as	standards.		
However,	 to	 draw	 direct	 comparison	 between	 Ct	 values	 from	 separate	 rotor	 runs,	 the	 same	
fluorescence	 threshold	must	be	used	 to	analyse	each	 rotor	 run	 [537].	 	The	mean	 fluorescence	
threshold,	 for	 each	 primer	 pair,	 was	 used	 to	 re-analyse	 the	 four	 biological	 repeats	 of	 each	
standard	 curve.	 	 A	 regression	 line,	 per	 biological	 repeat,	 was	 fitted	 and	 used	 to	 generate	
estimates	of	the	variables	a	and	b,	which	were	then	averaged	across	the	repeats	to	give	a	 final	






The	 performance	 and	 variability	 between	 qPCR	 rotor	 runs	 was	 assessed	 using	 a	 method	
described	by	Grant	et	al.	[536].		In	brief,	a	single	linear	regression	line	was	fitted	to	the	Ct	values	
of	the	four	biological	repeats	of	each	standard	curve.		Treating	Ct	values	as	random	samples	from	
a	 normal	 distribution,	 variability	 reflected	 in	 the	 confidence	 intervals	 was	 deemed	 to	 be	 an	
artefact	of	qPCR	rotor	runs.		Standards	of	known	concentration	(103	genome	copies	per	reaction;	
arbitrarily	chosen)	were	used	to	pass/fail	rotor	runs	based	on	the	following	criteria:	to	pass	 i)	
the	 standard	 deviation	 of	 Ct	 values	must	 be	 less	 than	 1.0	 and	 ii)	 the	mean	 Ct	 value	must	 fall	
within	+/-	two	standard	deviations	of	the	standard	curve.		If	any	one	of	the	criteria	listed	above	
were	 not	 met,	 qPCR	 rotor	 runs	 were	 deemed	 to	 have	 failed	 and	 all	 experiments	 repeated.		
Individual	 experimental	 samples	 were	 also	 subject	 to	 quality	 control	 based	 on	 the	 following	





Confidence	 intervals	around	 the	estimated	number	of	genome	copies	of	experimental	 samples	
were	 generated	 using	 a	 Bayesian	 approach,	 as	 previously	 described	 by	 Grant	 et	 al.	 [536].	 	 In	
brief,	using	simple	 linear	regression	to	estimate	the	standard	curve	equation	variables	a	and	b	
also	allowed	confidence	intervals	around	the	mean	number	of	genome	copies	to	be	derived	on	
the	 log10	 scale.	 	 To	 make	 interference	 about	 individual	 experimental	 samples	 prediction	
intervals	 were	 generated	 to	 provide	 a	 measure	 of	 the	 degree	 of	 uncertainty	 surrounding	 the	
estimated	number	of	 genome	copies.	 	However,	 converting	prediction	intervals	 from	 the	 log10	
back	to	 the	original	scale	 is	non-trivial,	and	so	a	Bayesian	approach	to	model	 fitting	was	used.		
This	approach	used	a	numerical	Markov	chain	Monte	Carlo	algorithm,	implemented	in	the	open	
source	 package	 WinBUGS	 [538,	 539],	 to	 fit	 the	 model.	 	 For	 each	 experimental	 sample,	 95%	
credible	 intervals	 for	 the	 predicted	 number	 of	 genome	 copies	 were	 calculated	 by	 taking	 the	
2.5th	 and	 97.5th	 percentiles	 in	 each	 case.	 	 Instead	 of	 measuring	 uncertainty	 in	 the	 mean	
estimates,	 this	 interval	 is	 generated	 centred	 about	 the	 median	 of	 the	 estimated	 number	 of	
genome	copies,	reflecting	the	fact	that	there	is	the	same	probability	of	lying	above	the	interval	as	
below	 it.	 	 This	 work	was	 performed	 using	 adaptation	 of	 a	 bespoke	 R	 script	 written	 by	 post-
doctoral	 research	 associate	 Dr	 Trevelyan	 J.	 McKinley	 (Department	 of	 Veterinary	 Medicine,	





Analytical	 sensitivity	 refers	 to	 the	 ability	 of	 an	 assay	 to	 accurately	 detect	 very	 low	
concentrations	of	a	given	substance.		Typically,	for	qPCR	analytical	sensitivity	is	expressed	as	the	
limit	 of	 detection,	 which	 is	 the	 lowest	 concentration	 that	 can	 be	 detected	 with	 reasonable	
certainty;	usually	95%	probability	(theoretically,	three	copies	per	PCR	is	the	most	sensitive	limit	
of	detection	possible)	[535].		Limit	of	detection	was	determined	by	performing	ten	replicates	per	
dilution	 over	 the	 range	~100	 -	 102	 genome	 copies	 per	 reaction.	 	 The	 dilution	with	 the	 lowest	
concentration	meeting	 the	 following	 requirements	was	deemed	 to	be	 the	 limit	 of	detection:	 i)	
the	standard	deviation	of	Ct	values	must	be	 less	than	1.0	and	 ii)	 the	number	of	replicates	with	
positive	detection	must	be	greater	than	95%.		The	mean	Ct	value	of	the	lowest	concentration	was	





accurately	 quantified	with	 95%	 confidence	 [535].	 	 Limit	 of	 quantification	was	 calculated,	 per	
primer	pair,	using	the	equation:	
!! (!"#"$ !" !"#$%&'&(#%&)$) = !! (!"#"$ !" !"#"$#%&')  − 2 !!! (!"#"$ !" !"#"$#%&') 	






state	 of	 natural	 genetic	 transformation	 (competence)	 in	 S.	suis	 under	 laboratory	 conditions	
[490].		The	ComS	protein-encoding	sequence	(SSU0050)	was	used	as	a	BLASTn	query	to	identify	







by	 Postdoctoral	 Research	 Associate	 Dr.	 Edoardo	 Zaccaria	 (Department	 of	 Animal	 Sciences,	
subdivision	 HMI,	 Wageningen	 University,	 the	 Netherlands),	 while	 I	 was	 a	 Visiting	 Research	
Fellow	 and	 guest	 of	 Prof.	 Jerry	M.	Wells’	 research	 group.	 	 Standard	 spliced	 overlap	 extension	





















































culture	 and	 added	 to	 5	 µL	 of	 ComS	 (final	 concentration	 250	mM)	 and	 1	 µL	 of	 naked	 double-
stranded	 donor	DNA	 (~100	 ng/µL).	 	 The	 ComS	 peptide,	 to	 induce	 the	 transient	 physiological	
bacterial	 state	 of	 natural	 competence,	 was	 purchased	 from	 JPT	 Peptide	 Technologies	 (Berlin,	
Germany).	 	 Samples	were	 incubated	 for	 2h	 at	 37	 ˚C,	 and	 then	 diluted	 and	 plated	 onto	 Todd-





Experimental	 infection	 of	 Greater	 Wax	 Moth	 (G.	 mellonella;	 see	 section	 1.1.4.4)	 larvae	 with	
isolates	of	S.	suis	was	performed	as	previously	described	by	Velikova	et	al.	[423].	 	Greater	Wax	
Moth	 caterpillars	 in	 the	 final-instar	 larval	 stage	 were	 purchased	 from	 Livefood	 UK	 Ltd.	
(Somerset,	 UK),	 and	 stored	 in	 the	 dark	 at	 15	 ˚C.	 	 All	 larvae	 were	 used	 within	 five	 days	 of	




1x	106	 or	 1x	105	 CFU/mL	 was	 used	 to	 infect	 the	 hemocel	 of	 G.	 mellonella	 larvae	 via	 the	 last	
posterior	 left	proleg.	 	Before	experimental	 infection	the	area	of	 injection	was	cleaned	using	an	
alcohol	 swab.	 	 Injections	were	performed	using	 a	Tridak	 STEPPER	with	27G	 x	 0.5	microlance	
hypodermic	needles	(Becton,	Dickinson	and	Company	Ltd.).		Post	experimental	infection	larvae	
were	 stored	 in	 90	mm	Petri	 dishes	 in	 the	 dark	 and	 incubated	 at	 37	 ˚C	with	 5%	 CO2.	 	 Larvae	
survival	was	 inspected	every	24	h	up	to	144	h	post-infection.	 	Larvae	were	considered	dead	 if	
unresponsive	 to	 touch.	 	 All	 experiments	 were	 performed	 using	 groups	 of	 15	 larvae,	 and	
experiments	repeated	using	larvae	from	a	different	batch;	data	from	replicate	experiments	was	










The	detection	of	 the	S.	suis	species	 in	 asymptomatic	 carrier	herds	 is	 of	 little	 practical	 value	 in	
predicting	 likelihood	 of	 future	 clinical	 relevance	 [11].	 	 Instead,	 the	 value	 of	 future	molecular	
tools	 for	 surveillance	and	preventive	health	management	 lies	 in	 the	detection	of	S.	suis	 strains	
that	have	genetically	 increased	potential	 to	cause	disease	and	are	colonising	presently	healthy	
animals	[11].		At	present,	numerous	methods	exist	to	characterise	and	sub-type	S.	suis	isolates	as	
part	 of	 epidemiological	 studies,	 the	 most	 recent	 of	 these	 have	 been	 reviewed	 in	 chapter	 1	




A	 so-far	unexploited	method	 for	 the	 identification	of	 virulence-associated	 factors	 in	S.	suis	 are	
the	 genome-wide	 association	 studies	 (GWAS).	 	 Although	 the	use	 of	GWAS	 is	 common	 for	 SNP	
and	 small	 indel	 analyses	 of	 eukaryotic	 genomes,	 only	 relatively	 recently	 have	 these	methods	
been	adapted	for	bacterial	genomics.		At	present,	as	a	result	of	advances	and	reductions	in	cost,	
the	whole-genome	sequencing	of	multiple	 isolates	of	 the	 same	species	has	opened	up	exciting	
possibilities	 to	 reassess	 diagnostic	 and	 surveillance	 programs	 for	 bacteria	 that	 behave	 as	
asymptomatic	commensal-like	strains	contributing	to	the	normal	oral	microflora,	as	well	as,	an	
infectious	agent	responsible	for	invasive	disease;	such	as	S.	suis	[141,	477,	493,	541].		In	fact,	this	
explosion	 in	 the	 amount	 of	 whole-genome	 sequencing	 data	 has	 provided	 the	 necessary	






and	 the	 acquisition	 of	 antimicrobial	 resistance	 genes	 as	 studied	 in	 Streptococcus	 pneumonia	




the	 Discriminant	 Analysis	 of	 Principal	 Components	 method	 (DAPC)	 has	 been	 used	 to	 detect	
genotypes	 associated	 with	 temporal	 variation	 in	 seasonal	 influenza	 (H3N2)	 [517,	 518],	 and	
PLINK	 [549]	 has	 been	 used	 to	 detect	 genotypes	 associated	with	 the	 phenotypes	 toxicity	 (the	
ability	to	destroy	host	cell	membranes)	and	adhesion	(the	ability	to	adhere	to	human	tissues)	in	
Staphylococcus	aureus	[550].	 	 Such	 studies	 sought	 to	 identify	 associations	 between	phenotype	
and	genotype	that	would	improve	surveillance	and	diagnostic	tools,	as	well	as	contribute	to	an	
increased	 understanding	 of	 the	 respective	 pathogens	 –	 potentially	 leading	 to	 new	 treatment	
strategies.	
	
As	mentioned	 in	 chapter	1,	previous	bioinformatics	analyses	 in	our	group	revealed	significant	
genomic	 differences	 between	 invasive	 disease-associated	 isolates	 and	 non-disease	 associated	
S.	suis	isolates	recovered	from	the	upper	respiratory	tract	of	pigs	on	farms	in	England	and	Wales	
[141].	 	 In	 fact,	 in	 the	 corresponding	 Nature	 Communications	 publication	 disease-associated	
isolates	were	described	as	having	smaller	genomes,	and	as	a	result,	a	reduced	gene	content,	 in	
comparison	 to	 non-disease	 associated	 isolates.	 	 However,	 despite	 this	 it	 was	 also	 found	 that	
S.	suis	 isolates	 causing	 invasive	 disease	 in	 pigs	 had	 an	 overrepresentation	 of	 genes	 previously	
reported	to	be	associated	with	virulence	[141,	360].	 	This	chapter	builds	on	these	findings	and	
describes	first	the	identification	and	then	compilation	of	a	shortlist	of	genetic	markers	in	S.	suis	
isolates	 that	 were	 found	 to	 have	 statistically	 significant	 associations	 with	 the	 phenotypes	 i)	
invasive	disease	or	 ii)	asymptomatic	carriage	on	the	palatine	tonsils	of	pigs	on	UK	farms.	 	The	
work	described	 in	 this	 chapter	used	 the	whole-genome	sequencing	data	of	 a	 collection	of	115	
isolates	of	S.	suis	recovered	from	pigs	on	farms	in	England	and	Wales,	that	had	previously	been	





In	 order	 to	 define	 a	 shortlist	 of	 genetic	 markers	 associated	 with	 our	 phenotypic	 groups	 that	
could	 potentially	 be	 exploited	 to	 pathotype	 S.	suis,	 three	 complementary	 approaches	 are	
described	i)	a	comparison	of	observed	and	expected	frequencies	of	protein-encoding	sequences	
using	 the	 Chi-squared	 test	 for	 independence,	 ii)	 a	 consideration	 of	 the	 impact	 that	 bacterial	
population	structure	had	on	these	findings,	using	the	Cochran-Mantel-Haensael	Chi-squared	test	
for	 count	 data	 (an	 approach	 also	 used	 in	 the	 software	 PLINK	 [549]	 and	 iii)	 the	 multivariate	
Discriminant	Analysis	 of	Principal	Components	 [518].	 	All	 of	 these	 approaches	 can	be	used	 to	
investigate	both	SNPs	within	the	core-genome	and/or	variation	in	the	pan-genome	(in	the	form	
of	 presence	 and	 absence	 of	 protein-encoding	 sequences).	 	 However,	with	 future	 intentions	 to	
create	 a	 simple	 molecular	 tool	 to	 pathotype	 S.	suis,	 using	 techniques	 such	 as	 a	 mPCR,	 the	
decision	was	made	to	investigate	the	variation	in	the	presence	and	absence	of	protein-encoding	
sequences	 in	 the	 accessory	 genome	 of	 the	 115	 isolates	 of	 the	 original	 training	 collection.	 	 In	


















fact,	 historically	 serotyping	 has	 commonly	 been	 used	 as	 a	 proxy	 for	 virulence	 potential.		
Therefore,	 investigation	 of	 the	 serotype	 prevalence	 in	 the	 S.	suis	 isolates	 of	 the	 training	
collection	 was	 an	 obvious	 starting	 point	 of	 this	 PhD	 project.	 	 Table	 3.1	 shows	 the	 serotype	
assigned	 to	 each	 of	 the	 115	 training	 collection	 isolates	 using	 two	 approaches,	 i)	 traditional	
capillary	 precipitation	 and	 ii)	 adaptation,	 for	 in	 silico	 use,	 of	 the	 mPCR	 assays	 described	 by	
Liu	et	al.	[74].	 	 Figure	3.1	 summarises	 the	 information	 in	Table	3.1,	 and	 shows	 the	 cumulative	
frequency	of	isolates	assigned	to	one	of	the	35	(1-34	and	1/2)	serotypes	originally	described	for	
S.	suis.	 	 Serotype	 2	 was	 the	 most	 frequently	 identified	 serotype	 in	 the	 training	 collection,	
regardless	 of	 observed	 clinical	 phenotype.	 	 Serotype	 2,	 based	 on	 the	 'gold-standard'	 capillary	
precipitation	data,	was	also	the	serotype	most	frequently	assigned	(n=28,	of	a	total	53;	54%)	to	
the	 invasive	 disease-causing	 isolates,	 in	 agreement	 with	 previously	 published	 reports	 in	 the	
literature.		Despite	good	agreement,	discrepancies	do	exist	between	the	traditional	and	in	silico	
approaches	 used	 to	 generate	 the	 serotyping	 data	 in	 Table	 3.1.	 	 The	most	 obvious	 being	 that	
adaptation,	 for	 in	 silico	 use,	 of	 the	 mPCR	 assays	 described	 by	 Liu	et	al.	was	 able	 to	 assign	 a	
serotype	 to	 34	 isolates	 deemed	 to	 be	 non-serotypable	 (NT)	 using	 the	 traditional	 capillary	
precipitation	 technique.	 	 Six	 other	discrepancies	 also	 exist	 between	 the	 in	silico	 approach	 and	
the	'gold-standard'	capillary	precipitation	approach	undertaken	at	the	APHA.		For	example,	the	
three	non-disease	associated	 isolates	 (LSS078,	LSS095	and	LSS096)	assigned	 to	 serotype	1	by	
the	 capillary	precipitation	 technique	were	deemed	 to	be	 serotypes	12,	11	and	11	 respectively	
using	the	in	silico	approach.		Other	important	observations	include	not	all	serotype	2	isolates	are	
associated	 with	 invasive	 disease,	 in	 fact,	 differences	 in	 disease	 association	 are	 present	 in	
numerous	 serotypic	 groups.	 	 Molecular	 'serotyping’	 assigned	 just	 one	 invasive	 disease-













		 		 		 Serotyping	
Isolate	 Collection	 Phenotype	 Capillary	precipitation	 In	silico	(Liu	et	al.	[74])	
P1/7	 Original	training		 Disease-associated	 2	 2&1/2	
SS002	 Original	training		 Disease-associated	 2	 2&1/2	
SS004	 Original	training		 Disease-associated	 2	 2&1/2	
SS005	 Original	training		 Disease-associated	 1	 1&14	
SS006	 Original	training		 Disease-associated	 2	 2&1/2	
SS007	 Original	training		 Disease-associated	 2	 2&1/2	
SS008	 Original	training		 Disease-associated	 2	 2&1/2	
SS010	 Original	training		 Disease-associated	 2	 2&1/2	
SS012	 Original	training		 Disease-associated	 14	 1&14	
SS003	 Original	training		 Disease-associated	 14	 1&14	
SS015	 Original	training		 Disease-associated	 9	 9	
SS016	 Original	training		 Disease-associated	 14	 1&14	
SS017	 Original	training		 Disease-associated	 1	 1&14	
SS018	 Original	training		 Disease-associated	 7	 7	
SS021	 Original	training		 Disease-associated	 1	 1&14	
SS022	 Original	training		 Disease-associated	 1	 1&14	
SS024	 Original	training		 Disease-associated	 7	 7	
SS025	 Original	training		 Disease-associated	 2	 2&1/2	
SS028	 Original	training		 Disease-associated	 2	 2&1/2	
SS029	 Original	training		 Disease-associated	 14	 1&14	
SS035	 Original	training		 Disease-associated	 2	 2&1/2	
SS036	 Original	training		 Disease-associated	 2	 2&1/2	
SS038	 Original	training		 Disease-associated	 2	 2&1/2	
SS041	 Original	training		 Disease-associated	 7	 7	
SS042	 Original	training		 Disease-associated	 2	 2&1/2	
SS044	 Original	training		 Disease-associated	 2	 2&1/2	
SS045	 Original	training		 Disease-associated	 1	 1&14	
SS046	 Original	training		 Disease-associated	 2	 2&1/2	
SS053	 Original	training		 Disease-associated	 3	 3	
SS057	 Original	training		 Disease-associated	 2	 2&1/2	
	 112	
SS058	 Original	training		 Disease-associated	 2	 2&1/2	
SS060	 Original	training		 Disease-associated	 2	 2&1/2	
SS062	 Original	training		 Disease-associated	 4	 4	
SS063	 Original	training		 Disease-associated	 14	 1&14	
SS065	 Original	training		 Disease-associated	 2	 2&1/2	
SS066	 Original	training		 Disease-associated	 1	 1&14	
SS068	 Original	training		 Disease-associated	 8	 8	
SS069	 Original	training		 Disease-associated	 2	 2&1/2	
SS071	 Original	training		 Disease-associated	 1	 1&14	
SS072	 Original	training		 Disease-associated	 1	 1&14	
SS077	 Original	training		 Disease-associated	 14	 1&14	
SS083	 Original	training		 Disease-associated	 7	 7	
SS085	 Original	training		 Disease-associated	 2	 2&1/2	
SS086	 Original	training		 Disease-associated	 2	 2&1/2	
SS087	 Original	training		 Disease-associated	 2	 2&1/2	
SS088	 Original	training		 Disease-associated	 9	 8	
SS093	 Original	training		 Disease-associated	 2	 2&1/2	
SS095	 Original	training		 Disease-associated	 2	 2&1/2	
SS096	 Original	training		 Disease-associated	 2	 2&1/2	
SS097	 Original	training		 Disease-associated	 16	 16	
SS098	 Original	training		 Disease-associated	 2	 2&1/2	
SS099	 Original	training		 Disease-associated	 2	 2&1/2	
SS100	 Original	training		 Disease-associated	 1/2	 2&1/2	
LSS001	 Original	training		 Non-disease	associated	 2	 2&1/2	
LSS003	 Original	training		 Non-disease	associated	 1/2	 2&1/2	
LSS009	 Original	training		 Non-disease	associated	 NT	 10	
LSS011	 Original	training		 Non-disease	associated	 NT	 31	
LSS018	 Original	training		 Non-disease	associated	 NT	 16	
LSS020	 Original	training		 Non-disease	associated	 4	 4	
LSS023	 Original	training		 Non-disease	associated	 NT	 24	
LSS025	 Original	training		 Non-disease	associated	 1/2	 2&1/2	
LSS027	 Original	training		 Non-disease	associated	 3	 10	
LSS030	 Original	training		 Non-disease	associated	 NT	 31	
LSS031	 Original	training		 Non-disease	associated	 NT	 24	
LSS032	 Original	training		 Non-disease	associated	 NT	 24	
LSS034	 Original	training		 Non-disease	associated	 NT	 8	
LSS037	 Original	training		 Non-disease	associated	 NT	 24	
LSS038	 Original	training		 Non-disease	associated	 NT	 NT	
LSS039	 Original	training		 Non-disease	associated	 NT	 31	
LSS040	 Original	training		 Non-disease	associated	 NT	 6	
LSS041	 Original	training		 Non-disease	associated	 NT	 21	
LSS042	 Original	training		 Non-disease	associated	 NT	 16	
LSS044	 Original	training		 Non-disease	associated	 NT	 15	
LSS047	 Original	training		 Non-disease	associated	 NT	 16	
LSS048	 Original	training		 Non-disease	associated	 NT	 31	
LSS049	 Original	training		 Non-disease	associated	 NT	 NT	
LSS053	 Original	training		 Non-disease	associated	 NT	 21	
LSS054	 Original	training		 Non-disease	associated	 NT	 NT	
	 113	
LSS055	 Original	training		 Non-disease	associated	 NT	 9	
LSS057	 Original	training		 Non-disease	associated	 4	 NT	
LSS058	 Original	training		 Non-disease	associated	 NT	 31	
LSS059	 Original	training		 Non-disease	associated	 NT	 10	
LSS060	 Original	training		 Non-disease	associated	 2	 31	
LSS061	 Original	training		 Non-disease	associated	 2	 2&1/2	
LSS062	 Original	training		 Non-disease	associated	 2	 2&1/2	
LSS063	 Original	training		 Non-disease	associated	 2	 2&1/2	
LSS064	 Original	training		 Non-disease	associated	 NT	 21	
LSS065	 Original	training		 Non-disease	associated	 NT	 10	
LSS067	 Original	training		 Non-disease	associated	 NT	 8	
LSS068	 Original	training		 Non-disease	associated	 NT	 8	
LSS069	 Original	training		 Non-disease	associated	 NT	 31	
LSS070	 Original	training		 Non-disease	associated	 NT	 9	
LSS071	 Original	training		 Non-disease	associated	 2	 2&1/2	
LSS072	 Original	training		 Non-disease	associated	 2	 2&1/2	
LSS075	 Original	training		 Non-disease	associated	 NT	 31	
LSS076	 Original	training		 Non-disease	associated	 NT	 8	
LSS077	 Original	training		 Non-disease	associated	 1/2	 2&1/2	
LSS078	 Original	training		 Non-disease	associated	 1	 12	
LSS079	 Original	training		 Non-disease	associated	 NT	 15	
LSS080	 Original	training		 Non-disease	associated	 NT	 31	
LSS081	 Original	training		 Non-disease	associated	 NT	 15	
LSS082	 Original	training		 Non-disease	associated	 NT	 16	
LSS083	 Original	training		 Non-disease	associated	 7	 7	
LSS084	 Original	training		 Non-disease	associated	 7	 7	
LSS085	 Original	training		 Non-disease	associated	 7	 7	
LSS086	 Original	training		 Non-disease	associated	 1/2	 2&1/2	
LSS088	 Original	training		 Non-disease	associated	 NT	 NT	
LSS089	 Original	training		 Non-disease	associated	 NT	 8	
LSS090	 Original	training		 Non-disease	associated	 NT	 31	
LSS091	 Original	training		 Non-disease	associated	 6	 6	
LSS092	 Original	training		 Non-disease	associated	 NT	 9	
LSS094	 Original	training		 Non-disease	associated	 4	 4	
LSS095	 Original	training		 Non-disease	associated	 1	 11	
LSS096	 Original	training		 Non-disease	associated	 1	 11	
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in	 other	 Gram-positive	 organisms	 has	 been	 shown	 to	 affect	 the	 virulence	 of	 S.	suis	 strains	
through	targeted	mutagenesis	studies	[299-301].		Therefore,	investigation	into	the	prevalence	of	
published	 putative	 "virulence-factors",	 extracted	 from	 a	 previous	 comprehensive	 review	 by	
Fittipaldi	 et	 al.	 [129],	was	 another	 obvious	 requirement	 for	 this	 PhD	 project.	 	 To	 do	 this,	 the	
protein-encoding	 sequence	 of	 71	 putative	 "virulence-factors"	 (Table	 1.3)	 was	 extracted	 from	
GenBank,	and	then	used	as	tBLASTn	queries	against	a	bespoke	BLAST	database	consisting	of	the	
draft	genome	assemblies	of	all	isolates	described	in	this	thesis.		Figure	3.2	shows	the	proportion	







(p-value	 <0.05)	 associations	 between	 the	 detection	 of	 protein-encoding	 sequences	 (genotype)	
and	 observed	 clinical	 phenotype,	 identifying	 14	 statistically	 significant	 associations	 (indicated	
with	 an	 asterisk)	 between	 published	 putative	 "virulence-factors"	 and	 the	 invasive	 disease-
associated	phenotype.		Of	note,	the	'virulence-associated	markers'	(rather	than	virulence	factors	
per	se)	 extracellular	protein	 factor,	muramidase-related	protein,	 as	well	 as,	 the	 thiol-activated	
toxin	 hemolysin,	 known	 as	 Suilysin	 were	 amongst	 the	 14	 published	 factors	 with	 statistically	
significant	association	with	the	invasive	disease	phenotype;	each	of	which	has	been	extensively	
used	 to	 characterise	 and	 predict	 the	 virulence	 potential	 of	 S.	suis	 strains	 in	 certain,	 mainly	
European	(UK,	Austria,	Germany,	and	Spain),	countries[129,	408,	409].		In	fact,	further	analyses	


































































3.2.3	 Identification	 of	 genetic	 markers	 in	 the	 Streptococcus	 suis	 accessory-
genome	associated	with	observed	clinical	phenotype	
The	identification	of	genetic	markers	associated	with	observed	clinical	phenotype	was	achieved	
using	 prevalence	 data	 for	 7261	 protein-encoding	 sequences	 deemed	 to	 be	 in	 the	 S.	suis	
accessory-genome	(i.e.	genes	absent	from	one	or	more	isolates	or	unique	to	a	given	isolate).	 	A	
combination	of	 three	complementary	approaches	was	used	to	define	a	preliminary	shortlist	of	
markers,	 that	 included	 i)	 7261	 independent	Chi-squared	 tests	 for	 independence	were	used	 to	
identify	 statistically	 significant	 associations	 between	 genotype	 (protein-encoding	 sequences)	
and	observed	clinical	phenotype	(n=383	 identified),	 ii)	a	consideration	of	any	 impact	bacterial	
population	 structure	 had	 on	 findings	 using	 the	 Cochran-Mantel-Haenszel	 Chi-squared	 test	 for	
count	 data	 and	 iii)	 the	multivariate	DAPC	 (n=221).	 	 That	 resulted	 in	 the	 identification	 of	 497	
unique	candidate	genetic	markers	to	pathotype	S.	suis.	
	
3.2.3.1	 The	 Chi-squared	 test	 for	 independence	 identified	 383	 statistically	
significant	associations	between	genotype	and	phenotype	
The	Chi-squared	test	for	independence	was	used	to	identify	statistically	significant	associations	
between	 protein-encoding	 sequence	 prevalence	 (genotype)	 and	 observed	 clinical	 phenotype.		
Assuming	genotype	and	phenotype	to	be	independent,	the	Chi-squared	test	compared	observed	
frequencies	 with	 expected,	 and	 Bonferroni	 adjustment	 (0.05/7261)	 was	 used	 to	 control	 for	
family-wise	error	associated	with	multiple	sampling.	 	Figure	3.3	shows	a	visual	representation	
of	the	-log10-transformed	p-value	for	7261	independent	Chi-squared	tests	for	independence,	of	
which	 383	 were	 deemed	 statistically	 significant	 (above	 the	 horizontal	 dotted	 line).	 	 Further	




protein-encoding	 sequences	were	 found	 to	 be	 over	 represented	 in	 disease-associated	 isolates	
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(>50%	of	 disease-associated	 and	 <50%	of	 non-disease	 associated	 isolates),	 and	 vice	 versa	 47	














































3.2.3.2	 The	 Cochran-Mantel-Haenszel	 Chi-squared	 test	 for	 count	 data	 deemed	
no	 statistically	 significant	 associations	 exist	 between	 genotype	 and	
observed	clinical	phenotype	
The	 CMH	 Chi-squared	 test	 for	 count	 data	 was	 used	 to	 minimise	 the	 number	 of	 spurious	
associations	 due	 to	 an	 underlying	 bacterial	 population	 structure.	 	 The	 Chi-squared	 model	





a	 protein-encoding	 sequence	 being	 present	 in	 invasive	 disease-associated	 isolates	 compared	
with	non-disease	 associated	 isolates.	 	 Independent	 CMH	Chi-squared	 test	 for	 count	 data	were	
performed	on	the	383	protein-encoding	sequences	for	which	the	detection	of	was	deemed	to	be	
associated	 with	 observed	 clinical	 phenotype	 using	 the	 Chi-squared	 test	 for	 independence.		






tests	 increases	 so	does	 the	 likelihood	of	 a	 rare	 event,	 and	with	 it	 the	 likelihood	of	 incorrectly	
rejecting	 the	null	 hypothesis	 (Type	 I	 error).	 	The	 classic	 approach	 to	 the	multiple	 comparison	
problem	 is	 to	 control	 the	 familywise	 error	 rate,	 and	 the	 most	 common	 method	 is	 with	 a	
Bonferroni	adjustment	(α/n).		However,	a	common	criticism	of	the	Bonferroni	correction	is	that	
it	 can	 be	 somewhat	 conservative	 for	 a	 large	 number	 of	 tests,	 at	 the	 cost	 of	 increasing	 the	
probability	 of	 producing	 false	 negatives	 (Type	 II	 error).	 	Without	 Bonferroni	 adjustment,	 the	
CMH	Chi-squared	test	 for	count	data	 identified	nine	protein-encoding	sequences	deemed	to	be	
associated	 with	 observed	 clinical	 phenotype	 (p-values	 <0.05;	 summarised	 in	 Table	 3.2).		
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However,	 close	 investigation	 of	 the	 length	 and	 predicted	 biological	 function	 of	 these	 nine	
protein-encoding	 sequences	 revealed	 none	 to	 be	 suitable	 targets	 for	 a	 mPCR	 pathotyping	
assay/tool.	 	 Based	 on	 the	 mean	 sequence	 length	 seven	 protein-encoding	 sequences	 were	
considered	inappropriate	as	potential	pathotyping	markers	because	they	were	less	than	500	bp	
in	 length	 (based	 on	 the	manufacturer’s	 recommendations	 for	 primer	 design	 using	 the	Qiagen	
Multiplex	 PCR	 Plus	 kit).	 	 The	 two	 other	 protein-encoding	 sequences	 were	 also	 ruled	 out	 as	























0001	 0.03	 0.83	 0.06	 939	 Transposase	
1668	 0.01	 1.00	 0.47	 261	 Copper	sensing	
transcriptional	repressor	
1846	 0.03	 0.81	 0.05	 204	 Hypothetical	protein	
1950	 0.02	 0.55	 0.02	 360	 Hypothetical	protein	
2740	 0.03	 0.83	 0.06	 939	 Transposase	
	 	 	 	 	 	
0002	 0.01	 0.06	 0.47	 480	 Transposase	
2141	 0.03	 0.06	 0.44	 150	 Hypothetical	protein	
2145	 0.02	 0.06	 0.58	 183	 YcfA-like	protein	
2229	 0.01	 0.06	 0.47	 480	 Transposase	
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3.2.3.3	 The	 Discriminant	 Analysis	 of	 Principal	 Components	 identified	 221	
statistically	significant	genetic	differences	between	phenotypic	groups	
In	addition	to	univariate	methods	adjusted	for	multiple	sampling	the	DAPC	[517,	518]	was	also	
used	 to	 identify	 genetic	 differences	 between	 pre-defined	 (disease-associated	 and	 non-disease	
associated	 groups)	 phenotypic	 groups.	 	 DAPC	 is	 a	 multivariate	 genome-wide	 association	
approach	 that	 identified	 genetic	 structures	 without	 making	 assumptions	 about	 underlying	
population	 genetic	 models.	 	 DAPC	 is	 a	 two-step	 approach	 that	 i)	 identified	 genetic	 variation	
using	 a	 principal	 components	 analysis	 (Figure	 3.4	 (a))	 and	 ii)	 then	 summarised	 the	 best	
discrimination	 of	 between	 group	 variation	 with	 a	 discriminant	 analysis	 (Figure	 3.4	 (b)).		
Figure	3.4	(a)	shows	the	first	two	principal	components	of	the	data.	 	Principal	components	are	
ordered	 so	 that	 the	 first	 few	 represent	 as	 much	 of	 the	 variation	 in	 the	 original	 dataset	 as	
possible.	 	 PCA	 showed	81%	 (n=43)	of	disease-associated	 isolates	 (red)	 form	a	distinct	 cluster	
based	on	information	held	in	the	first	principal	component	(X-axis),	indicating	differences	in	the	
positive	 detection	 of	 protein-encoding	 sequences	 are	 present	 between	 phenotypic	 groups.		
Figure	3.4	(b)	shows	the	Discriminant	Analysis	(of	the	Principal	Component	Analysis)	that	uses	
data	 transformation	 of	 the	PCA	 to	 achieve	 the	 best	 discrimination	 of	 isolates	 into	pre-defined	
(phenotypic)	 groups.	 	 Clear	 separation	 between	 invasive	 disease-associated	 (red)	 and	 non-
disease	 associated	 (grey)	 phenotypic	 groups,	 despite	 a	 small	 number	 of	 exceptions,	 indicated	
differences	 in	the	prevalence	of	protein-encoding	sequences	 in	the	accessory-genome	could	be	
responsible	 for	 invasive	 S.	suis	 disease.	 	 Importantly,	 the	 total	 amount	 of	 original	 variation	
retained	in	the	DAPC	model	affected	which	genetic	markers	contributed	most	to	the	separation	
of	genetic	structures	in	the	training	collection.		As	a	result,	to	assess	the	impact	the	total	amount	
of	 original	 variation	 retained	 had	 on	 the	 DAPC	model	 four	 independent	 DAPC	 analyses	 were	
performed	 retaining	 60,	 70,	 80	 or	 90%	 of	 the	 original	 genetic	 variation.	 	 The	 1%	 of	 genetic	
markers	ranked	(highest-to-lowest)	based	on	their	contribution	to	the	first	principal	component	



































































1	 1_a	 1	 1	 1	 0	
2	 1_b	 1	 1	 1	 1	
3	 10_a	 0	 0	 1	 0	
4	 1263	 0	 0	 0	 1	
5	 1282_a	 0	 0	 0	 1	
6	 1342_a	 1	 0	 0	 0	
7	 1342_b	 1	 0	 0	 0	
8	 1375	 0	 0	 0	 1	
9	 1406_a	 1	 1	 1	 0	
10	 1406_b	 1	 1	 1	 0	
11	 1416	 0	 0	 0	 1	
12	 1529	 0	 0	 0	 1	
13	 1532_b	 1	 1	 0	 1	
14	 1541	 0	 0	 0	 1	
15	 1542	 0	 0	 0	 1	
16	 1572	 0	 0	 0	 1	
17	 1586	 0	 0	 1	 0	
18	 1630	 0	 0	 1	 1	
19	 1631	 1	 1	 0	 1	
20	 1636	 1	 1	 1	 1	
21	 1642	 0	 1	 0	 0	
22	 1643	 0	 1	 1	 1	
23	 1647	 0	 0	 1	 0	
24	 1648	 0	 0	 1	 0	
25	 1655	 1	 1	 1	 1	
26	 1668	 0	 0	 1	 1	
27	 1687_a	 1	 1	 1	 0	
28	 1688_b	 0	 1	 1	 0	
29	 1692	 0	 0	 1	 0	
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30	 1702	 0	 1	 1	 0	
31	 1705	 1	 1	 1	 0	
32	 1706	 1	 1	 1	 0	
33	 1707	 1	 1	 1	 0	
34	 1708	 1	 1	 1	 0	
35	 1709	 1	 1	 1	 0	
36	 1710	 1	 1	 1	 0	
37	 1711_a	 0	 0	 1	 0	
38	 1712	 0	 1	 0	 0	
39	 1713_a	 1	 1	 1	 0	
40	 1715_b	 1	 1	 1	 0	
41	 1716	 0	 1	 0	 0	
42	 1717	 1	 1	 1	 0	
43	 171	 1	 1	 1	 0	
44	 1720	 1	 1	 1	 0	
45	 1721	 1	 1	 1	 1	
46	 1722	 1	 1	 1	 0	
47	 1724	 1	 1	 0	 0	
48	 1725	 1	 1	 0	 0	
49	 1726	 1	 1	 1	 0	
50	 1729	 1	 1	 1	 0	
51	 1730	 0	 0	 1	 0	
52	 1731	 0	 0	 1	 0	
53	 1733	 1	 1	 1	 0	
54	 1740	 0	 0	 0	 1	
55	 1746	 1	 1	 0	 0	
56	 1749	 0	 0	 1	 0	
57	 1750	 1	 0	 0	 0	
58	 1751_b	 1	 1	 0	 0	
59	 1752_b	 1	 1	 1	 0	
60	 1753	 0	 0	 1	 0	
61	 1758	 1	 1	 1	 1	
62	 1764	 0	 0	 1	 0	
63	 1773	 0	 0	 1	 0	
64	 1776	 1	 1	 1	 0	
65	 1779	 0	 0	 1	 0	
66	 1782_b	 1	 1	 0	 0	
67	 1784_b	 1	 1	 1	 0	
68	 1789_a	 1	 1	 0	 0	
69	 1796	 1	 0	 1	 0	
70	 18_a	 0	 1	 0	 0	
71	 1806	 0	 1	 0	 0	
72	 1807	 0	 0	 1	 0	
73	 1808	 0	 0	 1	 0	
74	 1809	 1	 1	 0	 0	
75	 1811	 1	 1	 0	 1	
76	 1818	 1	 1	 1	 0	
77	 1819	 0	 1	 0	 0	
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78	 1820	 1	 1	 0	 0	
79	 1821	 1	 1	 1	 0	
80	 1823	 1	 0	 0	 0	
81	 1827	 1	 0	 1	 0	
82	 1828	 0	 1	 0	 0	
83	 1829_b	 1	 1	 1	 0	
84	 1846	 1	 1	 1	 1	
85	 1850	 1	 1	 1	 0	
86	 1852	 1	 1	 1	 0	
87	 1853	 1	 1	 1	 0	
88	 1854	 1	 1	 0	 0	
89	 1855	 1	 1	 1	 0	
90	 1858	 1	 1	 1	 0	
91	 1859	 1	 1	 1	 1	
92	 1860	 1	 1	 0	 0	
93	 1861	 1	 1	 0	 0	
94	 1862	 1	 1	 0	 0	
95	 1863	 1	 0	 0	 0	
96	 1864	 1	 1	 1	 0	
97	 1865	 1	 1	 0	 0	
98	 1866	 1	 1	 1	 0	
99	 1867	 1	 1	 1	 0	
100	 1868	 1	 1	 1	 0	
101	 1869	 1	 1	 1	 0	
102	 1870	 1	 1	 1	 0	
103	 1871	 1	 1	 1	 0	
104	 1872	 1	 1	 0	 0	
105	 1874	 1	 1	 1	 0	
106	 1875	 1	 1	 0	 0	
107	 1876	 1	 1	 0	 0	
108	 1877	 1	 1	 1	 0	
109	 1878	 1	 0	 0	 0	
110	 1879	 1	 1	 1	 0	
111	 1880	 1	 1	 0	 0	
112	 1881	 1	 1	 1	 0	
113	 1883	 1	 1	 1	 0	
114	 1885	 1	 1	 0	 0	
115	 1886	 1	 1	 1	 0	
116	 1893	 0	 0	 1	 0	
117	 1894	 0	 0	 1	 0	
118	 1895_b	 0	 0	 1	 0	
119	 1896_a	 1	 1	 0	 0	
120	 1898	 1	 1	 0	 0	
121	 1900_a	 0	 0	 1	 1	
122	 1902	 1	 1	 1	 0	
123	 1905	 0	 0	 1	 0	
124	 1907	 0	 0	 1	 0	
125	 1911	 1	 1	 1	 0	
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126	 1912	 0	 0	 1	 1	
127	 1914	 0	 0	 1	 1	
128	 1915	 0	 0	 1	 1	
129	 1950	 0	 0	 0	 1	
130	 1955	 1	 0	 0	 0	
131	 1972	 0	 1	 0	 1	
132	 1982	 1	 1	 0	 0	
133	 1996	 1	 1	 1	 1	
134	 1999_a	 0	 0	 0	 1	
135	 2_a	 1	 1	 1	 0	
136	 2_c	 0	 0	 0	 1	
137	 2000	 1	 0	 0	 0	
138	 2003	 0	 1	 0	 1	
139	 2004_b	 0	 1	 0	 0	
140	 2007	 0	 1	 0	 0	
141	 2012	 0	 0	 0	 1	
142	 2015	 0	 0	 1	 0	
143	 2028	 1	 1	 1	 0	
144	 2031	 0	 0	 1	 0	
145	 2039	 0	 0	 0	 1	
146	 2040	 0	 1	 1	 0	
147	 2042_a	 0	 0	 0	 1	
148	 2056_a	 1	 0	 0	 0	
149	 2073	 0	 0	 0	 1	
150	 2074_b	 0	 0	 0	 1	
151	 2096	 0	 1	 0	 0	
152	 2111_b	 0	 0	 0	 1	
153	 2120	 1	 0	 0	 0	
154	 2121	 1	 0	 0	 0	
155	 2123	 0	 0	 0	 1	
156	 2125	 0	 0	 0	 1	
157	 2126	 0	 0	 0	 1	
158	 2127	 0	 0	 0	 1	
159	 2128	 0	 0	 0	 1	
160	 2131	 0	 0	 0	 1	
161	 2137	 0	 0	 0	 1	
162	 2141	 0	 0	 0	 1	
163	 2145	 0	 0	 1	 1	
164	 2148	 1	 0	 0	 0	
165	 2174	 0	 0	 0	 1	
166	 2195	 1	 0	 0	 0	
167	 2229	 0	 0	 0	 1	
168	 2258	 0	 0	 1	 1	
169	 2259	 0	 0	 1	 1	
170	 2260	 0	 0	 1	 1	
171	 2261	 0	 0	 1	 1	
172	 2262	 0	 0	 1	 1	
173	 2263	 0	 0	 1	 1	
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174	 2264	 0	 0	 1	 1	
175	 2289	 0	 0	 0	 1	
176	 2295	 0	 0	 1	 0	
177	 2297_b	 0	 0	 0	 1	
178	 2305	 0	 0	 0	 1	
179	 2312	 0	 0	 0	 1	
180	 2318	 0	 0	 0	 1	
181	 2329	 0	 0	 0	 1	
182	 2356	 0	 0	 0	 1	
183	 2417	 0	 0	 1	 1	
184	 2445	 0	 0	 1	 0	
185	 2456	 0	 0	 0	 1	
186	 2482	 0	 0	 0	 1	
187	 2555_b	 0	 0	 0	 1	
188	 26_a	 1	 1	 1	 1	
189	 2602	 0	 0	 1	 0	
190	 2621	 0	 0	 0	 1	
191	 2676	 0	 0	 1	 0	
192	 2740	 1	 1	 1	 1	
193	 2749	 0	 0	 0	 1	
194	 2776	 0	 0	 0	 1	
195	 2851	 0	 0	 0	 1	
196	 2932	 0	 0	 0	 1	
197	 2996	 0	 0	 0	 1	
198	 3222	 0	 0	 0	 1	
199	 3423	 0	 0	 0	 1	
200	 3432	 1	 0	 0	 0	
201	 3614_b	 0	 0	 0	 1	
202	 3615_b	 0	 0	 0	 1	
203	 37_b	 0	 0	 0	 1	
204	 3744	 0	 0	 0	 1	
205	 3749	 0	 0	 0	 1	
206	 4072	 0	 0	 0	 1	
207	 4258	 0	 0	 0	 1	
208	 43_b	 1	 1	 1	 1	
209	 4547	 1	 1	 0	 0	
210	 6_b	 0	 0	 0	 1	
211	 6053	 0	 0	 0	 1	
212	 7507	 0	 0	 0	 1	
213	 7508	 0	 0	 0	 1	
214	 7510	 0	 0	 0	 1	
215	 7511	 0	 0	 0	 1	
216	 7512	 0	 0	 0	 1	
217	 7513	 0	 0	 0	 1	
218	 7514	 0	 0	 0	 1	
219	 7515	 0	 0	 0	 1	
220	 7516	 0	 0	 0	 1	
221	 7517	 0	 0	 0	 1	
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3.2.4	 Reduction	 of	 the	 preliminary	 list	 of	 genetic	 markers	 associated	 with	
observed	clinical	phenotype	to	a	suitable	number	for	logistic	regression	
A	preliminary	list	of	497	genetic	markers	with	the	potential	to	pathotype	S.	suis	was	created	by	
combining	 the	 output	 of	 i)	 the	 Chi-squared	 test	 for	 independence	 (n=383)	 and	 ii)	 the	 DAPC	
(n=221;	 total	 n=497	 unique	 protein-encoding	 sequences).	 	 To	 reduce	 the	 preliminary	 list	 of	
genetic	markers	 associated	with	observed	 clinical	 phenotype	 to	 a	 suitable	number	 for	 logistic	
regression	analysis	a	multi-step	process	was	followed.		Here	genetic	markers	were	retained	only	
if	 i)	 detected	 in	 >50%	 of	 invasive	 disease-associated	 and	 <50%	 of	 non-disease	 associated	























0043	 0.81	 0.06	 1210	 Type	I	restriction-modification	
system	S	protein	(virA)	
1655	 1.00	 0.44	 1655	 Pyridine	nucleotide-disulfide	
oxidoreductase	
1708	 0.92	 0.32	 759	 Binding	protein-dependant	
transport	system	protein	
1720	 0.91	 0.26	 837	 AraC	family	transcriptional	regulator	
1721	 0.91	 0.42	 699	 GNAT	family	acetyltransferase	
1726	 0.92	 0.29	 1017	 Replication	initiation	factor	
1733	 0.85	 0.40	 864	 Transcriptional	regulator	
1796	 0.74	 0.15	 1350	 Deoxyguanosinetriphosphate	
triphosphohydrolase		
1821	 0.77	 0.10	 1464	 Type	I	restriction-modification	
system	M	protein	
1844	 0.75	 0.06	 786	 Hydroxyethylthiazole	kinase	
4547	 0.91	 0.32	 959	 Cation	transport	ATPase	
	 	 	 	 	
2003	 0.19	 0.52	 693	 Hypothetical	protein	
2028	 0.11	 0.65	 1221	 Pectinacetylesterase	








To	 do	 this,	 all	 annotated	 protein-encoding	 sequences	 of	 isolate	 P1/7	 (GenBank	 accession:	
AM946016)	[477,	510],	were	used	as	BLASTn	queries	against	a	bespoke	BLAST	database	of	all	
draft	genome	assemblies	and	known	published	complete	genome	sequences	for	S.	suis.		Protein-
encoding	 sequences	with	 identities	>95%	across	>80%	of	 the	 total	 length	of	 each	query	were	
then	 used	 to	 query	 the	 NCBI	 non-redundant	 (nr)	 database	 to	 identify	matches	 only	 to	 S.	suis.		
Table	3.5	summarises	the	three	most	conserved	protein-encoding	sequences	of	the	S.	suis	core-
genome	 that	 have	 a	 minimum	 sequence	 identity	 in	 excess	 of	 98%	 across	 >80%	 of	 the	 open	















SSU0220	 312	 98.08	 Conserved	hypothetical	protein	 Colicin	V	production	CvpA	
SSU0323	 675	 98.07	 Putative	membrane	protein	 Aldolase-type	TIM	barrel	





genes	 absent	 from	 one	 or	 more	 isolates	 or	 unique	 to	 a	 given	 isolate)	 associated	 with	 the	
observed	 clinical	 phenotypes	 i)	 invasive	 disease	 or	 ii)	 asymptomatic	 carriage	 on	 the	 palatine	
tonsils	 of	 pigs	 on	UK	 farms.	 	 Initial	 analyses	 of	 the	 original	 training	 collection	were	unable	 to	
identify	 any	 single	 genetic	marker	 of	 invasive	 disease	 prevalent	 in	 >95%	 of	 invasive	 disease-
associated	isolates	and	not	positively	identifiable	in	<5%	of	non-disease	associated	isolates.		To	
avoid	restricting	our	analyses	to	previously	published	reports	and	not	 taking	 full	advantage	of	
the	 statistical	 power	 of	 our	 WGS	 data	 set,	 we	 used	 three	 complementary	 genome-wide	
association	studies	and	 then	a	multi-step	process	 to	reduce	 the	number	of	preliminarily	 listed	
genetic	markers	 associated	with	 observed	 clinical	 phenotype	 to	 a	number	 suitable	 for	 logistic	
regression	 analysis.	 	 In	 the	 future,	 using	 logistic	 regression	 analysis	 for	 the	 final	 selection	 of	
genetic	markers	to	pathotype	S.	suis	(described	later	in	chapter	4)	will	allow	for	the	possibility	
that	multiple	genetic	markers	might	best	describe	 the	S.	suis	pathotype.	 	Also	described	 in	 this	





Objective	 1.	 	 Investigation	 of	 serotype	 prevalence	 revealed,	 in	 agreement	 with	 previously	
published	 observations	 [41],	 serotype	 2	 was	 the	 most	 frequently	 identified	 serotype	 in	 the	




procedure	 [26,	 39].	 	 However,	 traditional	 serotyping	 techniques	 are	 time-consuming,	 and	
preparing	 the	reference	antisera	 is	not	easy	due	 to	 the	high	cost	and	 labor	associated	with	 its	
production.	 	Molecular	 'serotyping'	 based	 on	PCR	 amplification	 of	 serotype-specific	 genes	 has	
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been	explored	as	an	attractive	alternative	and/or	complement	 to	 the	existing	 serological	 tests	




reasons,	 for	 example	 i)	 user	 interpretation	 of	 the	 capillary	 precipitation	 technique,	 ii)	 the	
diagnostic	 laboratory	(APHA)	not	keeping	the	expensive	stocks	of	reference	antisera	 for	all	35	
serotypes	or	iii)	potential	down-regulation	of	capsule	gene	expression	[41].		In	addition,	in	silico	
analyses	 assigned	a	 'serotype'	 to	 six	 isolates	 that	was	different	 to	 that	 identified	by	 the	 'gold-
standard'	 capillary	 precipitation	 technique	 at	 the	 APHA.	 	 For	 example,	 three	 non-disease	
associated	 isolates	 were	 deemed	 to	 be	 serotype	 1	 by	 capillary	 precipitation,	 but	 based	 on	 in	
silico	analyses	 were	 assigned	 to	 serotypes	 11	 (n=2)	 and	 12	 (Table	 3.1).	 	 The	 reason	 for	 this	





agreement	 with	 previous	 observations	 in	 the	 literature	 [52-56].	 	 However,	 most	 disease-
associated	 isolates	belong	 to	relatively	 few	serotypes	(1-9,	14	or	1/2)	 indicating	 that	serotype	
could	 be	 a	 good	 indicator	 and	 useful	 proxy	 for	 virulence,	 although	 there	 is	 room	 for	
improvement.	
	





be	 an	 effect	 of	 previous	 studies	 being	 limited	 to	 small	 numbers	 of	 isolates	 often	 restricted	 to	
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serotype	 2	 [41].	 	 Further	 analyses	 revealed	 14	 of	 the	 31	 putative	 "virulence-factors"	 whose	
detection	varied	between	phenotypic	groups	to	have	statistically	significant	association	with	the	
invasive-disease	 phenotype.	 	 Of	 note,	 the	 protein-encoding	 sequences	 of	 the	 'virulence-
associated	factors'	EF	(encoded	by	the	epf	gene	[329]),	MRP	(encoded	by	the	mrp	gene)	[178])	
and	 SLY	 (encoded	 by	 the	 sly	 gene)	 [367,	 369])	 were	 amongst	 the	 14	 published	 factors	 with	
statistically	 significant	 association	 with	 the	 invasive	 disease	 phenotype.	 	 Closer	 inspection	
revealed	these	protein-encoding	sequences	(independent	of	one	another)	were	overrepresented	
in	 disease-associated	 isolates	 and	 underrepresented	 in	 non-disease	 associated	 isolates.		
Originally	associated	with	S.	suis	disease	in	the	1990s,	to	date	the	exact	roles	of	EF	and	MRP	in	
virulence	 remain	 unclear.	 	 In	 fact,	 it	 has	 been	 suggested	 that	 the	 synthesis	 of	 these	 proteins	
might	be	only	coincidently	associated	with	virulence,	rather	 than	them	being	virulence-factors	
per	 se.	 	 However,	 from	 an	 evolutionary	 perspective	 this	 is	 confusing.	 	 The	 synthesis	 of	 these	
proteins,	 and	 secretion	 (EF)	 or	 translocation	 to	 the	 surface	 of	 the	 bacterial	 cell	 (MRP),	would	




Spain)	 and	not	 others	 such	 as	North	America	 [129,	 408,	 409]	 indicates	 that	 other,	 potentially	
more	important,	factors	are	responsible	for	virulence.	
	
Other	published	putative	 "virulence-factors",	 amongst	 the	31	whose	detection	varied	between	
phenotypic	 groups	 (Figure	 3.2),	 include	 the	 protein-encoding	 sequences	 cps2E	 and	 cps2F	
(encoding	different	 glycosyltransferases	 involved	 in	 the	 synthesis	of	 the	 serotype	2	CPS	 [78]).		
As	 both	 feature	 in	 Figure	 3.2,	 this	 could	 potentially	 indicate	 that	 serotype	 2	 is	 an	 important	
virulence	 factor.	 	However,	 the	 fact	 that	 two	genes	 involved	 in	 the	synthesis	of	 the	serotype	2	
CPS	 appear	 amongst	 the	 31	 protein-encoding	 sequences	 should	 not	 simply	 be	 interpreted	 as	




example	of	 the	effect	of	bacterial	population	structure	 could	have	on	our	approach	 to	 identify	
novel	genetic	markers	associated	with	disease.		In	this	instance,	this	is	not	the	case	and	curiously	
only	 the	 cps2E	 gene	 is	 deemed	 to	 be	 significantly	 associated	 with	 the	 invasive	 disease	
phenotype,	and	without	further	targeted	investigation	the	reason	for	this	is	unclear.	
	
The	 protein-encoding	 sequences	 revS	 and	 virA,	 both	 significantly	 associated	with	 the	 invasive	
disease	 phenotype,	 attract	 attention	 in	 Figure	 3.2	 because	 they	 were	 detected	 in	 a	 large	
proportion	(>0.75)	of	invasive	disease-associated	isolates	and	a	comparatively	small	proportion	
(<0.10)	 of	 non-disease	 associated	 isolates.	 	 Identification	 of	 such	 striking	 differences	 in	
prevalence	 is	 exciting	 and	 might	 indicate	 that	 a	 molecular	 approach	 to	 diagnosis	 and	
surveillance,	targeting	these	genes,	could	be	a	very	powerful	tool	if	such	a	distribution	is	found	
in	 other	 isolate	 collections.	 	 Interestingly,	 the	 protein	 encoded	 by	 revS	 is	 considered	 to	 be	 a	
response	regulator	[351],	while	the	protein	encoded	by	virA	considered	to	be	a	Type	I	restriction	
modification	system	specificity	domain	[378].	 	However,	neither	has	been	the	subject	of	S.	suis	














intestinal	 epithelium	 [555],	 as	well	 as,	 adhesion	 to	monocyte/macrophage	 immune	 cells	 [41].		
Indeed	 SadP	 has	 also	 been	 proposed	 to	 be	 an	 important	 virulence	 factor	 involved	 in	 the	
development	of	meningitis	in	pigs	on	farms	in	the	UK	as	per	the	“modified	Trojan	horse	theory”	






was	 achieved	 using	 a	 combination	 of	 three	 complementary	 approaches,	 resulting	 in	 the	
compilation	of	a	preliminary	list	of	497	candidates	to	pathotype	S.	suis.	 	An	important	caveat	of	
this	approach	is	that	the	Chi-squared	test	for	independence	nor	DAPC	control	for	any	potential	
effect	 of	 bacterial	 population	 structure.	 	 Attempts	 to	 minimise	 the	 number	 of	 potentially	
spurious	 associations	 due	 to	 any	 underlying	 S.	suis	 population	 structure	 (defined	 by	 Bayesian	
Analysis	of	Population	Structure	previously	described	for	S.	suis	by	Weinert	et	al.	[141])	reduced	
the	 number	 of	 candidate	 pathotyping	 markers	 to	 nine,	 all	 of	 which	 were	 deemed	 to	 be	
unsuitable	 to	 pathotype	 S.	suis	 using	 a	 mPCR	 assay/tool.	 	 Therefore,	 it	 is	 important	 to	
acknowledge	 that	 any	 association	 between	 the	 497	 potential	 molecular	 markers	 in	 the	




given	 that	 statistical	 power	 will	 be	 heavily	 influenced	 by	 amount	 of	 recombination,	 it	 is	 not	
straightforward	to	perform	a	power	calculation.	
	
Another	 important	 caveat	 of	 pathotyping	 tool	 design	 is	 consideration	 of	 the	 observed	 clinical	
phenotype	associated	with	each	 isolate	as	 the	 'gold	standard'	 to	characterise	S.	suis	 isolates	as	




all	 additional	 factors	 can	 be	 accounted	 for,	 such	 as	 i)	 host-immune	 status,	 ii)	 concurrent	
infections,	 or	 iii)	 environmental	 conditions	 that	 could	 influence	 the	 susceptibility	 of	 a	 host	 to	
S.	suis-associated	disease.		Indeed,	reports	of	in	vivo	challenge	studies	can	be	readily	found	in	the	
S.	suis	literature,	although	most	describe	data	limited	to	a	small	number	of	isolates	that	is	often	
restricted	 to	 serotype	2	 [41],	 and	under	very	different	 conditions	making	 the	extrapolation	of	
findings	difficult	 to	 interpret.	 	An	 ideal	 standard	would	require	an	agreed	panel	of	 isolates	 for	
which	 a	 series	 of	 consistently	 controlled	 experimental	 infection	 challenge	 studies	 had	 been	








combination	 of	 multiple	 factors	 with	 potentially	 subtle	 cumulative	 contributions	 (similar	 in	
nature	to	diabetes	susceptibility	genes	[557,	558])	are	required	for	invasive	S.	suis	disease.		This	
fits	 with	 clinical	 observations	 that	 S.	suis	 associated	 disease	 shows	 complex	 dependence	 on	
environmental	factors	and	pig	immune	status.		To	reduce	the	preliminary	list	of	genetic	markers	
associated	 with	 the	 invasive	 disease	 and	 non-disease	 associated	 phenotypes	 (n=497)	 to	 a	
number	suitable	for	logistic	regression	a	multi-step	process	was	followed	that	resulted	in	a	final	
shortlist	 of	 14	 genetic	 markers	 for	 generalised	 linear	 modelling	 (11	 associated	 with	 the	
phenotype	of	invasive	disease	and	three	associated	with	asymptomatic	carriage	on	the	palatine	
tonsils	 of	 pigs	 on	 UK	 farms).	 	 Curiously,	 two	 Type	 I	 restriction	modification	 system	 proteins	
appear	in	the	shortlist	of	11	molecular	markers	associated	with	the	invasive	disease	phenotype	
(one	 of	 which,	 virA	 has	 been	 discussed	 earlier	 due	 to	 its	 previous	 association	with	 virulence	
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Out	 of	 the	 genetic	 markers	 associated	 with	 the	 invasive	 disease	 phenotype	 in	 Table	 3.4,	 the	
"Type	I	restriction	modification	system	S	protein	(virA)",	could	arguably	be	considered	the	'best'	
single	molecular	marker	to	pathotype	S.	suis;	due	to	the	fact	it	was	detected	in	a	high	proportion	
(0.81)	 of	 invasive	 disease-associated	 isolates	 and	 a	 comparatively	 small	 proportion	 (0.06)	 of	
non-disease	 associated	 isolates.	 	 Traditionally	 Type	 I	 restriction	 modification	 systems	 are	
protein	 complexes	associated	with	defence	of	 the	host	bacterium	against	 foreign	DNA	such	as	
that	borne	by	bacteriophages	[559].	 	The	reason	why	a	protein-encoding	sequence	linked	with	
host	bacterium	defence	is	associated	with	the	invasive	disease-associated	phenotype	is	unclear	
and	 could	 be	 spurious.	 	 Although,	 as	 discussed	 earlier	 published	 information	 on	 the	 range	 of	
functions	 that	Type	 I	restriction	modification	systems	may	have	 is	expanding	and	proposed	to	
include	 stabilising	 mobile	 genetic	 elements	 and	 gene	 regulation,	 potentially	 providing	
evolutionary	 fitness	 advantages	 and	 virulence	 under	 certain	 conditions	 [560].	 For	 example,	
fixing	 plasmids	 or	 a	 prophage	 in	 a	 bacterial	 chromosome	 that	 carries	 tetracycline	 resistance	
genes	 would	 be	 beneficial	 to	 that	 clone	 in	 a	 bacterial	 population.	 	 As	 a	 result,	 it	 has	 been	







that	 potentially	 provide	 the	 most	 flexibility	 with	 respect	 to	 future	 mPCR	 primer	 design.		
Annotated	as	a	hypothetical	protein	by	Prokka	and	in	GenBank,	SSU0577	was	identified	by	the	
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is	 able	 to	 form	an	endospore	and	exist	 in	a	 stripped	back	dormant	 state	 that	 is	 revived	 in	 the	
nutrient	rich	bloodstream	or	on	solid	agar	plates	in	the	laboratory.		However,	a	common	feature	
of	 endospores	 is	 a	 tolerance	 of	 high	 temperatures	 and	 chemical	 disinfectants,	 something	 that	
S.	suis	 does	 not	 demonstrate	 [127]	 (see	 sections	 1.1.2.1.3	 and	 1.1.2.1.6.4).	 	 In	 contrast,	 it	 is	
possible	that	S.	suis	has	lost	the	ability	to	form	endospores	and	that	the	presence	of	SSU0577	is	a	


















chapter	 1	 (section	 1.1.1).	 	 Indeed,	 simple	 biochemical	 tests	 are	 capable	 of	 species	 level	
identification	 from	diseased	pigs.	 	However,	 isolation	and	 identification	of	S.	suis	 isolates	 from	
carrier	pigs	 is	much	more	complicated.	 	The	fact	 that	most	pigs	harbour	S.	suis	on	their	tonsils	
means	that	detection	in	asymptomatic	carrier	herds	is	often	of	little	practical	value	in	predicting	
the	 likelihood	 of	 future	 clinical	 relevance.	 	 Due	 to	 this,	 chapter	 3	 of	 this	 thesis	 describes	 the	




isolates,	 and	 remains	 an	 important	 part	 of	 the	 routine	 diagnostic	 procedure	 [11,	 17].	 	 The	
observation	of	multiple	serovars,	as	well	as,	non-serotypable	strains	present	in	the	same	animal	
is	common.		In	general,	S.	suis	serotype	2	predominates	among	clinical	cases	of	disease	in	most	
countries,	 although	 serovars	 1-9,	 14	 and	 1/2	 have	 been	 reported	 to	 be	 important	 serotypes	
associated	with	S.	suis	disease	in	certain	geographical	locales	[42,	60,	393,	409,	562].		Chapter	3	





assays/tools	 to	 amplify	 serotype-specific	 cps	 genes	 and	 assign	molecular	 ‘serotypes’	 to	 S.	suis	






Discussed	 in	 chapter	 3,	 a	 wide	 range	 of	 homologs	 of	 virulence	 factors	 found	 in	 other	 Gram-
positive	 organisms	 has	 been	 shown	 to	 affect	 the	 virulence	 of	 S.	suis	 strains	 through	 targeted	
mutagenesis	 studies	 [299-301].	 	 However,	 clear	 associations	 with	 specific	 roles	 in	 the	
development	of	disease	have	not	been	found	for	many	proposed	factors	[129].		Despite	this,	the	
'virulence-associated	markers'	(rather	than	virulence	factors	per	se)	EF	and	MRP,	as	well	as,	the	
thiol-activated	 toxin	 hemolysin	 SLY	 have	 been	 extensively	 used	 to	 predict	 the	 virulence	
potential	 of	 S.	suis	 strains	 in	 certain,	 mainly	 European	 (UK,	 Austria,	 Germany,	 and	 Spain),	
countries	 [129,	 408,	 409].	 	 Large	 and	 small	 size	 variants	 of	 epf	 and	mrp	 (reviewed	 in	 section	
1.1.3.1.3)	 have	 been	 described	 leading	 to	 determination	 of	 the	 genotype	 of	 these	 protein-
encoding	 sequences	 being	 included	 in	 the	 routine	 diagnostic	 typing	 of	 S.	suis	 in	 several	




producing	 countries,	 such	 as	 North	 America	 [129,	 408,	 409],	 indicates	 that	 other	 potentially	
more	important	factors	are	responsible	for	virulence.	
	
One	 of	 the	 most	 recent	 methods	 used	 to	 characterise	 and	 sub-type	 S.	suis	 is	 minimum	 core	
genome	 (MCG)	 sequence	 typing,	 a	 method	 that	 uses	 the	 Bayesian	 clustering	 to	 establish	
population	 genetics-based	 sub-divisions	 for	 strain	 identification	 and	 typing	 [115,	 116].		
Multilocus	 sequence	 typing	 has	 become	 the	 preferred	method	 for	 genotyping	many	biological	
species,	 due	 to	 its	 ability	 to	 identify	 major	 phylogenetic	 clades,	 molecular	 groups,	 or	
subpopulations	 of	 a	 species,	 as	 well	 as	 individual	 strains	 or	 clones.	 	 However,	 MLST	 can	
sometimes	 lack	 the	 discriminatory	 power	 to	 differentiate	 bacterial	 strains	 into	 virulent	 and	
avirulent	 sub-populations,	which	 limits	 its	 use	 in	 epidemiological	 investigations.	 	 Rather	 than	
characterise	 isolates	 based	 on	 the	 slowly	 accumulating	 variation	 in	 the	 seven	 core	metabolic	
(housekeeping)	 genes	 described	 for	 MLST[90],	 MCG	 sequence	 typing	 is	 one	 approach	 that	




S.	suis	 core-genome	 (Table	1.2),	 and	during	 its	design	all	highly	virulent	 isolates	and	epidemic	
isolates	tested	were	reported	to	be	assigned	to	MCG	group	1	[115].	
	
Ease	 of	 use	 and	 reliability	 are	 important	 factors	 that	 should	 be	 considered	when	 designing	 a	
novel	diagnostic	 tool.	 	The	 term	"pathotyping"	 tool	 is	used	 to	describe	a	diagnostic	assay/tool	
that	 can	 predict	 the	 potential	 of	 an	 isolate	 to	 cause	 invasive	 clinical	 disease,	 based	 on	 the	
detection	(or	not)	of	biomarkers	targeted	by	the	assay.		This	is	particularly	relevant	for	S.	suis,	a	
bacterium	 that	 can	 be	 found	 as	 an	 asymptomatic	 commensal-like	 strains	 or	 (primary	 or	
secondary)	pathogen.	 	Thus,	the	ability	to	predict	whether	an	isolate	has	the	potential	to	cause	
invasive	clinical	disease	would	be	useful	and	highly	desirable.		Furthermore,	the	ideal	diagnostic	
tool	 from	 the	 end	 users’	 perspective	 should	 include	 i)	 minimal	 culture/purification	 steps,	 ii)	




linear	 model)	 for	 S.	suis.	 	 Starting	 with	 the	 shortlist	 of	 14	 genetic	 markers	 associated	 with	
observed	clinical	phenotype	compiled	in	chapter	3	(Table	3.4),	this	chapter	describes	the	use	of	
logistic	regression	to	select	 three	statistically	significant	markers	 for	pathotyping.	 	Subsequent	
work	focuses	on	evaluating	the	ability	of	these	three	genetic	markers	to	predict	the	potential	of	
S.	suis	isolates	in	the	training	collection	to	cause	invasive	disease.		Evaluation	is	then	extended	to	
include	 an	 out-of-sample	 'test'	 collection	 of	 138	 previously	 uncharacterised	 isolates	 of	 S.	suis,	
and	 in	doing	 so	 comparisons	 are	drawn	between	 the	newly-defined	pathotyping	markers	 and	
other	popular	published	methods	used	to	characterise	and	subtype	S.	suis	isolates.	 	Finally,	this	






1.		 To	select	 the	 fewest	possible	genetic	markers	associated	with	observed	clinical	





isolates	 to	cause	 invasive	disease	 in	comparison	to	observed	clinical	phenotype	
using	an	out-of-sample	'test'	collection	of	S.	suis	isolates	
4.	 To	evaluate	the	ability	of	any	genetic	markers	selected	to	predict	the	potential	of	
isolates	 to	 cause	 invasive	disease	 in	 comparison	 to	popular	published	methods	
used	to	characterise	and	subtype	S.	suis	isolates	
5.	 To	determine	whether	the	mPCR	component	of	the	pathotyping	tool	can	be	used	






4.2.1.1	 Three	 genetic	markers	 associated	 with	 defined	 clinical	 phenotype	 are	
required	to	explain	~95%	of	the	invasive	disease-associated	phenotype	
The	 complexity	 of	 multiplex-PCR	 design	 increases	 as	 the	 number	 of	 targets	 increases,	 and	
compromises	 in	optimal	 size	differences	between	amplicons	and	 in	primer	placement	become	
inevitable.		Working	with	a	UK-biased	collection	a	conscious	decision	of	design	was	to	create	the	
simplest	mPCR	with	 a	minimum	number	 of	markers	 possible	 so	 that	 as	 genome	 analyses	 are	
expanded	 to	 include	 isolates	 from	 other	 countries	 additional	 markers	 important	 to	 other	
geographical	 locales	 can	 easily	 be	 incorporated	 into	 our	mPCR	pathotyping	 tool.	 	 To	 trade-off	
simplicity	 against	 the	 ability	 to	 reliably	 identify	 the	 disease-associated	 isolates	 the	 minimum	
number	of	genetic	markers	required	to	explain	the	 invasive	disease-associated	phenotype	was	
estimated.	 	To	do	 this,	 the	minimum	number	of	 genetic	markers	 (shortlisted	 in	 chapter	3,	 see	
Table	 3.4)	 required	 to	 pathotype	 S.	suis,	 the	 proportion	 of	 the	 invasive	 disease-associated	
phenotype	 explained	 by	 increasing	 the	 cumulative	 number	 of	markers	was	 calculated	 using	 a	
bespoke	R	script	written	by	Post	Doctoral	Research	Associate	Dr	Lucy	Weinert	(Department	of	

























4.2.1.2	 Selection	 of	 three	 genetic	 markers	 associated	 with	 observed	 clinical	
phenotype	to	pathotype	Streptococcus	suis	





to	 protein-encoding	 sequence	 prevalence	 data	 for	 the	 training	 collection	 included	 all	 14	
shortlisted	 genetic	 markers	 described	 in	 chapter	 3	 (Table	 3.4)	 and	 produced	 an	 Akaike	
information	criterion	(AIC)	=	-63.34.		The	addition	of	explanatory	variables	to	logistic	regression	
models	will	always	increase	statistical	validity	because	addition	of	another	explanatory	variable	
will	 always	 explain	 a	 little	 more	 variance	 of	 the	 log	 odds.	 	 However,	 adding	more	 and	more	
explanatory	 variables	 to	 a	 model	 is	 inefficient	 and	 leads	 to	 overfitting	 (and,	 as	 a	 result,	 the	
inclusion	 of	 unnecessary	 primers	 and	 amplicons	 to	 resolve	 in	 our	 mPCR	 assay).	 	 Therefore,	
backwards	 step-wise	 selection,	 using	 penalised	 likelihood	 ratio	 tests,	 was	 used	 to	 select	 the	
fewest	 statistically	 significant	 genetic	markers	 to	differentiate	 invasive	disease-associated	 and	
non-disease	associated	phenotypic	groups	(AIC	=	-76.84).		The	AIC	is	an	estimator	of	the	relative	
quality	 of	 a	 statistical	 model	 for	 a	 given	 data	 set	 and	 useful	 for	 comparison	 and	 selection	 of	
models,	although,	is	also	a	measure	that	should	be	treated	with	caution	as	it	gives	no	indication	
of	absolute	quality	of	a	model.	 	The	AIC	was	used	as	a	statistical	sanity	check,	and	the	AIC	of	 -
76.84	 in	 comparison	 to	 -63.34	 indicated	 the	 trade-off	of	 complexity	and	goodness	of	 fit	 of	 the	
























0043	 SSU1589	 Disease-association	 0.81	 0.06	 2.57e-06	
2261	 SSUST30534	 Non-disease	association	 0.02	 0.55	 4.37e-02	
4547	 SSU0207	 Disease-association	 0.91	 0.32	 1.23e-02	
	 	 	 	 	 	





















mPCR	 amplicon	 pattern	 (as	 anticipated	 based	 on	 in	 silico	 analyses)	 of	 these	 two	 isolates	
resembles	 that	 of	 the	 invasive	 disease-associated	 isolates	 of	 the	 training	 collection.	 	 Sanger	
sequencing	 was	 used	 to	 confirmed	 mPCR	 amplicons	 to	 be	 the	 targeted	 regions	 of	 invasive	






































































































the	data	presented	 in	Table	4.3,	 and	demonstrates	how	 the	choice	of	 cutoff	 threshold	affected	
the	performance	metrics	false	negative	rate	and	F1	score	(a	weighted	measure	of	accuracy)	for	
the	 training	 collection.	 	 To	 choose	 the	 cutoff	 of	 0.43	 the	 closest	 F1	 score	 to	 1	 was	 traded-off	
against	a	false	negative	rate	closest	to	0.	
	
Using	 the	 0.43	 cutoff	 threshold	 the	 pathotyping	 tool	 predicted	 correct	 classification,	 in	
comparison	 to	 the	 observed	 clinical	 metadata,	 of	 84%	 (accuracy)	 of	 the	 115	 isolates	 in	 the	
original	 training	 collection.	 	 Table	 4.2(iii)	 is	 an	 extended	2x2	 contingency	 table	 that	 reports	 a	















93 53 40 0.57 0.43
mPCR	result	positive True	positive False	positive Positive	predictive	value False	discovery	rate
22 0 22 0.00 1.00








85 52 33 0.61 0.39
mPCR	result	positive True	positive False	positive Positive	predictive	value False	discovery	rate
30 1 29 0.03 0.97








61 48 13 0.79 0.21
mPCR	result	positive True	positive False	positive Positive	predictive	value False	discovery	rate
54 5 49 0.09 0.91








42 40 2 0.95 0.05
mPCR	result	positive True	positive False	positive Positive	predictive	value False	discovery	rate
73 13 60 0.18 0.82
























4.2.2.1.2	 Estimation	 of	 a	 ~0.0001	 ng	 limit	 of	 detection	 for	 the	 multiplex-PCR	
component	of	the	pathotyping	tool	for	Streptococcus	suis	
To	determine	the	analytical	sensitivity	of	the	mPCR	assay	the	approximate	limit	of	detection	was	
estimated	 from	 10-fold	 serial	 dilutions	 of	 S.	suis	 genomic	 DNA	 of	 known	 concentration.	 	 DNA	
extracted	 from	 four	 isolates	 (two	 disease-associated	 and	 two	 non-disease	 associated)	 of	 the	
training	 collection	 was	 mixed	 in	 equal	 quantities	 so	 that	 templates	 for	 each	 mPCR	 amplicon	
would	 be	 present	 in	 all	 reactions,	 and	 a	 series	 of	 10-fold	 dilutions	 then	 performed	 to	 create	
mPCR	templates	decreasing	in	DNA	concentration.		Figure	4.5	shows	mPCR	amplicons	following	
gel	 electrophoresis,	 photographed	 under	 UV	 transillumination.	 	 The	 limit	 of	 detection	 was	
estimated	 to	 be	 ~0.0001	 ng	 of	 S.	suis	 genomic	 DNA	 (equivalent	 to	 ~45	 genome	 copies),	 the	





To	 evaluate	 specificity	 of	 the	 mPCR	 assay	 for	 the	 S.	suis,	 field	 isolates	 of	 Streptococcaceae	
commonly	 recovered	 from	 the	upper	 respiratory	 tract	 of	 pigs	 on	 farms	 in	England	 and	Wales	
were	used	as	a	panel	of	negative	controls.	 	Sourced	from	research	project:	BB/L003902/1,	the	
collection	 included	 isolates	 of	 Streptococcus	 gallolyticus,	 Streptococcus	 orisratti,	 Streptococcus	
pneumoniae,	 and	 Streptococcus	 uberis.	 	 In	 addition,	 commensal	 Pasteurellaceae	 including	
Actinobacillus	 indolicus,	Actinobacillus	minor,	Actinobacillus	porcinus,	 and	Haemophilus	parasuis	
(Nagasaki	 and	 SW140)	were	 also	 included,	 as	 well	 as,	 an	 Alcaligenaceae	 isolate	 of	Bordetella	
bronchiseptica	RB50	(NC_002927)	[563].	 	No	mPCR	amplicons,	after	35	thermal	cycles	and	gel	























To	evaluate	 further	 the	mPCR	pathotyping	 tool	 (GLM	and	mPCR)	out-of-sample	 testing	of	138	
(69	 disease-associated	 and	 69	 non-disease	 associated)	 previously	 uncharacterised	 S.	suis	
isolates	 was	 performed	 in	 vitro.	 	 Out-of-sample	 forecasting	 is	 a	 common	 approach	 used	 to	
evaluate	 the	 performance	 of	 binary	 diagnostic	 tests.	 	 Figures	 4.6	 and	 4.7	 show	 the	 mPCR	
amplicons	produced	from	genomic	DNA	extracted	from	each	of	the	138	'test'	collection	isolates.		
A	 number	 of	 the	 gel	 lanes	 in	 Figure	 4.6	 have	 not	 been	 labelled	 as	 the	mPCR	was	 performed	
before	 detailed	 clinical	 metadata	 corresponding	 to	 the	 invasive	 disease-associated	 isolates	
(originally	 a	 collection	 of	 105	 isolates)	was	made	 available	 by	 the	 APHA.	 	 Unlabelled	 isolates	






































































































































































































to	 the	S.	suis	 species-specific	marker.	 	 Protein-encoding	 sequence	detection	data,	based	on	 the	
production	of	mPCR	amplicons	(corresponding	to	the	pathotyping	markers),	was	then	input	into	
the	pathotyping	GLM	and	the	predict	function,	implemented	in	the	R	package:	logistf	[521],	used	
to	 generate	 fitted	 values	 for	 each	 isolate.	 	 Table	 4.3	 shows	 the	 performance	 metrics	 of	 the	
pathotyping	 tool	 once	 the	 0.43	 cutoff	 threshold	 was	 applied	 to	 the	 fitted	 values	 in	 order	 to	
generate	a	binary	class	decision	(disease	=	1/non-disease	=0)	for	each	isolate.		The	pathotyping	
tool	 predicted	 correct	 classification,	 in	 comparison	 to	 the	 observed	 clinical	metadata,	 of	 80%	
(accuracy)	 of	 the	 138	 isolates.	 	 False	 negative	 rate	 deemed	 the	 most	 valuable	 performance	
metric	 for	 pathotyping	 was	 0.20,	 assuming	 clinical	 metadata	 as	 the	 ‘gold	 standard’.	 	 Other	
popular	 performance	 metrics	 commonly	 used	 to	 compare	 binary	 diagnostic	 tests	 were;	









4.2.2.2.1	 Comparison	 of	 the	 pathotyping	 tool	 to	 published	 methods	 used	 to	
characterise	disease	associated	isolates	of	Streptococcus	suis	
To	 compare	 the	 pathotyping	 tool	 to	 published	 methods	 used	 to	 characterise	 and	 sub-type	
disease-associated	 isolates	 of	 S.	suis,	 the	 molecular	 serotype,	 'virulence-associated'	 gene	 (epf,	
mrp,	and	sly)	profile	and	minimum	core-genome	sequence	 type	were	 first	determined	in	silico.		






Traditional	 (coagglutination)	 serotyping	 data	 was	 unavailable	 for	 all	 isolates	 of	 the	 out-of-
sample	 'test'	 collection,	 therefore,	 molecular	 'serotyping'	 was	 performed	 and	 used	 for	
comparison	against	the	pathotyping	tool.		Figure	4.8	shows	the	cumulative	frequency	of	isolates	
assigned	 to	 the	 35	 (1-34	 and	 1/2)	 originally	 reported	S.	suis	 serotypes.	 	 Serotype	 2	 (and	 1/2,	
indistinguishable	 by	 the	 Liu	et	al.	[74]	method	due	 to	 closely	 related	 cps	 genes)	was	 assigned	
most	frequently	to	isolates	in	test	collection.		Four	(a	total	of	6%	of)	invasive	disease-associated	
isolates	 in	 the	 test	collection	were	assigned	 'serotypes'	other	 than	1-10,	14	and	1/2	(the	most	
common	 serotypes	 recovered	 from	 clinical	 samples).	 	 A	 total	 of	 16	 non-disease	 associated	
isolates	 were	 assigned	 'serotypes'	 other	 than	 1-10,	 14	 and	 1/2.	 	 Isolates	 that	 could	 not	 be	
assigned	 to	one	of	 the	35	originally	described	S.	suis	 serotypes	were	present	 in	 test	 collection,	




















the	 first	 of	 which	 targets	 the	 cps	 genes	 of	 serotypes	 1-10,	 14	 and	 1/2.	 	 To	 draw	 direct	 and	
meaningful	comparison	to	a	published	tool	to	characterise	and	subtype	S.	suis	isolates	serotypes	
targeted	 by	 the	 first	 Liu	 et	 al.	 mPCR	 were	 used	 as	 a	 binary	 classifier	 to	 predict	 disease	
association.	 	 To	 compare	 the	 pathotyping	 tool	 to	 the	 use	 of	 serotype	 as	 a	 proxy	 for	 virulence	
potential,	the	serotypes	1-10,	14	and	1/2	were	considered	markers	of	disease	association	and	all	
other	serotypes	considered	markers	of	non-disease	association	(including	isolates	deemed	to	be	
non-serotypable).	 	 Table	 4.4	 shows	 use	 of	 the	 12	 serotypes	 (1-10,	 14	 and	 1/2)	 to	 predict	
disease-association	 performed	 with	 a	 sensitivity	 of	 0.91	 (n=6	 type	 II	 errors),	 superior	 in	



























approach	 for	 the	 identification	 of	 virulent	 strains	 is	 the	 detection	 of	 'virulence-associated'	
factors	EF	(encoded	by	epf),	MRP	(encoded	by	mrp)	and	the	thiol-activated	haemolysin	known	
as	 SLY	 (encoded	 by	 sly).	 	 To	 draw	 direct	 and	 meaningful	 comparison	 to	 a	 published	 tool	 to	
characterise	S.	suis	 isolates	 adaptation,	 for	 in	silico	 use,	 of	 the	method	described	by	 Silva	et	al.	




of	 invasive	 disease-associated	 isolates	 (black).	 	 Interestingly,	 all	 three	 genes	 were	 positively	





















































In	silico	 analyses	 of	 the	 distance	 between	 primer	 sequence	 matches	 targeting	 the	 epf	 gene	




additional	 (singleplex)	PCR	assay	 to	differentiate	 the	genes	 that	encode	 the	known	variants	of	
MRP.		Investigation	of	the	distance	between	mrp	singleplex	primer	sequence	matches	identified	
five	 out	 of	 the	 six	 known	 mrp	 size	 variants	 in	 the	 253	 isolates	 described	 in	 this	 thesis.		
Figure	4.10	shows	the	proportion	of	isolates	testing	positive	for	each	known	mrp	size	variant,	of	


















epf,	 mrp	 and	 sly	 in	 the	 original	 'training'	 collection.	 	 Following	 the	 same	 logistic	 regression	
analysis	methodology	 as	 before	 a	GLM	was	 fitted	 to	 the	 'training'	 collection	 and	 then	 a	 cutoff	
threshold	 selected	 (0.12)	 to	 convert	 the	 fitted	 values	 into	 a	 binary	 class	 decision.	 	 Table	 4.5	
shows	the	influence	cutoff	threshold	had	on	performance	metrics.		Again,	the	closest	F1	score	to	
1	was	 traded-off	 against	 a	 false	 negative	 rate	 closest	 to	 0	 to	 select	 the	 cutoff	 threshold.	 	 The	
predict	 function,	 implemented	 in	 the	R	package:	 logistf	[521],	was	then	used	to	generate	 fitted	
values	for	the	detection	data	of	epf,	mrp	and	sly	for	each	of	the	138	isolates	in	the	test	collection.		
Table	4.6	summarises	 the	classification	of	 isolates	as	disease/non-disease	associated	based	on	
the	 detection	 of	 epf,	 mrp	 and	 sly	 in	 comparison	 to	 the	 'gold-standard'	 observed	 clinical	
phenotype.		The	effect	of	mrp	length	variations	on	virulence	to	date	remains	unclear,	therefore,	
in	order	to	make	fair	comparisons	to	an	existing	sub-typing	tool	the	decision	was	made	to	draw	
comparison	 against	 the	 Silva	 et	 al.	 [400]	 mPCR	 assay	 designed	 to	 capture	 epf,	 mrp	 and	 sly	
irrespective	 of	 the	 size	 variations	 in	mrp.	 	 Table	 4.6	 summaries	 the	 classification	 of	 the	 test	
collection	and	performance	of	epf,	mrp	and	sly	in	comparison	to	the	clinical	metadata	(assumed	
to	be	the	'gold	standard').	 	The	virulence-associated	markers	perform	with	a	sensitivity	of	0.93	
(n=5	 type	 II	 errors),	 that	 is	 superior	 in	 comparison	 to	 th	 pathotyping	 tool	 (sensitivity	 =	 0.80,	
n=14	type	II	errors;	McNemar’s	Chi-squared	test	for	Count	Data	p-value	=	0.00270).	 	However,	
again	 the	 trade-off	 for	 a	 high	 sensitivity	 (equivalent	 to	 a	 low	 false-negative	 rate;	 0.07)	 is	 a	
statistically	worse	positive	predictive	value	 (0.50	 in	comparison	 to	1.00;	weighted	generalised	
score	 statistic	 for	 comparison	 of	 predictive	 values	 p-value	 =	 4.77396e-15)	 –	 incidentally	
performing	 no	 better	 than	 chance	 (Exact	 binomial	 test	 p-value	 =	 1).	 	 Specificity	 is	 also	
substantially	worse	(0.09	in	comparison	to	1.00;	McNemar’s	Chi-squared	Test	for	Count	Data	p-
value	=	0.00006),	 as	 is	 the	negative	predictive	value	 (0.55	 in	 in	 comparison	 to	1.00;	weighted	

























proxy	 for	 virulence	 classified	 isolates	 with	 a	 significantly	 worse	
sensitivity	and	negative	predictive	value	
Lastly,	the	pathotyping	tool	was	compared	to	the	use	of	one	of	the	most	recent	methods	used	to	
characterise	 and	 sub-type	 S.	suis,	 minimum	 core	 genome	 sequence	 typing	 [115,	 116].		





training	 collection.	 	 Therefore,	 assignment	 to	MCG	 group	 1	was	 used	 as	 a	 binary	 classifier	 to	
indicate	disease	association.	 	Table	4.7	 summaries	 the	 classification	of	 the	out-of-sample	 'test'	
collection	and	performance	of	assignment	to	MCG	group	1	as	an	indicator	of	disease	association	
in	comparison	to	the	clinical	metadata	(assumed	to	be	the	‘gold	standard’).		Here.	assignment	to	
MCG	 group	 1	 performs	 with	 a	 statistically	 worse	 sensitivity	 of	 0.52	 (n=33	 type	 II	 errors)	 in	
comparison	 to	 the	 pathotyping	 tool	 (sensitivity	 =	 0.80,	 n=14	 type	 II	 errors;	 McNemar’s	 Chi-




























4.2.3	 Pilot	 study	evaluation	of	 the	pathotyping	 tools	ability	 to	 screen	pooled	
oral	fluid	collected	from	cotton	chew	ropes	
Before	 screening	 valuable	 field	 swabs	 a	 small	 pilot	 study	was	 performed	 to	 investigate	 if	 the	
pathotyping	 tool	 could	 be	 used	 to	 screen	 material	 from	 the	 upper	 respiratory	 tract	 of	 pigs	
without	 culture	 and	 first	 isolating	 single	 clones/colonies.	 	 To	 do	 this,	 total	 genomic	 DNA,	
extracted	directly	from	transport	swabs	and	used	as	mPCR	templates.		PCR	inhibitors	in	salivary	
fluid	have	been	reported	to	be	problematic	in	various	studies	working	with	oral	fluid,	a	problem	
that	 can	 be	 offset	 by	 diluting	 PCR	 template	 material.	 	 Figure	 4.12	 (a)	 shows	 PCR	 products	
amplified	 using	 the	 universal	 primers	 (U16SRT-F	 and	 U16SRT-R;	 PCR	 product	 size	~200	 bp)	
designed	by	Clifford	et	al.	[564]	to	target	the	bacterial	16S	gene,	and	were	used	here	to		confirm	
the	 presence	 of	 bacterial	 DNA	 in	 DNA	 extraction	 eluate.	 	 Figure	 4.12	 (b)	 then	 shows	 mPCR	
amplicons	produced	from	DNA	extracted	directly	from	oral	fluid	and	subjected	to	a	series	of	10-
fold	 dilutions.	 	 From	 undiluted	 DNA	 five	 (including	 both	 size	 variants	 of	 SSU0207)	 mPCR	
amplicons	can	easily	be	seen	under	UV	transillumination	that	become	increasingly	more	difficult	
to	see	as	PCR	template	DNA	template	was	diluted	10-fold.		All	amplicons	were	Sanger	sequenced	
using	 the	 Source	 Bioscience	 Lifesciences	 sequencing	 service	 and	 confirmed	 to	 be	 the	 correct	
target	regions	of	the	mPCR	primers	(data	not	shown).		In	addition	to	the	722	bp	mPCR	amplicon	
corresponding	 to	 the	 S.	suis	 species-specific	 marker	 (SSU0577),	 both	 disease-associated	 and	
non-disease	associated	markers	were	also	amplified	from	the	same	experimental	sample.	 	This	
was	 not	 observed	 in	 either	 the	 training	 collection	 (n=115)	 or	 out-of-sample	 'test'	 collection	























4.2.3.1	 Screening	 swabs	 of	 oral	 fluid	 and	 swabs	 of	material	 scraped	 from	 the	
palatine	 tonsils	 of	 pigs	 for	 invasive	 disease-associated	 strains	 of	
Streptococcus	suis	revealed	invasive	disease-associated	and	non-disease	
associated	strains	frequently	coexist	on	the	tonsils	of	colonised	pigs	
The	 pathotyping	 tool	 was	 used	 to	 screen	 (paired	 samples)	 swabs	 of	 oral	 fluid	 and	 swabs	 of	
material	scraped	from	the	palatine	tonsils	of	pigs	on	three	UK	farms	(without	obvious	signs	of	
streptococcal	disease)	for	invasive	disease-associated	strains	of	S.	suis.		Figure	4.13	shows	mPCR	
amplicons	produced	 from	DNA	recovered	 from	 five	 randomly	 selected	 swabs	 from	each	of	 six	
groups	sampled	(three	farms	at	two	time	points,	five	weeks	and	20	weeks	of	age).		In	agreement	
with	reports	of	S.	suis	being	endemic	in	all	sampled	pig	populations,	the	amplicon	of	size	722	bp	
corresponding	 to	 the	 S.	suis	 species	 specific	 marker	 was	 produced	 in	 all	 groups	 sampled.		
Surprisingly,	 more	 often	 than	 not	 the	 disease-associated	 (SSU1589;	 347	 bp)	 and	 non-disease	
associated	(SSUST30534;	892	bp)	mPCR	amplicons	were	produced	from	the	same	experimental	





















































































































































































































































































































































































































































































































Two	 genetic	markers	were	 positively	 associated	with	 the	 invasive	 disease	 phenotype,	while	 a	
third	 (SSUST30534)	 was	 positively	 associated	 with	 the	 non-disease	 associated	 phenotype	
(asymptomatic	 commensal-like	 carriage	 on	 the	 palatine	 tonsils	 of	 pigs	 on	 UK	 farms).	 	 The	
practical	 usefulness	 of	 the	 genetic	 marker	 positively	 associated	 with	 asymptomatic	 carriage	
might	 not	 be	 immediately	 obvious,	 but	 its	 statistical	 significance	 in	 the	 GLM	 did	 prompt	
discussions	about	 the	concept	of	antivirulence	genes	and	gene	 loss	 in	 the	evolution	 from	non-
pathogenic	commensals	to	bacterial	pathogens	as	a	mechanism	of	fine	tuning	pathogen	genomes	
for	 maximal	 fitness	 in	 new	 host	 environments;	 in	 short	 when	 regulation	 of	 the	 invasion,	
replication	and	transmission	processes	is	altered,	virulence	can	emerge.		Genome	reduction	via	
gene	 loss	 and	 pseudogenisation	 resulting	 in	 enhanced	 pathogenicity	 has	 previously	 been	
described	in	other	bacteria,	such	as	Rickettsia	spp.,	Shigella	spp.	and	Yersinia	spp.	[509].		In	fact,	
genome	reduction	through	the	loss	of	genes,	potentially	interfering	with	host	infection,	has	also	
been	proposed	 in	S.	suis	[141].	 	Therefore,	 as	 the	elimination	of	 the	genetic	marker	associated	
with	 asymptomatic	 commensal-like	 carriage	 from	 the	 GLM	 could	 not	 be	 done	 without	 a	
statistically	 significant	 loss	 of	 fit	 (p-value	 <0.05)	 it	 was	 retained	 and	 its	 practical	 usefulness	
evaluated	further.	
	
Objective	 2.	 	 In	 vitro	 evaluation	 of	 the	 three	 genetic	 markers	 selected	 to	 pathotype	 S.	suis	
showed	100%	agreement	with	 in	silico	analyses.	 	 In	order	to	evaluate	the	ability	of	the	genetic	
markers	to	predict	the	potential	of	 isolates	to	cause	invasive	clinical	disease	a	cutoff	 threshold		
(0.43)	was	chosen	to	convert	the	fitted	values	(or	probability	of	causing	disease)	from	the	GLM	
into	a	binary	class	decision,	disease	 (1)	or	non-disease	 (0).	 	To	do	 this,	 the	 false	negative	 rate	
(0.09;	 equivalent	 to	 1	 –	 true	 positive	 rate	 (sensitivity))	 was	 chosen	 as	 the	 most	 valuable	
performance	metric	 for	a	S.	suis	pathotyping	 tool	with	a	view	 to	establish	and	 then	maintain	a	
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pig	 population	 free	 of	 invasive	 disease-associated	 strains.	 	 Using	 the	 cutoff	 of	 0.43,	 the	
pathotyping	tool	was	found	to	predict	the	correct	classification	of	84%	(accuracy)	of	the	isolates	




negatives	 (analogous	 to	 type	 II	error,	 i.e.	predicted	 to	be	non-disease	associated	but	originally	
classified	 as	 being	 responsible	 for	 an	 invasive	 disease	 phenotype).	 	 Often	 S.	suis	 strains	 are	
described	 as	 opportunistic	 or	 secondary	 pathogens	 that	 without	 a	 weakened	 host	 immune	
status	 (due	 to	 stress	 or	 concurrent	 infection)	 would	 normally	 be	 carried	 asymptomatically	
contributing	to	the	normal	oral	microflora	of	pigs	[121].		This	is	the	most	likely	explanation	for	










considered	to	be	 false	positives	(type	I	errors).	 	Table	4.2(iii)	shows	13	 isolates	of	 the	original	
training	collection,	that	were	recovered	from	the	tonsil	or	trachea	of	pigs	not	showing	obvious	
signs	 of	 streptococcal	 disease,	 were	 predicted	 by	 the	 pathotyping	 tool	 to	 have	 the	 ability	 to	
cause	 invasive	 disease.	 	 Deemed	 to	 be	 'false'	 positives	 (in	 comparison	 to	 the	 'gold-standard'	
observed	clinical	metadata)	these	predictions	could	in	fact	be	correct	predictions	and	examples	
of	what	the	research	described	in	this	thesis	is	attempting	to	achieve	–	the	identification	of	S.	suis	
strains	with	 the	potential	 to	 cause	 invasive	disease	 in	 the	upper	 respiratory	 tract	 of	 pigs.	 	 An	
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important	 unmentioned	 caveat	 of	 pathotyping	 tool	 design	 is	 the	 source	 of	 S.	suis	 isolates	
considered	 to	 be	 non-disease	 associated.	 	 While	 all	 efforts	 were	 made	 to	 accurately	 define	
disease-associated	 and	 non-disease	 associated	 phenotypic	 groups	 it	 is	 important	 to	
acknowledge	 that	 the	 non-disease	 associated	 isolates	 of	 the	 original	 training	 collection	 were	
recovered	 from	 routine	 submissions	 to	 the	 APHA,	 and	 that	 these	 pigs	were	 not	 healthy	 even	
though	 they	did	not	 show	signs	of	 typical	 streptococcal	disease;	 instead	clinical	 features	were	
consistent	with	disease	caused	by	other	non-S.	suis	infectious	agents.		The	palatine	tonsils	of	pigs	
are	considered	the	natural	habitat	of	S.	suis.	 	Therefore,	 it	 is	feasible	that	the	mortality	of	these	
13	pigs	was	due	to	clones	of	isolates	recovered	from	the	tonsil	or	trachea-bronchus	yet	was	not	
identified	due	to	a	concurrent	infection	presenting	a	more	obvious	phenotype	such	as	diarrhoea.		
Despite	 this	 caveat	 there	 is	 evidence	 in	 the	 literature	 that	 virulent	 strains	 of	 S.	suis	 can	 be	




It	 is	 important	 to	mention	 that	although	primer	 (BLASTn)	and	mPCR	specificity	 for	S.	suis	has	
been	assessed	to	the	best	of	our	ability	at	the	time,	additional	experiments	should	be	considered.		
The	most	obvious	is	a	control	of	pig	(and	human)	genomic	DNA,	in	order	to	be	certain	no	false	












phenotypic	 groups	 (disease/non-disease	 associated)	 based	 on	 the	 observed	 clinical	metadata.		
Comparison	of	the	predicted	classification	of	isolates	to	the	observed	clinical	phenotype	(again	
assumed	to	be	the	 'gold-standard')	found	the	pathotyping	tool	performed	with	a	false	negative	
rate	 =	 0.20	 (sensitivity	 =	 0.80),	 accuracy	 =	 0.80,	 true	 negative	 rate	 (specificity)	 =	 1,	 positive	
predictive	 value	 =	 1	 and	 a	 negative	 predictive	 value	 =	 0.83	 (Table	 4.3).	 	 Out-of-sample	
forecasting	 often	 produces	 worse	 performance	 metrics	 in	 comparison	 to	 in-sample	 testing	
where	the	model	trained	on	the	original	data	set	is	evaluated	back	on	itself.		Chosen	as	the	most	
valuable	 performance	 metric	 for	 a	 S.	suis	 pathotyping	 tool	 the	 0.20	 false	 negative	 rate	
corresponds	to	14	false	negatives	(or	type	II	errors);	where	non-disease	associated	pathotyping	
tool	 predictions	 were	 made	 for	 isolates	 linked	 with	 invasive	 disease	 clinical	 metadata.		
Speculation	as	to	the	reason	for	such	observations	has	been	discussed	earlier.		As	with	any	new	
diagnostic	 tool	 it	 is	 important	 to	draw	 comparison	 against	 an	 agreed	 'gold-standard'	 allowing	
meaningful	comparisons	to	be	drawn	regarding	the	commonly	used	performance	metrics,	such	
as	 sensitivity,	 specificity,	 and	 the	overall	 accuracy	of	 the	new	 tool	 -	 and	an	 ideal	 standard	has	
been	 discussed	 earlier.	 	 The	 pathotyping	 tool	 described	 so	 far	 highlights	 the	 value	 of	 future	




[17].	 	 Considering	 the	 assignment	 to	 molecular	 'serotypes'	 1-10,	 14	 and	 1/2	 as	 markers	 of	
disease-association	 predicted	 the	 correct	 classification	 of	 isolates	 to	 the	 observed	 phenotypic	




the	original	 training	collection	 recovered	 from	pigs	on	 farms	 in	England	and	Wales	 (Table	3.1	
and	 Figure	 3.1).	 	 Indeed,	 even	 non-encapsulated	 strains	 have	 been	 recovered	 from	 cases	 of	
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invasive	 disease	 and	 described	 as	 virulent	 in	 experimental	 infection	 models	 [134,	 135],	
indicating	that	the	capsular	polysaccharide	is	not	a	good	indicator	of	virulence	[11].		Therefore,	
it	 is	 unsurprising	 to	 see	 the	 trade-off	 for	 a	 high	 sensitivity	 is	 a	 statistically	 worse	 positive	
predictive	value	(i.e.	the	proportion	of	isolates	predicted	to	be	disease	isolates	that	were	actually	
recovered	 from	 a	 systemic	 site;	 0.80	 vs.	 1.0,	 p-value	 =	 0.00016)	 and	 specificity	 (i.e.	 the	
proportion	of	 isolates	actually	recovered	from	the	upper	respiratory	tract	of	a	healthy	pig	and	
predicted	to	be	non-disease	isolates;	0.77	vs.	1.0,	p-value	=	0.00006).		Indicating,	that	while	the	




cps	 genes	 have	 reduced	 the	 scope	 for	 user	 error/interpretation	 associated	 with	 traditional	
serotyping	techniques,	such	as	capillary	precipitation.		However,	the	first	round	of	the	Liu	et	al.	
[74]	mPCR	serotyping	scheme	requires	a	combination	of	20	primers	to	target	the	most	common	
S.	suis	 serotypes	(1-10,	14	and	1/2)	associated	with	clinical	disease.	 	 In	comparison,	 the	mPCR	
assay	of	 the	newly-described	pathotyping	 tool	 (mPCR	and	GLM)	 is	 considerably	 simpler	using	
just	 eight	primers	 (of	which	 two	are	 for	 a	S.	suis	 species-specific	marker),	 to	which	 additional	
markers/primers	could	easily	be	added	to	as	genome	analyses	are	expanded	to	include	isolates	
from	 important	 pig	 producing	 countries	 other	 than	 the	 UK.	 	 In	 fact,	 only	 using	 molecular	
serotypes	1,	 2,	 14	 and	1/2	 (the	most	 common	 serotypes	 associated	with	S.	suis	 disease	 in	 the	
UK)	 predicts	 disease-association	 with	 a	 sensitivity	 significantly	 worse	 than	 the	 mPCR	





the	 serotypic	 groups	 limits	 the	 interpretation	 of	 epidemiological	 have	 been	well	 documented	
[53,	 178,	 400],	 and	 limits	 the	 interpretation	 of	 epidemiological	 studies	 that	 include	 only	
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serotyping.	 	 Indeed,	 other	 markers	 have	 been	 suggested	 to	 characterise	 and	 subtype	 S.	suis	
isolates,	 one	 such	 approach	 for	 the	 identification	 of	 virulent	 strains	 is	 the	 detection	 of	 the	
'virulence-associated'	 factors	 EF	 [329],	 MRP	 [345]	 and	 the	 thiol-activated	 haemolysin	 SLY.		
Using	a	GLM	 fit	 to	prevalence	data	of	 the	 'virulence-associated'	 genes	epf,	mrp	 and/or	sly	 as	 a	
predictor	 of	 disease	 association	 also	 predicted	 the	 correct	 classification	 of	 isolates	 with	 a	





large	number	of	 false-positives.	 	Despite	 first	being	associated	with	S.	suis	 disease	 in	 the	early	
1990s	 [178,	 329,	 367,	 369]	 and	 the	 genotyping	 of	 epf	 and	 mrp	 being	 incorporated	 into	 the	
routine	diagnosis	procedure	for	S.	suis	in	several	laboratories,	the	exact	contribution	of	proteins	
EF	and	MRP	to	virulence	still	remains	unclear	[131].		Further	confounding	evidence	indicates	the	




most	 recent	 methods	 used	 to	 characterise	 S.	suis	 isolates.	 	 Here	 MCG	 sequencing	 typing	 was	
found	 to	perform	with	 a	 significantly	worse	 sensitivity	 (0.80	 vs.	 0.50;	p-value	=	0.00001)	 and	
worse	negative	predictive	value	(0.68	vs.	0.83;	p-value	=	0.00001).	 	During	its	design	all	highly	
virulent	 isolates	 and	 epidemic	 isolates	 tested	 were	 reported	 to	 be	 assigned	 to	 MCG	 group	 1	
[115],	 an	 observation	 also	 seen	 for	 most	 of	 the	 invasive	 disease-associated	 isolates	 in	 the	
original	 training	 collection	 (Figure	 4.11).	 	 Assignment	 to	 MCG	 group	 1	 was	 used	 as	 a	 binary	






of	 material	 scraped	 from	 the	 palatine	 tonsils	 of	 pigs	 for	 invasive	 disease-associated	 S.	suis	
strains,	 total	genomic	DNA	was	extracted	from	experimental	samples	without	culture	and	first	
isolating	 single	 colonies/clones	 and	 used	 as	mPCR	 assay/tool	 templates.	 	 S.	suis	 is	 considered	
endemic	in	pig	populations,	but	despite	widespread	colonisation	few	invasive	disease-associated	
isolates	 are	 recovered	 from	 the	 upper	 respiratory	 tract	 [141].	 	 In	 pig	 herds	 infected	 with	
multiple	strains	of	S.	suis	sampling	error,	taking	one	or	two	samples	or	sampling	from	only	one	
or	 two	 pigs	 within	 a	 herd,	 may	 result	 in	 failure	 to	 identify	 a	 strain	 associated	 with	 a	 recent	
outbreak	 of	 disease	 herds	 [99,	 121].	 	 The	 reliance	 of	 pathogen	 detection	 on	 the	 culture	 of	
microorganisms	 and	 isolation	 of	 single	 colonies/clones	 is	 a	 major	 drawback	 that	 creates	 a	




S.	suis	 is	 a	 very	 successful	 coloniser	 of	 mucosal	 surfaces	 and	 the	 upper	 respiratory	 tract,	 in	
particular	the	deep	crypts	of	the	palatine	tonsils,	considered	the	natural	habitat	of	the	organism	
[11].	 	 The	 palatine	 tonsils	 are	 also	 considered	 a	 potential	 site	S.	suis	 uses	 to	 gain	 entry	 to	 the	
cardiovascular	 or	 lymphatic	 system	 and	 is	 arguably	 the	 best	 site	 to	 sample	 pigs	 [70,	 85].		
However,	 in	 comparison,	 oral	 fluid	 is	 much	 easier	 to	 recover	 from	 pigs!	 	 In	 agreement	 with	
reports	of	S.	suis	being	endemic	in	all	sampled	pig	populations	the	mPCR	amplicon	of	size	722	bp	
that	 corresponded	 to	 the	 S.	suis	 species	 specific	marker	was	 produced	 in	 all	 groups	 of	 swabs	
sampled.	 	 Surprisingly,	 mutually	 exclusive	 disease-associated	 (SSU1589;	 347	 bp)	 and	 non-
disease	associated	(SSUST30534;	892	bp)	mPCR	amplicons	were	frequently	produced	from	the	
total	 genomic	DNA	extracted	 from	a	 single	 swab,	 all	 of	which	were	 recovered	 form	herds	not	
showing	 obvious	 signs	 of	 disease,	 on	 farms	 in	 England	 and	 Wales	 without	 a	 history	 of	
streptococcal	 disease.	 	 Such	 an	 observation	 indicates	 a	 higher	 prevalence	 of	 invasive	 disease	
associated	 strains	 than	previously	described	 in	healthy	pigs,	 and	 the	 carriage	of	both	disease-
associated	 and	 non-disease	 associated	 S.	suis	 strains	 in	 the	 same	 pig.	 	 Alternatively,	 this	
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GLM)	 for	 S.	suis	 that	 predicted	 correct	 classification	 of	 84%	 (accuracy)	 of	 the	 isolates	 in	 the	
original	training	collection	in	comparison	to	the	observed	clinical	metadata,	managing	to	predict	
the	 correct	 classification	 of	 91%	 (sensitivity)	 of	 invasive	 disease-associated	 isolates	
(Table	4.2(iii)).	 	 Out-of-sample	 forecasting	 using	 a	 collection	 of	 previously	 uncharacterised	
S.	suis	isolates	unsurprisingly	produced	worse	performance	metrics	(sensitivity	=	80%,	accuracy	
=	 80%,	 specificity	 =	 100%,	 positive	 predictive	 value	 =	 100%	 and	 negative	 predictive	 value	 =	
83%),	 for	reasons	discussed	earlier.	 	Regardless,	 these	performance	metrics	are	 indicative	of	a	
well-rounded	 binary	 diagnostic	 test.	 	 In	 comparison	 to	 other	 commonly	 used	 methods	 to	
characterise	 and	 sub-type	 S.	suis	 the	 pathotyping	 tool	 performed	 with	 a	 worse	 sensitivity.		
However,	 the	 trade-off	 for	a	significantly	superior	sensitivity	was,	 in	 the	case	of	 the	virulence-
associated	 genes	 epf,	 mrp	 and	 sly,	 a	 positive	 predictive	 value	 no	 better	 than	 chance	 (Exact	
binomial	 test	 p-value	 =	 1).	 	 While	 false	 negative	 rate	 (1-sensitivty)	 was	 chosen	 as	 the	 most	
valuable	performance	metric	for	pathotyping	S.	suis	(with	a	view	to	establish	and	maintain	a	pig	
population	 free	 of	 invasive	 disease	 associated	 isolates)	 sacrificing	 other	 performance	metrics	
such	 as	 PPV	 and	 specificity	would	 result	 in	 the	 unnecessary	 removal	 of	 animals	 from	 a	 herd.		
Therefore,	 the	 mPCR	 pathotyping	 tool	 is	 a	 good	 proof	 of	 principal	 that	 with	 the	 inclusion	 of	
additional	biomarkers	could	become	a	very	powerful	diagnostic	tool	for	S.	suis.		Interestingly,	the	
frequency	with	which	the	disease-associated	marker	(SSU1589)	was	detected	in	material	 from	
the	 upper	 respiratory	 tract	 of	 pigs	 was	 unexpected	 and	 is	 explored	 further	 in	 chapter	 5,	 as	










S.	suis	 is	 considered	endemic	 in	pig	herds,	often	without	causing	signs	of	 clinical	disease	 [142,	
565,	566].		Some	strains	act	as	primary	pathogens,	causing	encephalitis	and	meningitis,	although	
others	 are	 thought	 to	 act	 as	 opportunistic	 or	 secondary	 pulmonary	 pathogens	 [121].	 	 The	














Increased	 awareness	 of	 S.	suis	 as	 a	 zoonotic	 pathogen	 has	 directed	 attention	 to	 the	 role	 of	
clinically	healthy	pigs	as	a	reservoir	for	disease-causing	strains,	where	there	has	been	little	focus	
on	potential	predisposing	differences	in	prevalence	and	on	diversity	of	carriage.	 	High	levels	of	
genomic	 diversity	 between	 isolates	 of	 S.	suis,	 combined	 with	 evidence	 for	 high	 levels	 of	
recombination	 indicate	 potential	 for	 emergence	 of	 novel	 disease-associated	 strains	 [141].	 	 In	
fact,	because	S.	suis	undergoes	such	extensive	recombination	widespread	across	the	genome,	an	
increase	 in	virulence	anywhere	in	the	world	could	have	a	global	 impact	over	a	short	timescale	




Despite	 widespread	 colonisation,	 relatively	 few	 disease-associated	 isolates	 of	 S.	suis	 are	
recovered	 from	 the	upper	 respiratory	 tract	 of	 pigs	 [141].	 	 In	 pig	 herds	 infected	with	multiple	
strains	of	S.	suis,	 sampling	bias	 (taking	one	or	 two	samples,	or	 sampling	 from	only	one	or	 two	
animals	in	a	herd)	may	result	in	failure	to	identify	a	strain	associated	with	a	recent	outbreak;	a	




agar	 plates	 creates	 a	 crippling	 bottleneck	 that	 if	 removed	 has	 the	 potential	 to	 improve	 the	




uncharacterised	S.	suis	 isolates	performed	with	 a	 sensitivity	 of	 0.80,	 specificity	 of	 1.0,	 positive	
predictive	 value	 of	 1.0	 and	 negative	 predictive	 value	 of	 0.83	 (assuming	 the	 observed	 clinical	
phenotype	to	be	the	'gold-standard').		Attempts	to	then	use	the	S.	suis	pathotyping	tool	to	screen	
swabs	 of	material	 scraped	 from	 the	 palatine	 tonsils	 of	 pigs	without	 culture	 and	 first	 isolating	
single	 colonies	 produced	 an	 interesting	 result	 -	 the	 production	 of	 both	 invasive	 disease-
associated	 and	 non-disease	 associated	 mPCR	 amplicons	 from	 the	 same	 experimental	 sample.		
Detection	of	more	than	one	strain	of	S.	suis	on	the	palatine	tonsils	of	a	pig	 is	unsurprising,	and	
supports	published	observations	of	more	 than	one	serotype,	 sequence	 type	and/or	 'virulence-
associated'	 factor	 profile	 being	 found	 when	multiple	 samples	 are	 taken	 from	 a	 single	 animal	
[568,	 569].	 	 However,	 what	 is	 surprising	 was	 to	 detect	 so	 frequently	 the	 invasive	 disease-
associated	genetic	markers	(and	infer	invasive	disease-associated	strains	of	S.	suis)	in	pig	herds	
not	 showing	 obvious	 signs	 of	 disease	 on	 farms	 in	 England	 and	 Wales	 without	 a	 history	 of	
streptococcal	 disease.	 	 This	 unexpected	 finding	 prompted	 investigation	 of	 the	 hypothesis	 that	





Quantitative	 real-time	 PCR	 (qPCR)	 provides	 fast,	 precise	 and	 accurate	 results,	 and	 like	
'traditional'	 PCR	 has	 become	 an	 established	 method	 for	 molecular	 diagnostics,	 in	 particular	
pathogen	detection	 [535,	570,	571].	 	However,	unlike	 'traditional'/endpoint	PCR	 that	 requires	
laborious	 post	 reaction	 processing	 (gel	 electrophoresis	 and	 image	 analysis),	 qPCR	 uses	
fluorescence-based	 methods	 to	 detect	 the	 accumulation	 of	 amplicons	 during	 the	 exponential	
amplification	 phase	 of	 the	 reaction	 after	 each	 thermal	 cycle	 in	 "real-time".	 	 A	 number	 of	
fluorescence-based	 qPCR	 chemistries	 exist,	 the	 most	 common	 use	 non-specific	 intercalating	
dyes	 such	 as	 SYBR	 Green	 I,	 or	 sequence-specific	 hydrolysis	 probes	 such	 as	 a	 dual	 labelled	
(reporter/quencher)	 TaqMan	 probe.	 	 In	 brief,	 both	 approaches	 are	 designed	 to	 generate	
fluorescence	 during	 the	 PCR,	 taking	 advantage	 of	 the	 linear	 relationship	 between	 detectable	
fluorescence	signal	and	the	amount	of	DNA.		Such	an	approach	provides	researchers	with	a	more	




The	simplest	 form	of	 fluorescence-based	qPCR	uses	DNA-binding	dyes.	 	 Intercalating	dyes	are	
inexpensive	(in	comparison	to	TaqMan	probes),	accounting	for	their	popular	use.		SYBR	Green	I	
is	the	most	commonly	used,	and	has	an	excitation	and	emission	maxima	of	494	nm	and	521	nm	
respectively.	 	 SYBR	 Green	 I,	 preferentially	 binds	 double-stranded	 DNA	 over	 single-stranded	
DNA.	 	 Fluorescent	 in	 its	 own	 right,	 SYBR	 Green	 I,	 in	 the	 presence	 of	 double-stranded	 DNA	
intercalates	with	the	minor	groove	of	the	DNA	double	helix.		This	alters	the	structure	of	the	dye	
and	 excitation	 of	DNA-bound	 SYBR	Green	 I	 produces	 a	much	 stronger	 fluorescent	 signal	 than	
unbound	dye.	 	The	advantages	of	 this	approach	are	 low	cost	and	simplicity,	 ideal	 for	 research	




Quantitative	real-time	PCR	using	an	 intercalating	dye	was	chosen	 for	a	pilot	 investigation	 into	
the	 prevalence	 of	 invasive	 disease-associated	 and	 non-disease	 associated	 isolates	 of	 S.	suis	 in	
material	 scraped	 from	 the	 palatine	 tonsils	 of	 clinically	 healthy	 pigs	 on	 farms	 in	 England	 and	
Wales.		Probe-based	chemistries	are	associated	with	superior	specificity.		However,	a	recurring	
feature	 of	 S.	suis	 genome	 analyses	 is	 a	 high	 level	 of	 recombination	 within	 the	 species,	
widespread	 throughout	 the	 genome	 [141].	 	 It	 is	 acknowledged	 that	 using	 a	 probe-based	











ii)	 pig	 age	 and	 iii)	 culture-based	 methods	 of	 detection	 in	 use	 today.	 	 Of	 which,	 the	 most	





1.	 To	 determine	 whether	 the	 newly	 defined	 pathotyping	 markers	 described	
previously	 in	 this	 thesis	 (chapters	 3	 and	 4)	 can	 be	 used	 to	 screen	 material	










5.2.1	 Establishment	 of	 quantitative	 real-time	PCR	 to	 screen	 tonsil	 swabs	 for	
disease-	and	non-disease	associated	strains	of	Streptococcus	suis	
Quantitative	real-time	PCR	was	used	to	assess	the	prevalence	of	invasive	disease-associated	and	
non-disease	 associated	 strains	 of	 S.	suis	 on	 the	 palatine	 tonsils	 of	 pigs.	 	 The	 online	 software,	
primer3	version	4.0.0	was	used	to	design	qPCR	primers	(Table	5.1).	Primers	were	designed	to	
have	 similar	 physical	 characteristics,	 enabling	 simultaneous	 amplification	 under	 the	 same	
thermal	cycling	conditions.		Primer	length	(18-24	bp),	GC	content	(~50%),	melting	temperature	
(~60	˚C;	and	within	1	˚C	of	each	other),	and	expected	amplicon	size	(80-200	bp;	not	exceeding	
400	 bp)	 were	 based	 on	 the	 manufacturer’s	 recommendations	 for	 primer	 design	 using	 the	





























the	 newly	 defined	 S.	suis	 species-specific	 marker	 (SSU0577)	 and	 one	 each	 of	 the	 disease-
associated	 (SSU1589)	 and	 non-disease	 associated	 (SSUST30534)	 markers	 targeted	 in	 the	
pathotyping	 tool	 described	 in	 chapter	 4.	 	 Of	 the	 two	 disease-associated	 pathotyping	markers	
described	 in	 chapter	 4,	 SSU1589	was	 chosen	 for	 qPCR	 in	 favour	 of	 SSU0207	 due	 to	 superior	
sequence	 homology	 in	 invasive	 disease-associated	 isolates	 recovered	 from	 pigs	 on	 farms	 in	
England	and	Wales.	 	 In	addition,	primers	were	also	designed	to	target	the	core-metabolic	gene	
recN,	 encoding	 a	 recombination/repair	 protein,	 to	 allow	 further	 evaluation	 of	 SSU0577	 as	 a	
robust	 species-specific	 marker	 for	 S.	suis.	 	 Previously,	 the	 recN	 gene	 has	 been	 used	 to	
differentiate	members	of	 the	genus	Streptococcus	based	on	partial	gene	sequencing	 [572],	and	
most	 recently	 as	 the	 S.	suis	 species-specific	 marker	 in	 a	 mPCR	 for	 the	 identification	 of	 six	
clinically	relevant	streptococci	[573].	
	





clinical	 phenotype.	 	 Figure	5.1	 shows	 the	 placement	 of	 qPCR	 primers	 SSU1589:0958F/1101R,	
designed	 to	 target	 the	 3’	 end	 of	 the	 protein-encoding	 sequence	 present	 in	 invasive	 disease-
















Robust	 and	 precise	 qPCR	 experiments	 are	 associated	with	 high	 PCR	 amplification	 efficiencies	
[535].		PCR	efficiencies	are	a	measurement	of	the	rate	at	which	a	PCR	amplicon	is	generated,	and	
are	 dependent	 on	 the	 primers	 used.	 	 Amplification	 efficiencies	 (or	 'primer	 efficiencies'),	 per	
primer	pair,	were	calculated	over	the	range	~1x	100	-	1x	107	genome	copies	per	reaction	using	a	
calibration	curve	(Figure	5.2	and	Figure	5.3)	and	the	equation:	







associated	and	non-disease	associated	strains	of	S.	suis	 on	 swabs	of	material	 scraped	 from	 the	















































Primer	pair	 Phenotype	 Amplicon	size	(bp)	 R2	 m	 Efficiency	 qPCR	
SSU1589:0874F/0975R	 Disease-associated	 101	 0.995	 -3.209	 1.05	 -	
SSU1589:0958F/1101R	 Disease-associated	 143	 0.998	 -3.449	 0.95	 Yes	
SSUST30534:0526F/0633R	 Non-disease	associated	 107	 0.996	 -3.406	 0.97	 Yes	
SSUST30534:1236F/1319R	 Non-disease	associated	 83	 0.966	 -3.464	 0.94	 -	
SSU0577:0462F/0562R	 Streptococcus	suis	 100	 0.999	 -3.378	 0.98	 Yes	
SSU0577:0544F/0683R	 Streptococcus	suis	 139	 0.998	 -3.439	 0.95	 -	
SSU1462:0032F/0178R	 Streptococcus	suis	(recN)	 146	 0.994	 -2.905	 1.21	 -	




Standard	 curve	 equations,	 per	 primer	 pair,	 were	 used	 to	 estimate	 the	 unknown	 number	 of	
genome	 copies	 in	 experimental	 samples	 (section	 5.2.2	 onwards).	 	 A	 standard	 curve	 was	
generated,	 for	 each	primer	pair,	 over	 the	 range	~1x	101	 -	 1x	105	 genome	 copies	per	 reaction.		
Each	 standard	curve	was	generated	 from	 four	biological	 repeats	using	 independent	 single-use	
qPCR	premixes,	and	each	biological	repeat	performed	in	triplicate	per	10-fold	serial	dilution	of	
template	 DNA.	 	 The	 concentration	 of	 DNA	 was	 linked	 to	 the	 number	 of	 thermal	 cycles	 (Ct)	
required	 to	 reach	 the	 fluorescence	 threshold	at	which	point	 individual	 amplification	 reactions	
contained	identical	amounts	of	DNA	using	the	standard	curve	equation:	





pair,	 for	 each	 rotor	 run.	 	 Instead,	 adaptation	 of	 a	method	 described	 by	Grant	 et	al.	 [536]	was	
used	to	calculate	robust	estimates	of	the	standard	curve	equation	for	each	primer	pair,	that	were	
then	 used	 to	 both	 assess	 the	 performance/variability	 between	 rotor	 runs	 and	 estimate	 the	
number	 of	 genome	 copies	 in	 experimental	 samples.	 	 Figure	 5.4(a)	 shows	 the	 four	 biological	
repeats	 used	 to	 calculate	 estimates	 of	 the	 standard	 curve	 equation	 for	 the	 invasive	 disease-
associated	marker	primer	pair	SSU1589:0958F/1101R.	 	The	"Auto-Find	Threshold"	function	of	
Rotor-Gene	 Q	 analysis	 software	 version	 2.3.1	 (Qiagen)	 was	 used	 to	 find	 the	 fluorescence	
threshold	that	delivered	the	best-fit	of	each	standard	curve	to	the	samples	defined	as	standards.		
However,	 to	 draw	 direct	 comparison	 between	 Ct	 values	 from	 separate	 rotor	 runs,	 the	 same	
fluorescence	 threshold	must	be	used	 to	analyse	each	 rotor	 run	 [537].	 	The	mean	 fluorescence	
threshold,	 for	 each	 primer	 pair,	 was	 used	 to	 re-analyse	 the	 four	 biological	 repeats	 of	 each	
standard	 curve.	 	 A	 regression	 line,	 per	 biological	 repeat,	 was	 fitted	 and	 used	 to	 generate	
estimates	of	the	variables	a	and	b,	which	were	then	averaged	across	the	repeats	to	give	a	 final	
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SSU1589:0958F/1101R	 Disease-associated	 0.25595	 -0.292	 9.987	 Conc.	=	10(-0.292(Ct)+		9.987)	
SSUST30534:0526F/0633R	 Non-disease	associated	 0.21078	 -0.291	 10.132	 Conc.	=	10(-0.291(Ct)+10.132)	
SSU0577:0462F/0562R	 	Streptococcus	suis	 0.20513	 -0.296	 10.013	 Conc.	=	10(-0.296(Ct)+10.013)	







Standards	 of	 known	 concentration	 (103	 genome	 copies	 per	 reaction;	 arbitrarily	 chosen)	were	
used	to	pass/fail	rotor	runs	based	on	the	following	criteria:	to	pass	i)	the	standard	deviation	of	
Ct	 values	must	 be	 less	 than	 1.0,	 and	 ii)	 the	mean	 Ct	 value	must	 fall	 within	 +/-	 two	 standard	













Primers	 Phenotype	 Marker	 Mean	Ct	 sd	 -2sd	 +2sd	
SSU1589:0958F/1101R	 Disease-associated	 SSU1589	 24.13	 0.63	 23.51	 24.76	
SSUST30534:0526F/0633R	 Non-disease	associated	 SSUST30534	 24.63	 0.74	 23.89	 25.37	
SSU0577:0462F/0562R	 Streptococcus	suis	 SSU0577	 23.86	 0.48	 23.38	 24.34	




Analytical	 sensitivity	 refers	 to	 the	 ability	 of	 an	 assay	 to	 accurately	 detect	 very	 low	
concentrations	of	a	given	substance.		For	qPCR,	analytical	sensitivity	is	typically	expressed	as	the	
limit	 of	 detection,	 which	 is	 the	 lowest	 concentration	 that	 can	 be	 detected	 with	 reasonable	
certainty,	usually	95%	probability	(theoretically,	three	copies	per	PCR	is	the	most	sensitive	limit	
of	detection	possible)	[535].		Limit	of	detection	was	determined	by	performing	ten	replicates	per	
dilution	 over	 the	 range	~100	 -	 102	 genome	 copies	 per	 reaction.	 	 The	 dilution	with	 the	 lowest	
concentration	meeting	 the	 following	 requirements	was	deemed	 to	be	 the	 limit	 of	detection:	 i)	
the	standard	deviation	of	Ct	values	must	be	 less	than	1.0	and	 ii)	 the	number	of	replicates	with	
positive	detection	must	be	greater	than	95%.		The	mean	Ct	value	of	the	lowest	concentration	was	
then	used	 to	calculate	 the	 limit	of	detection	and	expressed	as	a	number	of	genome	copies	per	













SSU1589:0958F/1101R	 Disease-associated	 14	 24	
SSUST30534:0526F/0633R	 Non-disease-associated	 6	 10	
SSU0577:0462F/0562R	 Streptococcus	suis	 13	 28	





Any	molecular	 test	 for	 S.	suis	 must	 be	 specific.	 	 The	 upper	 respiratory	 tract	 of	 pigs	 carries	 a	
diverse	 bacterial	 population,	 and	 being	 able	 to	 remove	 the	 culture	 and	 isolation	 of	 single	
colonies	 from	the	S.	suis	detection/diagnosis	procedure	would	require	any	alternative	assay	 to	
be	 capable	 of	 specifically	 detecting	 S.	suis	 from	 a	 mixed	 sample.	 	 Accurately	 replicating	 the	
diversity	 of	 the	 upper	 respiratory	 tract	 in	 vitro	 is	 extremely	 difficult,	 if	 not	 impossible.		
Therefore,	to	test	for	non-S.	suis	amplification	of	qPCR	markers,	genomic	DNA	from	field	isolates	
of	 closely	 related	 Streptococcaceae,	 Pasteurellaceae	 and	 Alcaligenaceae	 commonly	 recovered	
from	 the	 upper	 respiratory	 tract	 of	 pigs	were	 used	 as	 a	 panel	 of	 negative	 controls.	 	 No	 qPCR	
amplicons	were	produced	by	qPCR	primer	pairs	targeting	the	pathotyping	markers	described	in	
chapter	4.	 	However,	primer	pairs	targeting	SSU1462(recN)	did	produce	qPCR	amplicons	using	











curve	analysis	 for	 the	mixed	sample	 templates.	 	All	amplification	traces	and	the	endpoint	melt	
curve	analysis	produced	profiles	consistent	with	those	produced	by	qPCR	when	using	template	



























Estimates	of	 the	number	of	 invasive	disease-associated	genome	copies	were	 consistent	 across	
the	five	mixed	sample	templates	(range:	33-49,	mean:	41;	aim:	~50	genome	copies	per	reaction),	
and	 all	 within	 the	 95%	 confidence	 interval	 (28-81	 genome	 copies)	 calculated	 for	 50	 disease-
associated	genome	copies	detected	using	qPCR	primers	SSU1589:0958F/1101R.		In	comparison,	
estimates	 of	 the	 number	 of	 non-disease	 associated	 genome	 copies	 increased	 ~10-fold,	
consistent	with	estimates	when	using	template	DNA	from	a	single	source.	
	
Detection	 of	 the	 reverse	 ratio	 (non-disease	 associated	 strains	 at	 low	 levels	 in	 comparison	 to	
invasive	 disease-associated	 strains)	 was	 also	 possible	 and	 produced	 very	 similar	 results.		

























1:10,000	 38	 453,649	 481,415	 11,923:1	
1:1,000	 40	 32,368	 33,055	 801:1	
1:100	 33	 3,218	 3,063	 97:1	
1:10	 41	 256	 262	 7:1	
1:1	 49	 62	 67	 1:1	
10,000:1	 478,630	 45	 458,987	 1:10,637	
1,000:1	 64,977	 58	 58,998	 1:1,121	
100:1	 3,756	 47	 3,583	 1:80	
10:1	 267	 36	 302	 1:8	
1:1	 37	 43	 66	 1:1	
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5.2.1.7	 Two	different	 species-specific	markers	detect	Streptococcus	suis	on	 the	
tonsil	swabs	but	estimate	different	bacterial	load	
Chapter	 3	 of	 this	 thesis	 describes	 the	 identification	 of	 SSU0577,	 one	 of	 the	 most	 conserved	
protein-encoding	 sequences	 in	 the	S.	suis	 core-genome.	 	 SSU0577	 is	 then	 evaluated	 as	 a	 novel	
species-specific	genetic	marker	for	S.	suis	in	chapter	4.		To	further	evaluate	SSU0577	as	a	robust	























In	 addition	 to	 using	 a	 binary	 approach	 (detection/no	 detection)	 the	 estimated	 numbers	 of	
genome	 copies	 per	 swab	 were	 also	 compared.	 	 Table	 5.8	 shows	 the	 test	 statistics	 and	
corresponding	 p-values	 used	 to	 identify	 statistically	 significant	 differences.	 	 qPCR	 targeting	
SSU1462(recN)	consistently	estimated	significantly	higher	numbers	of	genome	copies	(used	as	a	
proxy	for	bacterial	load),	per	tonsil	swab,	in	comparison	to	SSU0577	(p-value	<0.05).		In	section	
5.2.1.6,	 it	 is	 reported	 that	 primer	 pairs	 targeting	 SSU1462(recN)	 produced	 qPCR	 amplicons	
using	 template	 DNA	 from	 strains	 of	 Streptococcus	gallolyticus	 and	 Streptococcus	 pneumoniae.		
This	was	inferred	to	be	the	reason	for	the	higher	estimates	of	the	number	of	genome	copies	on	
tonsil	swabs,	therefore,	where	necessary	to	draw	comparison	to	a	species-specific	marker	in	this	

















SSU0577	 0.87992;	0.00002	 -	 -	
-	 1718.5;	0.00465	
SSU1462(recN)	 0.94177;	0.00154	 -	 -	
	 	
	 213	
5.2.2	 Quantitative	 real-time	 PCR	 can	 be	 used	 to	 detect	 Streptococcus	suis	on	
tonsil	swabs	without	culture	and	first	isolating	single	colonies/clones	




the	 newly	 defined	 S.	suis	 species-specific	 marker	 SSU0577	 (identified	 as	 one	 of	 the	 most	
conserved	protein-encoding	sequences	 in	 the	S.	suis	 core-genome,	 see	section	3.3.5).	 	The	data	
presented	in	Figures	5.6	and	5.7	show	it	 is	possible	to	detect	very	 low	(~14)	to	comparatively	





Despite	 being	 detected	 in	 all	 six	 groups	 sampled,	 it	 was	 not	 possible	 to	 detect	 S.	suis	 in	 all	
experimental	samples.		In	Figure	5.6	and	Figure	5.7,	it	is	important	to	draw	attention	to	the	data	
presented	 as	 an	 'x',	which	has	 been	done	 to	 indicate	 that	 estimates	 of	 the	 number	 of	 genome	
copies	 are	not	 reported	with	95%	confidence.	 	 It	 is	 usual	not	 to	 report	 estimates	of	detection	
below	the	limit	of	detection	or	to	report	estimates	of	the	number	of	genome	copies	where	qPCR	
rotor	 runs	 are	 deemed	 to	 have	 failed	 quality	 control.	 	 However,	 due	 to	 time	 restrictions,	
repeating	all	qPCR	rotor	runs	deemed	to	have	failed	quality	control	was	not	possible.		Inclusion	
of	estimates	of	 the	number	of	genome	copies	unable	 to	be	reported	with	95%	confidence	was	
done	 so	 as	 to	 help	 highlight	 potential	 trends	 and	 avoid	 presenting	 misleading	 reports	 of	
detection	in	this	work.		It	has	also	served	the	purpose	of	highlighting	additional	work	required	in	


















































































































































































































































































































































































































































































































































































































Wilk	 test	 for	 normality	 alongside	 Quantile-Quantile	 (qq)-plots	 was	 used	 to	 determine	 if	 the	
























3	 5	 0.94145;	0.176	 2.829	 0.680	
5.1635;	0.00004	 -	
3	 20	 0.94562;	0.706	 1.754	 0.075	
4	 5	 0.93010;	0.274	 1.965	 0.177	
-	 111;	0.00355	
4	 20	 0.72131;	0.020	 -	 -	
5	 5	 0.93530;	0.467	 2.655	 0.388	
3.3252;	0.00430	 -	






was	used.	 	High	ambient	 temperature	has	been	proposed	as	 a	 risk	 factor	 responsible	 for	high	
S.	suis	bacterial	load	in	pork	derived	food	items	[265,	280].		Tonsil	swabs	used	in	this	pilot	study	
were	 originally	 collected	 over	 a	 12-month	 period	 as	 part	 of	 a	 separate	 longitudinal	 study	
designed	 to	 enable	 any	 effect	 of	 air	 temperature	 on	 the	 positive	 isolate	 rate	 of	 S.	suis	 to	 be	
evaluated.		No	significant	effect	(p-value	=	0.211)	of	ambient	air	temperature	on	the	number	of	
genome	 copies	 was	 found	 when	 using	 an	 ANOVA	 to	 partition	 the	 observed	 variance	 into	
different	sources	of	variation.	
	
5.2.3	 Invasive	 disease-associated	 strains	 of	 Streptococcus	 suis	 detected	 on	
tonsil	swabs	at	five	weeks	were	unable	to	be	detected	at	20	weeks	of	age	
To	 investigate	 if	 qPCR	 could	 be	 used	 to	 screen	 swabs	 of	 material	 scraped	 from	 the	 palatine	
tonsils	of	pigs	for	invasive	disease-associated	strains	of	S.	suis,	primers	were	designed	to	target	
the	 newly	 defined	 pathotyping	marker	 SSU1589.	 	 Figure	 5.8	 (five-weeks)	 and	 Figure	 5.9	 (20-
weeks)	 show	 the	 number	 of	 invasive	 disease-associated	 genome	 copies,	 per	 experimental	
sample,	 estimated	 using	 qPCR	 targeting	 the	 newly	 defined	 S.	suis	 invasive	 disease-associated	
pathotyping	marker	SSU1589.		On	all	three	farms	sampled	invasive	disease-associated	strains	of	
S.	suis	 could	be	detected	by	our	methods.	 	However,	 comparison	of	 Figure	5.8	with	Figure	5.9	


































































































































especially	 problematic	 in	 endemic	 herds	 [99,	 121].	 	 Figure	 5.10	 and	 Figure	 5.11	 show	 the	
number	 of	 non-disease	 associated	 genome	 copies,	 per	 experimental	 sample,	 estimated	 using	
qPCR	 targeting	 the	 newly	 defined	 S.	suis	 non-disease	 associated	 pathotyping	 marker	
SSUST30534.	 	On	all	three	farms	at	both	time	points	sampled	non-disease	associated	strains	of	



























































































































To	 test	 the	hypothesis	 that,	despite	widespread	colonisation,	 the	 reason	 few	disease-associated	
isolates	are	recovered	from	the	upper	respiratory	tract	of	pigs	is	because	the	ratio	of	non-disease-
associated:	 disease	 associated	 strains	 is	 greater	 than	3:1	 (respectively),	 the	number	of	 genome	
copies	 estimated	 using	 primers	 targeting	 the	 newly	 defined	 pathotyping	 markers	 SSU1589	
(invasive	 disease-associated)	 and	 ST30534	 (non-disease)	 were	 compared.	 	 Where,	 although	
chosen	 for	practical	 reasons,	 it	was	hypothesised	 that	 three	single	colony	picks	 from	solid	agar	
plates	 is	not	enough	to	generate	accurate	reports	of	 the	true	prevalence	of	S.	suis	 strains	on	the	
tonsils	of	pigs.		Table	5.10	shows	the	estimated	number	of	genome	copies	and	ratio	(non-disease-
associated:	 disease	 associated;	 rounded	 to	 one	 significant	 figure)	where	 both	 invasive	 disease-
associated	 and	 non-disease	 associated	 markers	 were	 detected	 in	 the	 sample	 experimental	






















F3_w05	 7	 3862	 1505	 1901	 1:1	
F3_w05	 8	 2350	 477	 1416	 3:1	
F3_w05	 9	 7636	 28	 2116	 80:1	
F3_w05	 10	 7036	 42	 223	 5:1	
F3_w05	 20	 3001	 78	 -	 -	
F4_w05	 7	 29	 7	 32	 5:1	
F4_w05	 11	 557	 186	 1054	 6:1	
F4_w05	 13	 28	 32	 104	 3:1	
F4_w05	 14	 -	 34	 -	 -	
F4_w05	 15	 87	 49	 326	 7:1	
F4_w05	 18	 157	 119	 845	 7:1	
F4_w05	 21	 111	 47	 -	 -	
F5_w05	 8	 3022	 97	 2570	 30:1	
F5_w05	 11	 436	 36	 394	 10:1	
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5.2.4	 Quantitative	 real-time	 PCR	 is	 more	 sensitive	 in	 comparison	 to	 classic	
culture-based	detection	methods	for	Streptococcus	suis	
To	compare	the	positive	detection	of	S.	suis	using	quantitative	real-time	PCR	targteing	the	novel	
species	 specfic	 marker	 (SSU0577)	 to	 detection	 using	 the	 standard	 culture-based	 method,	 all	
swabs	were	subjected	 to	both	detection	methods.	 	Classic	culture-based	 isolation	of	S.	suis	 from	
the	 upper	 respiratory	 tract	 is	 a	 laborious	 and	 time-consuming	 process	 associated	 with	 low	
sensitivity,	particularly	due	to	phenotypically	similar	streptococcal	species	difficult	to	distinguish	
on	 the	 basis	 of	 colony	 morphology	 alone	 [27].	 	 In	 contrast,	 qPCR	 provides	 fast,	 precise	 and	
accurate	results,	and	has	become	an	established	method	for	pathogen	detection	[571].		Table	5.11	




























S.	suis	 in	 comparison	 to	 detection	 using	microbiology	 techniques	 to	 isolate	 single	 colonies	 and	
then	biochemical	profiles	to	group	isolates	to	the	bacterial	species.			
	
Table	 5.12	 summarises	 the	 number	 of	 single	 colonies	 picked	 from	 solid	 agar	 plates	 that	 had	
biochemical	 profiles	 (API20	 Strep)	 associated	 with	 S.	suis,	 and	 then	 of	 these	 how	 many	 were	
confirmed	 to	 be	 S.	suis	 using	 whole-genome	 sequencing	 data.	 	 The	 information	 in	 Table	5.12	
highlights	 the	 difficulty,	 even	 for	 experienced	 technicians	 at	 the	 Scottish	 Agricultural	 College	
Consulting	Service,	of	identifying	S.	suis	based	on	colony	morphology	and	α/β	haemolysis	on	solid	
agar	plates	alone.		For	example,	for	five	of	the	six	groups	sampled	from	75	single	colony	picks	per	
group	 (three	 picks,	 from	 25	 swabs)	 suspected	 of	 being	 S.	suis	 single	 figure	 numbers	 were	
confirmed	to	be	S.	suis	using	whole-genome	sequencing.		Figure	5.12	is	a	visual	representation	of	
the	 data	 in	 Table	 5.12,	 showing	 the	 proportion	 of	 swabs,	 per	 group	 sampled,	 testing	 positive	
using	 qPCR	 (black)	 in	 comparison	 to	 swabs	 testing	 positive	 for	 S.	suis	 using	 culture-based	
methods	 (grey-scale).	 	 The	 five	 groups	 sampled	 where	 statistically	 significant	 (p-value	 <0.05)	























F3_w05	 52	 16	 0.64	 0.96	 -2.82843	 0.002342	
F3_w20	 13	 4	 0.16	 0.22	 -0.36811	 0.356437	
F4_w05	 11	 7	 0.28	 0.75	 -3.39683	 0.000342	
F4_w20	 8	 4	 0.16	 0.50	 -3.12889	 0.000880	
F5_w05	 9	 1	 0.04	 0.79	 -3.54654	 0.000196	

















This	 chapter	 describes	 the	 use	 of	 qPCR	 to	 screen	 swabs	 of	material	 scraped	 from	 the	 palatine	
tonsils	 of	 pigs	 for	 invasive	 disease-associated	 strains	 of	 S.	suis.	 	 qPCR	 is	 a	 technique	 capable	 of	
fast,	precise	and	accurate	results	that	has	become	an	established	method	for	pathogen	detection	
[571].	 	 In	 chapter	 4,	 attempts	 to	 use	 our	 S.	suis	 pathotyping	 tool	 to	 screen	 swabs	 of	 material	
scraped	 from	 the	 palatine	 tonsils	 of	 pigs	 without	 culture	 and	 first	 isolating	 single	 colonies	




were	 present	 in	 the	 pooled	 oral	 fluid	 collected	 from	 cotton	 chew	 ropes.	 	 The	 detection	 of	 the	
S.	suis	 spp.	 in	 asymptomatic	 carrier	 herds	 is	 of	 little	 practical	 value	 in	 predicting	 likelihood	 of	
future	 clinical	 relevance	 [11].	 	 Instead,	 the	 value	 of	 future	molecular	 tools	 for	 surveillance	 and	




S.	suis	 surveillance	 programs,	 a	 feature	 that	 would	 be	 of	 considerable	 benefit	 to	 better	 the	
understanding	of	subclinical	infection	dynamics	to	support	future	intervention	programs.	
	





the	past,	 and	 the	 tonsil	 remains	 a	popular	 sampling	 site	due	 to	 it	 being	 considered	 the	natural	
habitat	 of	 S.	suis	 [142,	 426,	 569].	 	 The	 upper	 respiratory	 tract	 is	 a	 diverse	 environment	 and	
accurately	 replicating	 the	 diversity	 of	 such	 a	 highly	 contaminated	 site	 in	 vitro	 is	 extremely	
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difficult,	if	not	impossible.		Evaluation	of	species-specificity	was	done	using	field	isolates	of	closely	
related	 Streptococcaceae,	 Pasteurellaceae	 and	 Alcaligenaceae	 commonly	 recovered	 from	 the	
upper	 respiratory	 tract	 of	 pigs.	 	 No	 qPCR	 amplicons	were	 produced	 indicating	 the	 qPCR	 assay	
described	in	this	chapter	reliably	targets	S.	suis,	and	false-positives	due	to	phenotypically	similar	
and	closely-related	field	isolates	are	low.	 	However,	 it	 is	 important	to	acknowledge	that	none	of	
the	 species-specificity	 experiments	 contained	 a	 pig	 (or	 human)	 genomic	DNA	 control,	which	 is	
important	to	be	absolutely	sure	that	no	false	positive	bands	have	been	produced.	
	
It	 is	 important	 to	 mention	 the	 primer	 pairs	 targeting	 SSU1462	 (recN)	 did	 produce	 qPCR	
amplicons	 using	 template	 DNA	 from	 strains	 of	 Streptococcus	gallolyticus	 and	 Streptococcus	
pneumoniae.	 	 The	 core-metabolic	 gene	 recN,	 encoding	 a	 recombination/repair	 protein,	 was	
included	to	continue	to	evaluate	SSU0577	as	a	robust	species-specific	marker	for	S.	suis	due	to	its	
previous	use	as	a	marker	 to	differentiate	members	of	 the	genus	Streptococcus	[572,	573].	 	Melt	
curve	 analyses	 indicated	 that	 these	 qPCR	 amplicons	 could	 be	 differentiated	 from	 those	
corresponding	 to	 S.	suis	 based	 on	 the	 higher	 temperature	 required	 for	 dissociation	 of	 dsDNA,	
indicating	a	different	length	or	GC	content	of	these	non-S.	suis	amplicons.		Indeed,	it	was	curious	




The	 performance	 of	 qPCR	 primers	was	 further	 evaluated	with	 a	mixed	 sample	 template	 using	
genomic	DNA	 from	 two	 closely	 related	 lab	 strains	 of	 S.	suis,	 P1/7	 (invasive	 disease-associated)	
and	 LSS034	 (non-disease	 associated).	 	 Mixed	 templates	were	 created	 to	 reflect	 the	 hypothesis	
that	disease-associated	strains	of	S.	suis	are	prevalent	at	low	levels	in	comparison	to	non-disease	
associated	strains	in	the	upper	respiratory	tract	of	pigs.		Although	by	no	means	representative	of	









in	 PBS	 and	 a	 DNA	 extraction	 performed	 using	 the	 Sigma-Aldrich	 GenElute	 Bacterial	 DNA	 Kit.		
Despite	the	acknowledged	reservations,	it	was	possible	to	use	qPCR	targeting	SSU0577	to	detect	
S.	suis	 on	 swabs	 of	material	 scraped	 from	 the	 palatine	 tonsils	 of	 pigs	without	 the	 need	 to	 first	
culture	 and	 isolate	 single	 colonies.	 	 The	 S.	suis	 gene	 SSU0577,	was	 evaluated	 in	 chapter	 4	 as	 a	
novel	 species-specific	 marker,	 after	 being	 identified	 as	 one	 of	 the	 most	 conserved	 protein-
encoding	sequences	 in	the	S.	suis	core-genome	(chapter	3).	 	 Inclusion	of	a	S.	suis	species-specific	
marker	in	the	mPCR	pathotyping	tool	described	in	chapter	4	was	for	two	purposes:	i)	a	positive	
control,	 to	 confirm	 PCRs	 were	 successful	 and	 ii)	 to	 infer	 disease-/non-disease	 associated	 PCR	
amplicons	were	due	to	the	presence	of	S.	suis.		In	qPCR,	SSU0577	was	used	for	the	same	purposes.		
However,	 qPCR-targeting	 SSU0577	 also	 produced	 estimates	 of	 the	 number	 of	 S.	suis	 genome	
copies	per	experimental	sample	regardless	of	association	with	a	particular	clinical	phenotype.		Of	
the	 three	 farms	 sampled,	 none	 had	 a	 recent	 history	 of	 S.	suis	 disease	 or	 house	 pigs	 showing	
obvious	signs	of	streptococcal	disease.		Detection	of	S.	suis	was	possible	in	all	six	groups	sampled	
(three	farms,	sampled	at	two	time	points	 five	weeks	and	20	weeks	of	age),	supporting	previous	
observations	 that	 consider	 S.	suis	 endemic	 in	 pig	 herds	 often	 without	 causing	 signs	 of	 clinical	
disease	 [142,	 565,	 566].	 	However,	 although	detected	 in	 all	 six	 groups	 sampled,	S.	suis	was	 not	
detected	 in	all	experimental	 samples	 (i.e.	 tonsil	 swabs).	 	Possible	 reasons	 for	 this	could	 include	
failure	of	 the	sampling	 techniques	 to	draw	material	 from	deep	within	 the	crypts	of	 the	palatine	
tonsils,	 where	 S.	suis	 tends	 to	 form	 confined	 groups	 [574]	 or	 the	 effect	 of	 PCR	 inhibitors	 in	
salivary	fluids	such	as	DNA	binding	agents	or	compounds	added	as	a	result	of	sample	processing	






Objective	 2.	 	 Most	 S.	suis	 strains	 are	 thought	 to	 act	 as	 opportunistic	 or	 secondary	 pathogens,	
although	 some	 can	 act	 as	 primary	pathogens	 causing	 invasive	disease	 such	 as	 encephalitis	 and	
meningitis	 [121].	 	With	 this	 in	mind	 this	 chapter	 reported	 the	 detection	 of	 not	 only	 the	 S.	suis	
species	but	also	detection	of	markers	associated	with	invasive	disease-causing	isolates	on	swabs	
of	 material	 scraped	 from	 the	 palatine	 tonsils	 of	 pigs.	 	 The	 detection	 of	 the	 invasive-disease	
associated	genetic	markers	 is	an	 interesting	 finding	 in	 itself,	 as	all	 three	 farms	sampled	did	not	
have	a	history	of	S.	suis	disease	or	at	the	point	of	sampling	house	pigs	showing	obvious	signs	of	
streptococcal	disease.		This	finding	supports	opinion	that	S.	suis	strains	with	a	heightened	genetic	
capacity	 to	 cause	 invasive	 disease	 are	 present	 on	 farms	without	 signs	 of	 streptococcal	 disease,	
and	potentially	 that	disease	onset	 is	dependent	on	animal	 stress	arising	 from	environment	and	
farm	management	practices	[85,	142].	
	
A	 notable	 finding	 described	 in	 this	 chapter	 was	 that	 despite	 20	 (27%,	 of	 n=75)	 swabs	 testing	
positive	(with	95%	confidence)	 for	the	disease-associated	marker	of	S.	suis	at	 five	weeks	of	age,	
the	 same	 genetic	marker	 could	 not	 be	 detected	with	 95%	 confidence	 in	 experimental	 samples	
collected	 at	 20	 weeks	 of	 age.	 	 This	 finding	 supports	 the	 previous	 observation	 that	 S.	suis	
associated	disease	 is	 less	prevalent	 in	older	pigs	approaching	slaughter	age,	 instead	being	most	
prevalent	during	the	post-weaning	period	when	pigs	are	commonly	mixed	and	maternal	derived	
passive	 antibody	 titres	 are	 in	 decline	 [126,	 426].	 	 It	 is	 interesting	 to	 speculate	 that	 this	
observation	 is	 linked	 to	 previous	 descriptions	 of	 disease-associated	 strains	 of	 S.	suis	 having	 a	
smaller	 genome	 size	 in	 comparison	 to	 non-disease	 associated	 strains	 [141].	 	 Clear	 genetic	
differences	between	disease-associated	and	non-disease	associated	strains	have	been	described	
and	although	disease-associated	strains	have	an	overrepresentation	of	putative	virulence	factors	
this	 finding	 could	 indicate	 that	 having	 fewer	metabolic	 genes	 could	 lead	 to	 disease-associated	
strains	being	less	able	to	survive	in	the	diverse	and	highly	competitive	environment	of	the	upper	
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Ambient	 temperature	 at	 the	 time	 of	 sampling	 was	 also	 investigated	 as	 a	 significant	 factor	
influencing	 the	 detection	 rate	 of	S.	suis	 on	 farms	 in	 England	 and	Wales.	 	 Previous	 reports	 have	
proposed	high	ambient	temperature	as	a	potential	risk	factor	responsible	for	high	S.	suis	bacterial	
load	in	pork	derived	food	items	and/or	human	disease	in	Asian	countries	[242,	265,	280].	 	Such	
an	 effect	 could	 potentially	 lead	 to	 enhanced	 carriage	 and	 shedding	 from	 clinically	 healthy	 pigs	
during	warmer	months.	 	However,	such	a	relationship	is	 likely	to	be	complicated.	 	 Interestingly,	
the	opposite	relationship	between	temperature	and	transmission	of	Streptococcus	pneumonia	has	
recently	been	described	–	where	temperature	and	prevalence	of	carriage	are	described	as	being	
repeatedly	 enhanced	 during	 cooler	months	 [576].	 	 In	 this	 study,	 no	 statistically	 significant	 (p-
value	 <0.05)	 effect	 of	 ambient	 temperature	 on	 the	 number	 of	 genome	 copies	 estimated	 using	
qPCR	was	found.		This	could	be	due	to	a	number	of	cultural	or	experimental	reasons,	although	it	is	
difficult	to	speculate	further	as	there	is	no	immune	response	in	dead	meat	and	such	a	comparison	




Objective	 3.	 	 S.	suis	 is	 considered	 endemic	 in	 pig	 herds	 [142,	 565,	 566],	 an	 observation	 also	
described	 in	 this	 chapter	 using	 qPCR.	 	However,	 despite	widespread	 colonisation,	 few	disease-
associated	 isolates	of	S.	suis	 are	 recovered	 from	the	upper	 respiratory	 tract	 [141].	 	 In	pig	herds	
infected	with	multiple	 strains	of	S.	suis,	 sampling	bias	might	 result	 in	 failure	 to	 identify	a	 strain	
associated	with	a	recent	outbreak;	a	 feature	especially	problematic	 in	endemic	herds	 [99,	121].		
Currently,	the	S.	suis	diagnosis	procedure	relies	on	culture	and	isolation	of	single	colonies.		This	is	
a	 major	 limiting	 factor	 of	 the	 detection/diagnosis	 procedure,	 and	 removal	 of	 the	 bottleneck	
created	 by	 picking	 single	 colonies	 from	 solid	 agar	 plates	 has	 the	 potential	 to	 improve	 the	
sensitivity	of	surveillance	programs	and	enable	more	detailed	investigation	of	infection	dynamics.		
Comparison	of	any	new	diagnostic	tool	should	be	to	an	agreed	'gold	standard',	and	in	this	study	






An	 important	 observation	 described	 in	 this	 chapter	 is	 the	 number	 of	 non-disease	 associated:	
disease-associated	genome	copies	detected	is	greater	than	3:1,	indicating	that	three	single	colony	
picks	 from	solid	agar	plates	 is	 insufficient	 to	be	confident	of	detecting	strains	of	S.	suis	with	 the	
potential	 to	 cause	 invasive	 disease.	 	 For	 practical	 and	 budgetary	 reasons	 three	 single	 colonies	
suspected	 of	 being	 S.	suis	 were	 picked	 from	 solid	 agar	 plates.	 	 It	 should	 be	 acknowledged	 that	
some	diagnostic	 laboratories	 now	use	 five	 single	 colony	 picks,	 this	 is	 important	 and	when	 this	
data	 is	 reviewed	 for	 publication	 in	 a	 peer	 reviewed	 scientific	 journal	 any	 additional	 analyses	
(where	possible)	should	be	adjusted	to	reflect	this.	 	Regardless,	increasing	this	number	of	single	
colony	picks	 to	exceed	 five	would	be	 impractical	 for	routine	surveillance.	 	Equally	using	whole-
genome	sequencing	data	to	confirm	isolates	recovered	using	culture-based	techniques	are	S.	suis	
is	excessive	(but	in	this	case	available	due	to	data	being	generated	as	part	of	a	separate	research	







Finally,	 this	 study	 describes	 the	 use	 of	 qPCR	 using	 an	 intercalating	 dye	 to	 detect	 dsDNA	 PCR	
amplicons	 due	 to	 its	 low	 cost	 and	 simplicity.	 	 To	 increase	 specificity	 development	 of	 a	 probe-
based	approach	should	be	considered,	although	such	an	approach	might	not	be	possible	for	such	
a	highly	recombinagenic	species.		Probe-based	qPCR	is	designed	to	be	more	specific	than	using	an	
intercalating	 dye.	 	 A	 number	 of	 approaches	 are	 available,	 including:	 hybridisation	 probes,	
hydrolysis	 probes	 or	 molecular	 beacon	 probes.	 	 Hydrolysis	 probes,	 such	 as	 TaqMan	 or	
PerfectProbe,	 are	 among	 the	 most	 popular.	 	 These	 are	 fluorescently	 labelled	 oligonucleotides	
designed	to	bind	downstream	of	one	of	the	qPCR	primers.		The	TaqMan	assay,	is	based	on	the	5’-
3’	exonuclease	activity	associated	with	Taq	DNA	polymerase	and	the	phenomenon	of	fluorescence	
resonance	 energy	 transfer	 (FRET).	 	 Each	 TaqMan	 probe	 contains	 a	 covalently	 attached	 5’	
fluorescent	reporter	(FAM;	6-carboxy-fluorescein	is	a	green	reporter;	others	include	VIC,	JOE	and	
CY5	which	emit	light	at	different	wavelengths);	and	a	3’	quencher	molecule	(TAMRA,	6-carboxy-
tetramethyl-rhodamine).	 	 Before	 the	 qPCR	 begins,	 the	 reporter	 and	 quencher	 are	 in	 close	
proximity	to	each	other,	allowing	FRET	to	occur;	meaning	the	fluorescent	signal	of	the	reporter	is	
quenched.	 	During	 the	qPCR,	 the	primers	 and	probe	anneal	 to	 the	 target;	 and	DNA	polymerase	
extends	the	primer	upstream,	of	the	probe.		If	the	probe	is	bound	to	the	correct	target	sequence	
5’-3;	 exonuclease	 activity	 of	 the	 Taq	 DNA	 polymerase	 cleaves	 the	 probe,	 releasing	 a	 fragment	
containing	the	reporter.		Cleavage	of	the	probe	separates	the	report	and	quencher	dyes;	resulting	





In	 conclusion,	 this	 chapter	 presents	 evidence	 for	 the	 development	 of	 a	 molecular-based	
diagnostic	 tool	 to	screen	material	scraped	from	the	palatine	tonsils	of	pigs	 for	 invasive	disease-
associated	strains	of	S.	suis	without	the	need	for	culture	and	isolation	of	single	colonies	from	solid	
agar	plates.	 	Due	to	time	restrictions	is	was	not	possible	to	repeat	all	experimental	samples	that	
failed	qPCR	quality	 control,	 and	 to	 avoid	 reducing	 sample	 size	 and	 the	 statistical	 power	of	 this	
study	 should	 be	 the	 first	 task	 of	 future	 work	 for	 a	 complete	 proof	 of	 concept.	 	 An	 interesting	
experiment	to	add	to	evaluation	of	proof	of	concept	would	be	plating	aliquots	of	material	from	the	
palatine	 tonsils	of	pigs	resuspend	 in	PBS	 from	which	DNA	extractions	were	performed	to	see	 if	
ratios	of	invasive	disease-associated:non-disease	associated	strains	can	be	replicated	at	the	bench	
quickly	 using	 colony	 PCR.	 	 Finally,	 a	 feature	 of	 S.	suis	 research	 is	 the	 lack	 of	 a	 comprehensive	
understanding	of	 the	 role	 virulence-factors	 have	 in	pathogenesis.	 	 At	 present	 the	 role(s)	 of	 the	
pathotyping	markers	identified	and	evaluated	in	this	thesis	are	also	unclear	and	efforts	should	be	










Recent	 progress	 in	 S.	suis	 'omics'	 research	 has	 generated	 a	 large	 amount	 of	 data	 on	 putative	
virulence-associated	 factors	 (summarised	 in	 Table	 1.3),	 however	 experimental	 evidence	 for	
possible	 function	and	 the	biological	 role	 in	 infection	 is	 available	 for	only	 a	 few	of	 these	 factors	
[129,	131,	302].	 	This	chapter	attempts	 to	address	 this,	describing	 the	design	and	evaluation	of	
two	 isogenic	 mutants	 designed	 to	 begin	 to	 better	 understand	 the	 role	 in	 pathogenesis	 of	 the	
newly	defined	pathotyping	marker	SSU1589.		Described	in	chapter	3,	SSU1589	was	identified	as	a	
genetic	marker	associated	with	the	observed	clinical	phenotype	of	invasive	S.	suis	disease	in	pigs	
on	 farms	 in	 the	 UK.	 	 Described	 in	 chapters	 4	 and	 5,	 SSU1589	 was	 then	 evaluated	 as	 a	 novel	
marker	of	 invasive	disease-association,	 indicating	that	S.	suis	 strains	capable	of	causing	 invasive	
disease	co-exist	with	non-disease	associated	asymptomatic	carriage	strains	on	the	palatine	tonsils	
of	colonised	pigs.	 	Leading	to	 the	hypothesis	 that	culture-based	approaches	to	surveillance	may	
be	 underestimating	 the	 true	 prevalence	 of	 strains	 with	 increased	 capacity	 to	 causing	 invasive	
disease.	
	
The	 protein-encoding	 sequence	 SSU1589,	 also	 known	 as	 virA,	 is	 included	 as	 part	 of	 the	




protein	 was	 predicted	 to	 have	 the	 putative	 function	 "similar	 to	 specificity	 determinant	 HsdS	
(Listeria	innocua	 Clip11262)",	 and	 (the	 STM	 mutant	 was)	 shown	 to	 be	 attenuated	 in	
experimentally	infected	CF-1	mice	and	in	both	intravenously	and	intraperitoneally	infected	CDCD	
pigs	 [319].	 	 Since	 2007,	 Li	 et	 al.	 has	 been	 the	 only	 group	 to	 publish	 research	 aimed	 at	
understanding	the	role	of	SSU1589	(hereafter	referred	to	as	virA,	denoting	virulence	gene	A)	 in	
pathogenesis	 and	 virulence	 of	 S.	suis;	 reporting	 that	 the	 intact	 virA	 protein-encoding	 sequence	
(1206	 bp)	 existed	 only	 in	 virulent	 isolates	 tested,	 and	 that	 it	 played	 an	 important	 role	 in	









In	general,	 restriction	endonucleases	do	not	correlate	with	virulence	 in	bacteria	 [378].	 	 Since	 it	
was	learnt	that	modification	of	a	cell’s	DNA	by	methylation	protected	DNA	whereas	the	absence	
of	modification	 on	 bacteriophage	DNA	 rendered	 it	 susceptible	 to	 restriction	 by	 endonucleases,	
Type	 I	 restriction	 modification	 (RM)	 enzymes	 have	 been	 associated	 with	 defence	 of	 the	 host	
bacterium	 against	 foreign	 DNA	 [559].	 	 However,	 advances	 in	 bioinformatics,	 whole-genome	
sequencing	and	very	 recently	methylome	analysis	by	next	 generation	 single-molecule	 real-time	
(SMRT)	 sequencing	 has	 allowed	 our	 understanding	 of	 the	 range	 of	 functions	 that	 RM	 systems	
have	 to	 expand	 to	 include	 stabilising	 mobile	 genetic	 elements	 and	 gene	 regulation	 potentially	
providing	 evolutionary	 fitness	 advantages	 and	 virulence	 under	 certain	 conditions	 [560].	 	 For	
example,	this	might	include	fixing	an	antibiotic	resistance	gene	within	the	bacterial	chromosome,	
where	the	gene	was	originally	introduced	to	the	bacterial	cell	by	a	bacteriophage	or	on	plasmid.		




and	 S-adenosylmethionine	 (SAM)	 for	 activity,	 and	 display	 both	 restriction	 endonuclease	 and	
modification	methyltransferase	activities.		Trimers	of	2M+S	can	act	solely	as	a	methyltransferase	
[577].	 	 Type	 I	 RM	 systems	 are	 encoded	 by	 three	 host	 specificity	 determinant	 genes	 (hsdM,	








specificities	 and	 is	 a	powerful	driver	of	Type	 I	RM	system	diversification	 [553,	578].	 	Recently,	




















and	 the	 epigenetic	 landscape	 of	 S.	suis	 has	 not	 been	 investigated.	 	 Interestingly,	 in	 the	 recent	
Willemse	et	al.	description	of	the	distribution	of	Type	I	RM	systems	in	S.	suis	the	authors	propose	
that	"S.	suis	uses	a	 'core'	 type	I	R–M	system	(SsuPORF1588P)	to	protect	 itself	 from	foreign	DNA	
and	 that	 additional	 type	 I	R–M	systems	might	 allow	 for	 further	phage	defense	and	possibly	 for	
regulatory	control"	[552].	 	However,	we	found	that	"SsuPORF1588P"	is	unable	to	be	detected	in	
all	 of	 the	 S.	suis	 isolates	 that	 we	 have	 sequenced	 (recovered	 from	 pigs	 on	 farms	 in	 the	 UK,	 as	
opposed	 to	 the	 Netherlands)	 and	 therefore	 should	 not	 be	 simply	 defined	 as	 a	 core-metabolic	
(housekeeping)	 system;	 although	 this	 does	 highlight	 that	 effort	 to	 understand	 the	 role	 of	
epigenetic	modification	in	S.	suis	is	currently	being	undertaken.		Indeed,	as	this	thesis	is	written	a	
hsdS	gene	 (locus_tag	ZY05719_RS06855)	belonging	 to	Type	 I	RM	system	"SsuZY05719II"	 in	 the	
Chinese	 virulent	 serotype	 2	 strain	 ZY05719	 was	 reported	 to	 facilitate	 anti-phagocytosis	 and	
survival	 in	microglia	and	whole	blood	through	positively	 impacting	the	expression	of	virulence-
associated	factors	[584].	 	It	is	worth	noting	that	SsuZY05719II	corresponds	to	operon	SSU1272-
1274	 in	P1/7	and	 is	neither	 the	Type	 I	RM	system	the	work	described	 in	 this	 thesis	 focuses	on	





A	pheromone-induced	mechanism	of	 natural	 genetic	 transformation	 (or	 competence)	 has	 been	




use	 of	 low-efficiency	 genetic	 approaches	 that	 use	 Escherichia	 coli	 shuttle	 vectors	 and	 suicide	
vectors	 [490].	 	This	opens	up	 the	possibility	of	 routine	genetic	manipulation	and	gene	deletion	
using	linear	DNA	fragments	assembled	with	common	PCR-based	techniques.	
	
Homologs	of	 the	 genes	 associated	with	natural	 competence	 are	widespread	among	both	Gram-
negative	and	Gram-positive	bacteria,	although	experimental	evidence	 for	natural	competence	 is	
limited	 to	~80	bacterial	 species;	 that	 includes	16	 species	 of	 the	 genus	Streptococcus	[585].	 	 All	
known	 naturally	 competent	 bacteria,	 with	 the	 exception	 of	 Helicobacter	 pylori,	 are	 thought	 to	
share	a	common	mechanism	of	DNA	uptake,	with	processing	and	recombination	controlled	by	a	
single	 master	 regulator.	 	 In	 the	 streptococci	 the	 single	 master	 regulator	 is	 thought	 to	 be	 the	
alternative	 sigma	 factor	 SigX	 (also	 known	 as	 ComX).	 	 The	 pheromone	 regulatory	 system	 for	
activation	 of	 competence	 used	 to	 generate	 the	 data	 described	 in	 this	 thesis	 has,	 in	 addition	 to	
S.	suis,	 also	 previously	 been	 described	 in	 Streptococcus	 mutans,	 Streptococcus	 pyogenes	 and	
Streptococcus	thermophiles	[490].		Where	a	Rgg-family	transcriptional	activator	(ComR)	positively	
regulates	 expression	 of	 ComX	 through	 allosteric	 interaction	 with	 a	 extracellular	 pheromone	
encoded	by	ComS	(SSU0050)	 [490].	 	Therefore,	 the	addition	of	exogenous	ComS	can	be	used	 to	
















This	 chapter	 describes	 the	 design,	 construction	 and	 evaluation	 of	 two	 isogenic	 virA	 operon	
knockout	mutants,	one	each	 in	S.	suis	 isolates	LSS089	and	P1/7.	 	Preliminary	studies	 looking	at	
the	 positive	 detection	 of	 virA	 protein-encoding	 sequence	 in	 the	 original	 training	 collection	
revealed	a	number	of	non-disease	associated	isolates	to	possess	a	truncated	virA,	and	are	missing	
the	 second	variable	TRD	 (Figure	6.3).	 	 As	 the	 immediate	 flanking	 regions	of	 disease-associated	
and	non-disease	associated	isolates	examined	are	almost	identical,	the	removal	of	both	versions	

















1.		 Design	and	construct	an	 isogenic	virA	 operon	knockout	mutant	 in	S.	suis	 isolates	
LSS089	and	P1/7	using	natural	genetic	transformation	(competence)	





6.2.1	 Differences	 in	 the	 virA	 protein-encoding	 sequence	 between	 invasive	
disease-associated	and	non-disease	associated	Streptococcus	suis	isolates	
An	 investigation	 into	 the	 positive	 detection	 of	 the	 virA	 protein-encoding	 sequence	 revealed	
striking	 differences	 between	 invasive	 disease-associated	 and	 non-disease	 associated	 isolates	 in	
the	original	training	collection.		The	virA	protein-encoding	sequence	is	1206	bp	in	length,	and	was	
positively	 detected	 in	 81%	 of	 the	 53	 invasive	 disease-associated	 isolates.	 	 In	 comparison,	 the	
1206	bp	virA	protein-encoding	sequence	was	positively	detected	in	just	6%	of	the	62	non-disease	
associated	 isolates	 in	 the	 original	 training	 collection.	 	 Closer	 inspection	 of	 the	 BLASTn	 output	





mutants	 strains	 in	 LSS034	 (arbitrarily	 chosen	 from	 the	 non-disease	 associated	 isolates	 with	 a	
truncated	 virA*	 protein-encoding	 sequence)	 and	 P1/7	 background,	 including	 i)	 a	 P1/7∆virA	
operon	 knockout	 ii)	 a	 LSS034∆virA	 operon	 knockout,	 as	 well	 as,	 two	 virA	 operon	 'exchange'	
mutants	 where	 the	 virA	 operon	 of	 P1/7	was	 exchanged	 for	 the	 LSS034	 virA*	 operon	 and	 vice	
versa.		Figure	6.5	shows	a	schematic	representation	of	the	strategy	employed	to	knockout	the	virA	
operon	in	S.	suis	isolate	P1/7.		The	same	approach	was	employed	to	knockout	the	truncated	virA*	










Disease_P1/7        TAGAACAAAAAGAGAGTAGAAAAGGAGGGACTATGACAAAAGAAAAATCAACCGTACCAC 
Non-disease_LSS034  TGAAACAAAAAGAAAGTAGAAAAGGAGGGACTATGACAAAAGAAAAATCAACAGTACCAC 
                    *  ********** ************************************** ******* 
 
Disease_P1/7        GATTGCGCTTCCCCGGATTCACGGACGCTTGGAAACAGCGTAAGTTGGGGGAGGTGGCGG 
Non-disease_LSS034  GATTGCGCTTCCCCGGATTCACGGACGCTTGGAAACAGCGTAAGTTGGGGGAGGTGGCGG 
                    ************************************************************ 
 
Disease_P1/7        ACTTTTCCATAAAAACAAACTCACTTTCTAGAGATAAGTTATCATCGTATTTTTATGAAG 
Non-disease_LSS034  ACTTTTCCATAAAAACAAACTCACTTTCTAGAGATAAGTTATCATCGTATTTTTATGAAG 
                    ************************************************************ 
 
Disease_P1/7        TTCAGAACATTCATTATGGGGATATTTTAACAAAATATGATGCTATTTTAGATGTATGTA 
Non-disease_LSS034  TTCAGAACATTCATTATGGGGATATTTTAACAAAATATGATGCTATTTTAGATGTATGTA 
                    ************************************************************ 
 
Disease_P1/7        ACAAAGAACTTCCATCAATTATTGGAAGTACGATTTCAGACTTTGCAGATGCTTTACTTA 
Non-disease_LSS034  ACAAAGAACTTCCATCAATTATTGGAAGTACGATTTCAGACTTTGTAGATGCTTTACTTA 
                    ********************************************* ************** 
 
Disease_P1/7        GTGAAGGAGATATTGTTTTCGCGGATGCGGCAGAAGACTCGACTGTTGGGAAAGCTATTG 
Non-disease_LSS034  TTGAAGGAGATATTGTTTTCGCGGATGCGGCAGAAGACTCAACTGTTGGGAAAGCTGTTG 
                     *************************************** *************** *** 
 
Disease_P1/7        AAGTTCGAAATTTTAAGGGTAAGAATGTTGTTTCTGGTTTACATACGATAGTTGCTAGGC 
Non-disease_LSS034  AAGTTCGAAATTTTAAGGGTAAGAATGTTGTTTCTGGTTTACATACGATAGTTGCTAGGC 
                    ************************************************************ 
 
Disease_P1/7        CGAAAGTTTCTTATGCCCCCTACTATTTAGGTTATCTAATTAATTCAACTGCATACCATA 
Non-disease_LSS034  CGAAAGTTTCTTATGCCCCCTACTATTTAGGTTATCTAATTAATTCAACTGCATATCATA 
                    ******************************************************* **** 
 
Disease_P1/7        ATCAAATTTTACCTTTAATGCAGGGGACAAAAGTGAGCTCAATTAGTAAGGCTAATTTAA 
Non-disease_LSS034  ATCAAATTTTACCTTTAATGCAGGGGACAAAAGTTAGCTCAATTAGTAAGGCTAATTTAA 
                    ********************************** ************************* 
 
Disease_P1/7        AATCCACGACAGTAGTGTTCCCCACCCTCCCTGAACAAGAAGCCATCGGCAGCTTCTTCT 
Non-disease_LSS034  AATCCACGACAGTAGTGTTCCCCACCCTCCCCGAACAATCCGCTATCGGCAGCTTCTTTT 
                    ******************************* ******   ** ************** * 
 
Disease_P1/7        CCGACCTAGATCAGCTTATTACTCTTCATCAGCGAAAATTAGATGATGTTAAAGAATTGA 
Non-disease_LSS034  CCGACCTAGATCAGCTTATTACTCTTCATCAGCGAAAA---------------------- 
                    **************************************                       
 
Disease_P1/7        AGAAGGCTTTGTTACAGAAAATGTTTCCGAAAGGGAATGGAAACGATTTTCCTGAGCTAA 
Non-disease_LSS034  ------------------------------------------------------------ 
                                                                                 
 
Disease_P1/7        GATTCCCAGAATTTACGGACGCTTGGAAACAGCGTAAGTTGGGGGAGTTTATGAAAGAAA 
Non-disease_LSS034  ------------------------------------------------------------ 
                                                                                 
 
Disease_P1/7        GTAAAATTTTAGGTAGTAAAGGAGATATAGCAAGGAAGTTAACTGTAAGATTATGGGGGA 
Non-disease_LSS034  ------------------------------------------------------------ 
                                                                                 
 
Disease_P1/7        GAGGAGTTGTTTCCAAGAAAGAAATTTATAGTGGTAGTTCAGCTACACAGTATTATATAA 
Non-disease_LSS034  ------------------------------------------------------------ 
                                                                                 
 
Disease_P1/7        GAAAATCAGGCCAGTTTATATATGGGAAATTAGACTTTTTAAATCAAGCTTTTGGAATTA 
Non-disease_LSS034  ------------------------------------------------------------ 
                                                                                 
 
Disease_P1/7        TTCCACCAGAACTTGATGGTTATGAATCAACTCTTGATTCGCCTGCTTTTGATTTATTGA 
Non-disease_LSS034  ------------------------------------------------------------ 
                                                                                 
 
Disease_P1/7        AAGGGATAAACGGGCAATTTCTGTTAGAATTTGTATCTCGCAAAGAATTTTATTATTATC 
Non-disease_LSS034  ------------------------------------------------------------ 
                                                                                 
 
Disease_P1/7        AAGGAAATATTGCAAATGGCTCTAGAAAAGCTAAAAGAATCCACACAGAAACTTTTCTTG 
Non-disease_LSS034  ------------------------------------------------------------ 
                                                                                 
 
Disease_P1/7        GCATGCCTATCTCCCTCCCCACCCTCCCTGAACAAGAAGCCATCGGTAGCTTCTTTTCCG 
Non-disease_LSS034  ------------------------------------------------------------ 
                                                                                 
 
Disease_P1/7        ACCTAGATCAGCTTATTACTCTTCATCAGCGAAAATGAGATTTCGAGTAAAAAATGAAAC 
Non-disease_LSS034  -----------------------------------TGAGATTTCGAGTAAAAAATGAAAC 











6.2.2	 Evidence	 for	 the	construction	of	 isogenic	virA	operon	knockout	mutants	
in	LSS034	and	P1/7	backgrounds	
Standard	 spliced	 overlap	 extension	 PCR	 techniques	 [540]	 were	 used	 to	 create	 the	 double-
stranded	DNA	constructs	consisting	of	three	parts	i)	a	flanking	region	downstream	of	the	operon,	
ii)	 a	 spectinomycin	 resistance	 cassette	 and	 iii)	 a	 flanking	 region	 upstream	 of	 the	 operon	
(Figure	6.6	(a)).	 	Figure	6.6	 (b)	 shows	successful	 first	 round	PCR	amplification	of	 the	 individual	
parts	 of	 each	 construct.	 	 Figure	 6.6	 (c)	 shows	 successful	 third	 round	 (final)	 spliced	 overlap	
extension	PCR	amplification	of	the	DNA	constructs	to	be	transformed	into	LSS034	and	P1/7.		DNA	
constructs	were	purified	before	being	checked	for	SNPs	by	Sanger	sequenced	(data	not	shown).	
Transformants	 cultured	 on	 solid	 agar	 plates	 supplemented	 with	 spectinomycin	 were	 checked	
using	 bespoke	 oligonucleotide	 primers.	 	 No	 transformants	 were	 generated	 using	 the	 LSS034	











































NT	3ab/3bc	 3ab/3c	 3a/3bc	 1ab/1bc	 1ab/1c	 1a/1bc	
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To	 investigate	 if	 knocking	 out	 the	 virA	 operon	 (SSU1588-SSU1590)	 had	 an	 effect	 on	 bacterial	
growth	in	vitro	the	strains	LSS089∆virA	and	P1/7∆virA,	as	well	as	their	respective	parent	strains,	
were	 grown	 under	 standard	 conditions	 in	 THB	 supplemented	 with	 0.2%	 yeast	 extract	 and	 a	
growth	 curve	performed.	 	OD595	measurements	were	used	as	 a	proxy	 for	bacterial	 growth,	 and	
were	recorded	every	1-hour	over	a	24-hour	period.		Figure	6.7	(a)	shows	two	growth	curves,	one	
for	 the	 P1/7∆virA	 operon	 mutant	 (grey-scale)	 and	 the	 second	 wild-type	 P1/7	 (black).	 	 Both	
mutant	 and	wild-type	 strains	 show	 similar	 growth	 characteristics,	 undergoing	 i)	 an	 initial	 one	
hour	lag	phase,	ii)	an	exponential	growth	phase	between	one	and	five	hours	post	inoculation	and	
iii)	a	stationary	phase	between	five	and	12-hours	post	inoculation.		At	12-hours	post	inoculation,	
rather	 than	 an	 expected	 decline	 in	 OD595	measurements	 typically	 associated	with	 death	 phase,	
OD595	measurements	for	both	mutant	and	wild-type	strains	increased	in	a	manner	characteristic	
of	 i)	 a	 second	 lag	phase	 (12-15	hours	 post	 inoculation),	 ii)	 a	 second	 exponential	 growth	phase	
(15-21	hours	post	inoculation)	and	iii)	a	second	stationary	phase	(21-22	hours	post	inoculation)	




<0.05)	 different	 growth	 characteristics	 in	 comparison	 to	 the	disease-associated	wild-type	P1/7	
(Figure	 6.7	 (b)).	 	 Despite	 producing	 a	 similar	 general	 pattern	 of	 growth	wild-type	 LSS089	was	
found	to	have	a	much	shorter	stationary	phase	(if	at	all)	at	approximately	five	to	six	hours	post	
inoculation.		Instead,	in	contrast	to	P1/7,	wild-type	LSS089	almost	immediately	entered	a	second	
lag	 phase	 (at	 five	 to	 six	 hours	 post	 inoculation)	 followed	 by	 a	 second	 exponential	 phase	 (8-17	
hours	 post	 inoculation)	 before	 a	 decline	 in	 OD595	 measurements	 typical	 of	 death	 phase	 began	
approximately	18-hours	post	inoculation.	
	
Figure	 6.7	 (b)	 also	 shows	 the	 growth	 characteristics	 of	 the	 LSS089∆virA	 operon	mutant	 (grey-
scale).	 	 In	 comparison	 to	 the	 wild-type	 parent	 strain,	 the	 LSS089∆virA	 operon	 mutant	 had	 a	
	 252	
similar	 one	 hour	 lag	 phase.	 	 However,	 between	 two	 and	 five	 hours	 post	 inoculation	 the	 OD595	
measurements	 of	 the	wild-type	 increased	 significantly	 quicker	 than	 the	mutant	 strain	 (p-value	
<0.05),	 indicating	 slower	 growth.	 	 Then	 at	 six	 hours	 post	 inoculation,	 as	 the	 wild-type	 strain	
briefly	entered	an	 initial	 stationary	phase	 the	LSS089∆virA	 operon	mutant	did	not,	 and	 instead	
appeared	 to	 continue	 to	 grow	exponentially	until	 ten	hours	post	 inoculation	when	 it	 reached	a	
peak	OD595	 of	~0.3	 and	 entered	 stationary	 phase.	 	 OD595	 remains	 constant	 until	 15	 h	 at	which	

















































effect	 on	 biofilm	 formation	 in	 vitro	 the	 strains	 LSS089∆virA	 and	 P1/7∆virA,	 as	 well	 as	 their	
respective	 parent	 strains,	 were	 grown	 under	 standard	 conditions	 in	 THB	 supplemented	 with	
0.2%	yeast	extract	and	the	formation	of	a	biofilm	assessed	using	a	crystal	violet	microtiter	plate	
assay	 (section	 2.2.2.1).	 	 Figure	 6.8	 shows	 OD595	 measurements	 after	 planktonic	 bacteria	 were	
removed	 at	 24	 hours	 post	 inoculation,	 and	were	 used	 as	 a	 proxy	 for	 biofilm	 formation.	 	 Both	
mutant	 strains	 in	 comparison	 to	 their	 respective	 wild-type	 parent	 strains	 had	 a	 statistically	
significant	(p-value	<0.05)	lower	A595,	indicating	biofilm	formation	was	disrupted	in	these	strains.		
No	statistically	significant	difference	in	A595	was	observed	between	wild-type	parent	strains	(data	
























































































Greater	 Wax	 Moth	 (G.	 mellonella)	 larvae	 have	 recently	 been	 explored	 as	 a	 simple	 and	 cost-
effective	in	vivo	experimental	 infection	model	 to	screen	the	virulence	potential	of	S.	suis	 isolates	
[423].	 	To	establish	and	evaluate	 the	Greater	Wax	Moth	 larvae	experimental	 infection	model	 in	
our	 laboratory,	 S.	suis	 isolates	 P1/7	 (disease-associated)	 and	 Henrichsen	 S735	 (deemed	 to	 be	
"weakly	virulent"	 in	newborn	gnotobiotic	pigs	 [284])	were	used	 to	 infect	 groups	of	 final	 instar	



























Inoculum	(CFU/mL)	 1x	105	 1x	106	 1x	107	 1x	108	 1x	109	
Log-rank	test	(p-value)	 0.150	 0.287	 0.035	 0.746	 -	
	 	
P1/7 109/8/7/6/5













































6.2.5.1	 The	 Greater	 Wax	 Moth	 larvae	 experimental	 infection	 model	 can	
differentiate	disease-associated	from	non-disease	associated	strains	
To	 further	 evaluate	 the	 use	 of	 Greater	 Wax	 Moth	 larvae	 survival	 as	 a	 robust	 experimental	
infection	 model	 for	 S.	suis,	 four	 invasive	 disease-associated	 (Figure	 6.11	 (a-d))	 and	 four	 non-
disease	associated	(Figure	6.12	(a-d))	field	strains	recovered	from	pigs	on	UK	farms	were	used	to	
infect	groups	of	final	instar	stage	caterpillars	and	larvae	survival	recorded	every	24-hours	over	a	
144-hour	period	post	 infection.	 	Figure	6.11	shows	dose-dependent	 larvae	survival	 for	 the	 four	
(a-d)	 invasive	disease-associated	 isolates	 tested.	 	 Infection	with	an	 inoculum	of	1x	109	CFU/mL	
resulted	 in	 no	 Greater	Wax	 Moth	 larvae	 survival	 at	 24-hours	 post	 infection.	 	 Infection	 with	 a	
1x	108	CFU/mL	inoculum	of	SS1008	resulted	in	~40%	larvae	survival	after	24-hours,	reducing	to	
~20%	at	 the	end	of	 the	144-hour	post-infection	time	course.	 	Other	 invasive	disease-associated	
isolates	resulted	in	less	larvae	survival	at	24-hours	post	infection,	SS1024:	~20%,	SS1066:	~10%	
and	 SS1072:	 0%.	 	 However,	 infection	 with	 an	 inoculum	 of	 1x	 107	 CFU/mL	 invasive	 disease-





















































































































































































































To	 evaluate	 differences	 in	 Greater	 Wax	 Moth	 larvae	 survival	 following	 infection	 with	 isolates	
grouped	 into	 invasive	disease-associated	 and	non-disease	 associated	phenotypic	 groups,	 larvae	
survival	 for	 all	 strains	 of	 a	 phenotypic	 group	 (disease/non-disease	 associated)	were	 drawn	 on	
one	plot.		Figure	6.13	(a)	shows	the	larvae	survival	following	infection	with	1x	108	CFU/mL	of	the	
four	invasive	disease-associated	(red)	and	four	non-disease	associated	(black)	strains.		The	mean	
larvae	 survival	 of	 phenotypic	 groups	 (disease-associated/non-disease	 associated)	 was	 then	
calculated	and	plotted	with	95%	confidence	bounds	(Figure	6.13	(b)).		The	log-rank	test	was	then	
used	 to	 demonstrate	 a	 statistically	 significant	 difference	 in	 the	 mean	 larvae	 survival	 between	


































Kaplan−Meier estimate with 95% confidence bounds





















6.2.5.2	 Removal	 of	 the	 virA	 operon	 had	 no	 effect	 on	 Greater	 Wax	 Moth	 larvae	
survival	in	comparison	to	wild-type	parent	strains	
To	investigate	if	knocking	out	the	virA	operon	had	an	effect	on	Greater	Wax	Moth	larvae	survival	
the	 strains	 LSS089∆virA	 and	P1/7∆virA,	 as	well	 as	 their	 respective	 parent	 strains,	were	 grown	
under	standard	conditions	and	then	used	to	inoculate	final	instar	stage	caterpillars	and	survival	
recorded	 every	24-hours	 over	 a	 144-hour	post	 infection	 time	 course.	 	Observing	3R	 guidelines	
only	the	highest	three	inocula	doses	(1x	109,	1x	108	and	1x	107	CFU/mL)	were	used	to	reduce	the	
number	 of	 larvae	 per	 experiment	 as	 no	 significant	 difference	 was	 observed	 in	 larvae	 survival	
infected	with	S.	suis	at	1x	106	and	1x	105	CFU/mL	(Figures	6.10/11/12).		Figure	6.14	shows	larvae	
survival	following	experimental	infection	with	(a)	wild-type	P1/7,	(b)	P1/7∆virA	operon	mutant,	
(c)	wild-type	LSS089,	 and	 (d)	LSS089∆virA	 operon	mutant.	 	No	 statistically	 significant	 (p-value	






































































































Objective	 1.	 	 Having	 described,	 in	 chapter	 3,	 the	 identification	 of	 novel	 genetic	 markers	
associated	 with	 S.	suis	 isolates	 causing	 invasive	 disease	 in	 pigs	 on	 UK	 farms,	 the	 research	
described	in	this	chapter	attempted	to	begin	to	address	the	lack	of	experimental	evidence	for	the	
newly	 defined	 pathotyping	marker	 SSU1589	 (also	 known	 as	 virA	 [378])	 by	 ambitiously	 setting	
out	to	create	four	independent	isogenic	virA	operon	mutants	using	the	only	recently	described	in	






created,	 whereby	 the	 recombination	 events	 occurred	 at	 undesirable	 locations.	 	 Clearly,	 the	
cloning	strategy	 for	operon	exchange	was	suboptimal.	 	With	more	 time,	 two	possible	strategies	
could	be	 implemented	 to	 create	 the	desired	operon	 'exchange'	mutants.	 	 Firstly,	 rethinking	 the	
cloning	 strategy	 using	 shorter	 flanking	 regions	 may	 prevent	 the	 incorrect	 crossover	 event.		




Natural	 competence	 has	 been	 described	 in	 ~80	 bacterial	 species,	 however	 a	 complete	
understanding	 of	 the	mechanisms	 underlying	 this	 process	 is	 not	 available	 [490,	 585].	 	What	 is	




a	100%	match	to	ComS	 in	P1/7	 it	was	not	possible	 to	 induce	 the	process	of	competence	 in	 this	
strain.		The	reason	for	this	is	unclear	and	could	be	due	to	a	number	of	reasons,	including	but	not	
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limited	 to	 i)	 other	 genes	 of	 the	 natural	 competence	 cascade	 being	 absent	 from	 LSS034,	 ii)	
premature	switching	off	of	natural	competence,	due	to	a	lack	of	our	current	understanding	of	the	
mechanisms	mediating	shut	down,	 iii)	composition	of	 the	growth	medium,	 iv)	bacterial	density,	
or	v)	a	 lack	of	other	necessary	environmental	 cues	 [491].	 	Because	 there	are	many	 factors	 that	
have	the	potential	to	affect	this	tightly	regulated	process,	it	is	difficult	to	determine	which	factor	
played	 the/an	 important	 role	 in	 preventing	 the	 process	 of	 natural	 competence	 in	 LSS034.		
Curiously,	 under	 the	 same	 experimental	 conditions,	 it	 was	 possible	 to	 induce	 the	 process	 of	
natural	 competence	 in	 non-disease	 associated	 field	 isolate	 LSS089,	 and	 go	 on	 to	 generate	 the	
desired	 virA*	 operon	 knockout	 mutant.	 	 Therefore,	 we	 hypothesise	 that	 the	 experimental	






the	 experiment	 (24-hours),	 indicating	 the	 'functional'	 virA	 operon	 does	 not	 play	 a	 role	 in	
regulating	 growth	 in	 artificial	 growth	 media	 (Figure	 6.7	 (a)).	 	 Although,	 it	 is	 important	 to	
acknowledge	that	this	might	not	be	the	case	in	the	natural	host,	where	such	a	high	abundance	of	
growth	 favouring	nutrients	 is	unlikely	 to	be	 found.	 	 In	 comparison,	 knocking	out	 the	 truncated	
virA*	operon	in	LSS089	appeared	to	result	in	significantly	faster	bacterial	growth	when	compared	
to	 the	wild-type	 parent	 strain	 (reaching	 peak	 OD595	 sooner	 because	 of	 the	 skipped	 second	 lag	
phase).		The	reason	for	this	is	unclear,	although	it	is	interesting	to	speculate	that	the	synthesis	of	
the	 proteins	 encoded	 by	 the	 virA	 operon	 require	 a	 significant	 energy	 expenditure	 and	 that	 the	






whole	 virA	 operon	 (that	 includes	 SSU1588)	 could	 be	 resulting	 in	 reduced	 methylation	 of	
promoter	sequences	of	genes	restricting/limiting	exponential	bacterial	growth.	
	
The	 ability	 of	S.	suis	 isolates	 to	 produce	 a	 biofilm	has	 previously	 been	 reported	 [532-534,	 587,	
588]	 and	 as	 in	 other	 bacteria	 proposed	 to	 be	 a	 virulence	 factor	 [589],	 where	 establishing	 a	
community	 structure	 provides	 i)	 enhanced	 protection	 from	 environmental	 stress,	 ii)	 increased	
exchange	 of	 genetic	material	 and	 iii)	 increased	 resilience	 to	 antibiotics,	 	 all	 of	 which	 result	 in	
persistent	colonisation	[590].		Knocking	out	the	virA	operon	in	both	LSS089	and	P1/7	resulted	in	
a	 statistically	 signification	 (p-value	 <0.05)	 reduction	 in	 biofilm,	 indicating	 that	 virA	 is	 in	 some	
capacity	 involved	 in	 biofilm	 production;	 most	 likely	 in	 regulation	 of	 the	 genes	 responsible	 for	
biofilm	production	rather	than	the	actual	process	itself	[378].		To	better	understand	the	effect	and	
context	of	knocking	out	the	virA	operon	on	biofilm	formation,	all	isolates	of	the	original	training	
collection	 (n=115)	 were	 subject	 to	 the	 crystal	 violet	 microtiter	 plate	 assay	 (Figure	 6.9).		
Comparison	to	 the	mutants	 to	 the	data	presented	 in	Figure	6.5	 indicated	 that	while	statistically	
significant	 in	 comparison	 to	 their	 respective	wild-type	parent	 strains	 (t-test;	p.value<0.05),	 the	
effect	 of	 knocking	 out	 the	 virA	 operon	 on	 biofilm	 production	 is	 probably	 not	 biologically	
significant.	 	 Indeed,	 the	 observation	 that	 removing	 the	 virA	 operon	 had	 a	 significant	 effect	 on	
biofilm	formation	may	be	an	effect	of	the	limited	sensitivity	of	the	microtiter	plate	assay.		It	might	
also	 be	 an	 effect	 of	 using	 96-well	 tissue	 culture	 plates	 that	 had	 been	 treated	 to	 enhance	 cell	
adhesion,	 which	 with	 hindsight	 should	 have	 been	 avoided.	 	 As	 an	 alternative,	 the	 presence	 of	
biofilms	 could	 be	 visualised	 using	 scanning	 electron	 microscopy.	 	 Although	 for	 improved	
visualisation	 of	 the	 structural	 architecture,	 transmission	 electron	 microscopy	 should	 be	 used	
[533].	 	However,	 both	 are	methods	 generate	qualitative	 rather	 than	quantitative	measures	 and	
precise	differences	between	strains	would	be	difficult	to	determine.	
	
Greater	 Wax	 Moth	 larvae	 have	 recently	 been	 explored	 as	 a	 simple	 and	 cost-effective	 in	 vivo	
experimental	infection	model	to	screen	the	virulence	potential	of	S.	suis	isolates	[423].		Described	
within	 this	 chapter	 is	 evidence	 that	 the	 increasingly	 popular	 Greater	 Wax	 Moth	 larvae	
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experimental	 infection	 model	 has	 been	 successfully	 established	 for	 the	 first	 time	 at	 the	
Department	 of	 Veterinary	Medicine	 (University	 of	 Cambridge).	 	 In	 fact,	 the	 characterisation	 of	
P1/7	 and	 Henrichsen	 S735	 was	 reproducible	 from	 previously	 published	 work	 (Figure	 6.10)	
[423].	 	 Positively,	 a	 statistically	 significant	 (p-value	 <0.05)	 difference	 in	 larvae	 survival	
experimentally	infected	with	108	CFU/mL	was	observed	between	the	invasive	disease-associated	
P1/7	 and	 "weakly	 virulent"	 [284]	 Henrichsen	 S735.	 	 Such	 an	 observation	 was	 also	 observed	
between	 disease-associated	 and	 non-disease	 associated	 field	 isolates	 recovered	 from	 pigs	 on	




the	 strains	 LSS089∆virA	 and	P1/7∆virA,	 as	well	 as	 their	 respective	 parent	 strains,	were	 grown	
under	standard	conditions	and	then	used	to	inoculate	final	instar	stage	caterpillars	and	survival	
recorded	 every	 24-hours	 over	 a	 144-hour	 post	 infection	 time	 course.	 	 Based	 on	 observed	
phenotypic	 data	 and	 the	 site	 of	 isolation	 LSS089	 was	 deemed	 to	 be	 a	 non-disease	 associated	
S.	suis	 isolate	 (see	 Table	 2.1).	 	 However,	 Greater	Wax	Moth	 larvae	 survival	 following	 infection	
with	 LSS089	was	 similar	 to	 that	 of	 larvae	 infected	with	 the	 invasive	 disease-associated	 isolate	
P1/7,	 and	 indeed	 any	 differences	 between	 larvae	 survival	 was	 not	 deemed	 to	 be	 statistically	
significant	 (p-value	<0.05).	 	The	 reason	 for	 this	observation	 is	unclear,	 although	could	again	be	
due	to	a	number	of	reasons.	 	Firstly,	 it	may	be	that	the	effect	of	knocking	out	the	virA	operon	is	
masked	by	one	or	both	of	 the	 two	other	Type	 I	RM	systems	also	known	 to	be	present	 in	P1/7	
[552].		To	address	this,	it	may	be	useful	to	create	a	P1/7	mutant	strain	that	has	had	all	three	Type	
I	 RM	 systems	 knocked	 out,	 although	 this	would	 not	 allow	 identification	 of	 the	 exact	 biological	
function	specifically	of	virA	but	the	effect	of	type	I	RM	systems	in	general.		Equally,	it	might	be	that	





show	further	phenotypic	characteristics	and	 is	an	option	 for	 further	rapid	screening	of	 the	virA	
operon	mutants	described	in	this	chapter.		Another	alternative,	and	to	my	knowledge	unexplored,	
non-mammalian	infection	model	is	the	Caenorhabditis	elegans	model.		However,	establishment	of	
this	model	 is	not	straightforward	and	would	require	working	at	a	highest	 temperature	of	21	 ˚C	
rather	 than	 37	 ˚C	 (personal	 communication	 with	 Professor	 Jerry	 Wells	 and	 Professor	 Jan	




be	 the	 natural	 host,	 and	 a	 number	 of	 options	 exist.	 	 Since	 S.	suis	 is	 endemic	 in	 almost	 all	 pig	
populations	 sampled	 [11],	 it	 has	 been	 suggested	 that	 CDCD	 pigs	 are	 the	 optimum	model.	 	 But	
CDCD	pigs	are	expensive	and	are	often	very	sensitive,	meaning	that	the	extrapolation	of	findings	
in	 CDCD	 pigs	 to	 pigs	 born	 naturally	 and	 exposed	 to	 maternal	 antibodies	 has	 been	 questioned	
[302].	 	 Most	 recently,	 whole	 blood	 killing	 and	 phagocytosis	 assays	 have	 been	 used	 to	 show	
significant	differences	between	Type	I	RM	system	isogenic	mutants	and	their	parent	S.	suis	strains	




In	 conclusion,	 knocking	 out	 the	 virA	 operon	 in	 P1/7	 resulted	 in	 no	 significance	 difference	 in	
growth	 characteristics,	 biofilm	 formation	 (no	 biological	 significance)	 or	 in	 Greater	 Wax	 Moth	
larvae	survival.		Future	evaluation	of	the	role	and	biological	function	of	virA	will	likely	use	SMRT	
DNA	 sequencing	 (Pacific	 Biosciences)	with	methylome	 analysis	 to	 identify	 the	 exact	 nucleotide	
target	 sequence	 recognised	by	 the	protein	encoded	by	virA	 (SSU1589).	 	 SMRT	DNA	sequencing	
will	also	be	able	to	provide	information	into	whether	the	effect	of	knocking	out	the	virA	operon	is	
masked	by	the	two	other	Type	I	RM	systems	in	P1/7.		Other	work,	not	related	to	virA,	could	take	
advantage	of	 the	biofilm	 formation	data	presented	 in	 this	chapter,	and	using	a	GWAS	 it	may	be	
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among	strains	of	S.	suis.	 	With	access	 to	an	 initial	 (training)	collection	of	115	 isolates	 recovered	
from	pigs	on	UK	farms	and	detailed	clinical	metadata,	I	aimed	to	identify	regions	of	the	genome	
associated	 with	 invasive	 disease	 caused	 by	 S.	suis.	 	 I	 then	 investigated	 the	 potential	 practical	
utility	of	these	genetic	markers,	and	compared	their	use	in	predicting	the	virulence	potential	of	an	
out-of-sample	 collection	 of	 S.	suis	 isolates	 to	 the	 use	 of	 commonly	 used	 virulence-associated	
factors	also	used	to	predict	virulence	potential.		Further	investigations,	using	these	novel	genetic	
markers,	estimated	 the	bacterial	 load	of	 invasive	disease-associated	and	non-disease	associated	
strains	 of	 S.	suis	on	 the	 palatine	 tonsils	 of	 pigs,	 in	 doing	 so	 allowing	 comparisons	 to	 be	 drawn	
against	 culture-based	 approaches	 for	 surveillance.	 	 Finally,	 attempts	 to	 investigate	 the	 function	





of	 the	same	species	has	opened	up	exciting	possibilities	 to	 reassess	diagnostic	and	surveillance	
programs	 for	 bacteria,	 including	 S.	suis.	 	 Taking	 advantage	 of	 these	 advances	 I	 have	 presented	
evidence	 for	 the	 use	 of	 three	 genetic	 markers	 (two	 associated	 with	 invasive	 disease	 and	 one	
associated	with	asymptomatic	carriage	on	the	palatine	tonsils	of	pigs	on	UK	farms)	and	a	novel	
species-specific	marker	to	pathotype	S.	suis.		There	is	an	urgent	need	for	an	agreed	set	of	criteria	






research	was	 to	 return	 to	 and	 rerun	 the	 pipeline	 of	 statistical	 analyses	 I	 have	 built	 to	 identify	
genetic	markers	 of	 disease	 association,	 but	 also	 include	 the	whole-genome	 sequencing	 data	 of	
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S.	suis	isolates	from	different	geographic	locales.		Recently	the	whole-genome	sequencing	data	of	a	
collection	 in	 excess	 of	 250	 S.	suis	 isolates	 recovered	 from	pigs	 on	 farms	 in	 Canada	 has	 become	
available	(for	which	I	undertook	the	sample	preparation	for	whole-genome	sequencing).		Further	
to	the	research	presented	in	this	thesis,	it	is	an	exciting	prospect	to	be	able	to	identify	and	inspect	
the	 genetic	 markers	 associated	 with	 invasive	 disease	 in	 these	 Canadian	 isolates.	 	 It	 is	 also	 an	
exciting	prospect	to	see	how	adapting	our	methods	to	include	a	random	forest	machine	learning	
statistical	approach	[591-595]	to	identify	and	rank	genetic	markers	would	influence	the	markers	
shortlisted	 as	 potential	 pathotyping	 markers	 for	 S.	suis	 –	 an	 approach	 not	 used	 in	 this	 thesis.		
Other	unpublished	collections	of	S.	suis	isolates	from	China	and	Vietnam	are	now	also	available	to	
our	group	and	incorporation	of	all	of	these	isolate	collections	would	only	add	statistical	power	to	
any	 subsequent	 analyses;	 increasing	 the	 size	 of	 the	 dataset	 should	 not	 be	 a	 problem	 for	 the	
computationally	efficient	statistical	tools	employed,	such	as	the	Discriminant	analysis	of	principal	





'gold-standard'	 to	 characterise	 isolates	 as	 virulent.	 	 This	 is	 an	 approach	 not	 without	 fault	 for	
reasons	 discussed	 throughout	 this	 thesis,	 including	 i)	 host	 immune	 status,	 ii)	 concurrent	
infections	 and	 iii)	 welfare	 conditions	 that	 could	 influence	 the	 susceptibility	 of	 a	 host	 to	 this	




screen	 the	 Canadian	 isolates	 for	 the	 newly-defined	 pathotyping	marker	 virA.	 	 Clear	 geographic	




certain	 European	 countries	 the	 genes	 encoding	 EF,	 MRP	 and	 SLY	 are	 often	 absent	 from	 both	
disease-associated	 and	 non-disease	 associated	 isolates	 recovered	 from	 pigs	 on	 farms	 in	 North	
America	[129,	393,	408,	409,	596].	 	By	expanding	the	number	of	genome	sequences	 included	in	
analyses	 it	would	be	desirable	 to	 be	 able	 to	 create	 a	 diagnostic/surveillance	 tool	 that	 could	 be	
used	globally.		However,	as	disease	caused	by	S.	suis	appears	to	be	influenced	by	the	environment	
and	 immune	 status	 of	 the	 host	 (and	 not	 solely	 by	 S.	suis	 genetics)	 this	 might	 not	 be	 possible,	
resulting	in	surveillance	tools	designed	to	target	specific	continents,	countries	or	a	combination	of	
geographic	 locales.	 	 Indeed,	 it	 would	 also	 be	 interesting	 to	 screen	 the	 strain	 collection	 of	 116	
isolates	 recently	 recovered	 from	 pigs	 on	 farms	 in	 the	 Netherlands	 and	 used	 to	 assess	 S.	suis	
population	 structure	 and	 the	 distribution	 of	 Type	 I	 RM	 systems	 in	 S.	suis	 [552,	 597,	 598].	 	 As	
numerous	non-disease	associated	 isolates	 in	our	UK	biased	strain	collection	do	not	possess	 the	
Type	 I	RM	enzyme	encoded	by	 the	operon	SSU1588-1590,	 I	 suggest	 this	 is	not,	 as	proposed	by	
Willemse	 et	 al.	 [552],	 a	 housekeeping	 operon.	 	 However,	 if	 all	 116	 Dutch	 isolates	 have	 been	
recovered	 from	systemic	 locations	of	diseased	pigs	 this	 is	 further	evidence	 that	virA	 could	be	a	
robust	 genetic	 marker	 of	 virulence	 in	 European	 countries.	 	 Indeed,	 arguably	 virA	 could	 be	
described	as	the	'best'	single	molecular	marker	to	pathotype	S.	suis	that	I	have	identified.		Having	




Alternatively,	an	option	not	yet	explored	 is	 the	 incorporation	of	epf,	mrp	 and	sly	 into	 the	newly	
described	pathotyping	tool	for	S.	suis.		Due	to	the	usefulness	of	epf,	mrp	and	sly	being	restricted	to	
European	countries	and	the	original	aim	of	 this	project	 to	develop	a	pathotyping	tool	 for	global	
use,	 the	approach	 I	used	 to	 identify	genetic	markers	 tried	not	 to	place	 substantial	 emphasis	on	
predicted	biological	function,	as	current	annotations	can	be	inaccurate.		This	strategy	should	also	
prevent	 the	 selection	 of	 genetic	markers	 for	 S.	suis	 that	may	 have	 simply	 been	 associated	with	
virulence	 in	 other	 bacterial	 species.	 	 Indeed,	 virA	 exemplifies	 this;	 before	 more	 recent	 papers	








present	 in	 the	 same	 isolate	 (chapter	 4).	 	 Therefore,	 incorporation	 of	 these	 genes	 into	 our	
pathotyping	 tool	 for	 S.	suis	might	 not	 significantly	 improve	 the	 sensitivity	 and/or	 specificity	 of	
binary	 classification.	 	 Based	 on	 this	 observation,	 it	 is	 interesting	 to	 speculate	 that	 the	
methyltransferase	activity	of	the	Type	I	RM	system,	for	which	virA	encodes	the	specificity	domain,	
has	 a	 regulatory	 effect	 on	 the	 expression	 of	 EF,	 MRP	 and	 SLY	 by	 modifying	 the	 bases	 of	 the	
upstream	 promoter	 regions	 and	 masking	 (or	 revealing)	 the	 DNA	 from	 transcription	 enzymes.		
Exciting	 follow	 up	 studies	 are	 planned	 to	 use	 RNA	 sequencing	 microarrays	 to	 investigate	 the	
effect	of	knocking	out	the	virA	operon	(SSU1588-1590)	in	S.	suis	isolate	P1/7	has	on	transcription,	
and	 could	 reveal	 which	 genes	 are	 susceptible	 to	 regulation	 by	 virA.	 	 In	 addition,	 the	 isogenic	






of	 pigs	 on	 farms	 without	 obvious	 signs	 or	 a	 recent	 history	 of	 streptococcal	 disease.	 	 When	
compared	 to	 culture-based	 surveillance	 technologies,	 the	 frequency	 of	 this	 observation	 was	
higher	 and	 could	 indicate	 that	 culture-based	 approaches	 are	 underestimating	 the	 true	 positive	
rate	of	subclinical	carriage	of	disease-associated	strains	 in	UK	pig	populations.	 	With	more	time	
this	observation	would	have	been	followed	up	by	using	quantitative	bacteriology	to	validate	the	
ratios	predicted	by	qPCR	of	non-disease	 associated:disease-associated	 for	 the	 same	 swab.	 	 It	 is	
important	 to	 mention	 that	 this	 aim	 of	 validating	 the	 ratio	 of	 non-disease	 associated:disease-
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associated	 isolates	 through	 quantitative	 bacteriological	 methods	 might	 not	 be	 possible	 as	
molecular	techniques,	although	typically	more	sensitive,	detect	DNA	and	not	necessarily	only	the	
DNA	 of	 viable	 bacteria,	 something	 that	 should	 at	 least	 be	 acknowledged	 in	 future	 diagnosis	 or	
surveillance	 developments.	 	 From	 a	 practical	 perspective,	 increasing	 the	 number	 of	 single	
colonies	 isolated	 for	 characterisation	 from	solid	agar	plates	 is	not	 a	 realistic	option	 to	 improve	
wide	scale	surveillance.		Indeed,	the	procedure	for	collection	of	palatine	tonsils	swabs	from	pigs	is	
not	 straightforward	 and	 it	 may	 be	 interesting	 to	 investigate	 the	 potential	 use	 of	 alternative	




As	S.	suis	 is	 considered	endemic	 in	pig	populations	 [17],	 it	 is	 interesting	 to	 speculate	 about	 the	
role	 non-disease	 associated	 isolates	 have	 on	 the	 development	 of	 invasive	 disease.	 	 From	 an	
evolutionary	perspective	crossing	the	blood	brain	barrier	and	causing	meningitis	 is	self-limiting	
as	 the	 infectious	organism	will	 kill	 the	host	 and	 itself.	 	 It	 could	be	 the	 case	 that	 lethal	 invasive	
disease	 caused	 by	 S.	suis	 is	 accidental	 and	 a	 product	 of	 being	 in	 possession	 of	 a	 significantly	
smaller	 genome	 (albeit	 enriched	 in	 proposed	 virulence-associated	 factors)	 [141].	 	 Previous	
analysis	 of	 the	 original	 training	 collection	 identified	 non-disease	 associated	 isolates	 to	 have	 a	
larger	genome	in	comparison	to	isolates	associated	with	invasive	disease.		Presented	in	chapter	6,	
the	observation	that	the	growth	characteristics	of	non-disease	associated	isolate	LSS089	revealed	
a	much	 shorter	 stationary	phase	between	 five	 and	12-hours	 could	 indicate	 that	 isolates	with	 a	
larger	genome	are	able	 to	move	 to	a	 second	carbon	 source	more	efficiently	 and	as	 a	 result	out	
compete	 invasive	 disease	 causing	 strains	 of	 S.	suis	 in	 the	 upper	 respiratory	 tract.	 	 As	 a	 result,	
disease	 associated	 strains	might	 be	 causing	 invasive	disease	 inadvertently	 as	 a	 consequence	 of	
adapting	to	a	less	competitive	environment	than	the	upper	respiratory	tract.	
	
A	 common	 theme	 in	 the	 literature	 for	 S.	suis	 is	 the	 urgent	 need	 for	 an	 agreed	 set	 of	 criteria	 to	




pig	 production	 in	 the	 1920s	 [11,	 141].	 	 As	 research	 groups	 continue	 to	 define	 virulence	
differently,	 the	 extrapolation	 of	 findings	 between	 groups	 is	 difficult	 [302,	 425].	 	 Indeed,	 in	 this	
thesis	 we	 used	 observed	 clinical	 phenotypes	 to	 define	 isolates	 as	 disease-associated	 or	 non-
disease	associated,	a	method	that	has	been	acknowledged	not	to	be	without	caveats.	 	Due	to	the	




used	 to	 detect	 differences	 in	 the	 virulence	 potential	 of	 invasive	 disease-associated	 and	 non-
disease	 associated	 field	 isolates	 recovered	 from	 pigs	 on	 UK	 farms.	 	 However,	 before	 such	 an	
experimental	 infection	model	 could	 be	 agreed	 upon	 as	 the	 standard	model	 defining	 strains	 of	
S.	suis	 as	 virulent,	 more	 thorough	 evaluation	 must	 be	 performed.	 	 Indeed,	 other	 simple	
experimental	 infection	 models	 also	 exist	 that	 are	 being	 explored	 for	 S.	suis,	 such	 as	 a	
Caenorhabditis	 elegans	 model.	 	 Pilot	 studies	 I	 conducted	 for	 this	 model,	 not	 presented	 in	 this	
thesis,	 suggest	 that	 when	 grown	 on	 bacterial	 lawns	 of	 disease-associated	 or	 non-disease	
associated	 S.	suis	 the	 differences	 in	 nematode	 development	 is	 very	 subtle.	 	 These	 early	
observations	 indicated	 that	 this	 model	 would	 therefore	 be	 unsuitable	 for	 worldwide	 use	 in	
laboratories	without	 extensive	 experience	 of	 the	 stages	 of	C.	 elegans	 development.	 	 At	 present,	
one	 rapidly	 advancing	 field	of	 science	 is	 the	development	of	 organoids,	 (an	 in	 vitro	3D	 cellular	




In	 conclusion,	 the	 complexity	 of	 S.	suis	 has	 allowed	 extensive	 discussion	 regarding	 the	 factors	

























Kaplan−Meier estimate with 95% confidence bounds
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BLASTn	query	 Isolate	 Phenotype	 	%	identity	 	Alignment	length	 	Evalue	
SSU0050_ComS	 LOLA-SS001.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 LOLA-SS002.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 LOLA-SS003.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 LOLA-SS005.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 LOLA-SS010.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 LOLA-SS011.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 P1/7.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 SS1001.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 SS1002.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 SS1004.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 SS1008.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 SS1010.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 SS1011.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 SS1012.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 SS1023.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 SS1024.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 SS1026.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 SS1028.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 SS1029.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 SS1032.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 SS1033.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 SS1036.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 SS1038.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 SS1039.gnm	 Disease-associated	 100	 66	 9.67E-28	
SSU0050_ComS	 SS1054.gnm	 Disease-associated	 100	 66	 9.67E-28	
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